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ABSTRACT OF DISSERTATION
Modulation of Type-I Interferon Mediated Immune Response: A Novel Innate Immune
Evasion Strategy of Equine Herpesvirus 1
Equine herpesvirus-1 (EHV-1) is one of the major viral pathogens causing respiratory disease,
abortion, perinatal mortality and neurologic disease among horses resulting in significant
economic losses to the equine industry. The virus can also remain latent in the horses and
recrudesce at any time. Type-I interferons (IFNs) act as a first line of defense against many viral
infections.
In this study we investigated the type-I IFN response against the neuropathogenic T953
strain of EHV-1 in equine endothelial cells (EECs). The results showed that after a transient
induction of IFN-β mRNA as well as protein at an early time (3h) post infection (p.i.), T953
strain of EHV-1 suppressed further induction of IFN-β at later times (12h onwards). Studies were
done to confirm that the suppression of type-I IFN induction at later time points was not due to
the normal IFN-β induction kinetics, it was rather because of the active interference by the virus.
Investigation of the mechanisms by which T953 interferes with IFN-β production revealed that
the virus degraded the endogenous level of the transcription factor, interferon regulatory factor 3
(IRF-3) and also down-regulated the activation of IRF-3 followed by its accumulation in the
nucleus. However, T953 infection caused degradation of nuclear factor κB (NF-κB) inhibitory
protein IκBα and also induced p50 subunit to translocate into nucleus from cytoplasm suggesting
activation of NF-κB signaling. This also indicated that inhibition in the type-I IFN production
was probably not due to the inhibition of NF-κB.
The results of these studies also indicated that T953 virus was resistant to the biological
effect of the recombinant equine IFN-α in vitro. Investigation of the reason of this resistance
showed that T953 virus interfered with the cellular JAK-STAT signaling mechanism by which
type-I IFN exerts its antiviral effect. Moreover, the studies revealed that downstream of the JAKSTAT signaling, T953 virus also inhibited the expression of cellular antiviral proteins including
interferon stimulated gene 56 (ISG56) and viperin. Altogether, these data indicate that the T953
strain of EHV-1 interfered with the host cell innate immune responses by modulating type-I IFN
mediated immune responses at multiple levels in vitro.

KEYWORDS: Equine herpesvirus-1, Interferon, Interferon regulatory factor-3, JAK-STAT
signaling, Interferon stimulated gene
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CHAPTER I: REVIEW OF LITERATURE

1.1 Introduction and History of Herpes:
The word ‘herpes’ was originally derived from the Greek word herpein meaning to creep or
crawl because of the creeping nature of the lesions on the skin caused by the viruses. The origin
of the word ‘herpes’ probably dates back more than twenty five centuries although the first
written documentation of human herpes virus infection is believed to be done by Hippocrates
(460 BC-377 BC) [1-3]. Similar signs of infections have also been mentioned in many other
ancient documents, e.g., the Sumerian Tablet (3rd Millenium BC), Egyptian Ebers Papyrus (circa
1500 BC) or in Avicenna’s documentation (880-1036 AD). Celsus was the first who described
the actual herpetic lesion as ‘initially round but then diffused like serpent’. These signs were
caused by the herpesvirus now known as varicella zoster virus (VZV) which was also
documented by Herodotus and later elaborated by Galen [2]. Over the centuries the term ‘herpes’
and its meaning have been changed several times to ‘formica’, furfur and again back to ‘herpes’.
In early medical history the word ‘herpes’ was attributed to many pathological conditions of the
skin like skin cancer, noma, erysipelas, and ringworm including lupus vulgaris [2, 3]. The
Byzantine author, Actuarius (John Zachary) is considered to be the first author to certainly use the
term ‘herpes’ for cutaneous ringworm (reviwed in [3]). In 1275, Saliceto considered ‘herpes’ to
be different from ‘erysipelas’ as the latter only involves the skin while ‘herpes’ involves also
underlying tissues (reviewed in [3]). Gorraeus recognized 3 different types of herpes i.e., ‘H.
esthiomenos’, ‘H. miliaris’ and ‘H.phlyctenodes’ [4]. In contrast to Saliceto, Daniel Sennert still
believed that ‘herpes’ and ‘erysipelas’ both were caused by same agents and he also mentioned 3
different types of herpes in his writings, such as ‘H. simplex’ (‘Herpes vero solam cutem
exulcerat’), ‘H. esthomenos’ or ‘H. exedens’ and ‘H. miliaris’ [5]. Daniel Turner, who gave more
modern descriptions compared to these previous authors, considered ‘herpes’ to be ‘a choleric
pustule’[6]. He is the one who described herpes simplex under its modern name [3]. In the
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pustule’[6]. He is the one who described herpes simplex under its modern name [3]. In the
beginning of the nineteenth century Robert Willian and Thoms Bateman contributed significantly
to the field of herpes virology. Bateman recorded 6 different species of ‘herpes’ which are H.
phlyctaenodes, H. zoster, H. circinatus, H. labialis, H. praeputialis and H. iris [3]. Unna in 1883
elaborately described the recurrence of herpes infection [7]. Three years later in 1886 a French
dermatologist, Jean Baptiste Emile Vidal, first showed that skin conditions caused by herpes
simplex were infectious and could be transmitted from human to human [2, 8]. The great
discovery of the first virus, tobacco mosaic virus and the fact that agents different and smaller
than bacteria can cause disease by Dmitri Ivanovski and Martinus Biejerinck in 1892 and 1898,
respectively, set the milestone for virology research [9, 10]. Within the same time period the first
book dedicated to herpes, ‘Les Herpes Genitaux’ was published in 1896 by the French doctors
Charles-Paul Diday and Adrien Doyon [11].
While herpesviruses have been considered to be evolving along with their hosts over a
period of about 400 million years, the subgroup alpha herpesviruses have diverged only 180-210
million years ago [12, 13]. Although human herpesvirus infections started a long time ago, it was
not until the past four centuries that clinical findings of equine herpes virus were recorded [14].

1.2 Importance of EHV-1 Infection to United States Horse Industry
Kentucky is considered to be the horse capital of the United States (US). The US equine
industry is a very diverse industry involving almost all the states in US providing an opportunity
for at least 460,000 direct full-time employment jobs (FTE). 4.6 million Americans of which 2
million are horse owners are directly involved, and many others are indirectly involved with this
industry, making every 1 out of 63 Americans involved with horses [15]. The industry involves
agriculture, business, and recreation impacting significantly at national, state and local
economies. The 102 billion US dollar (USD) equine industry consists of racing (26.1 billion),
showing (28.7 billion), recreation (31.9 billion), other (14.6 billion) USD (Figure 1.1) and pays
2

revenue of 1.9 billion to the US government which includes Federal (588 million), State (1017)
million and local (275 million) USD revenues [15].

Figure 1.1: Distribution of economic sectors of the US horse industry. Of the 102 billion USD
horse industry, the most significant contribution comes from recreation followed by showing,
racing and others. The figure is made from the information available from American Horse
Council Foundation [15].

Out of the 9.2 million horses in the US, Kentucky has about 320,200 horses and 194,300
Kentuckians are involved in the industry either as horse owners, service providers, employees or
volunteers [15]. The equine industry in Kentucky creates direct 51,900 FTE with a total impact of
96,000 job opportunities. The horse industry in Kentucky has an impact of 3.54 billion USD in
terms of gross domestic product added directly to US economy.
EHV-1 infection causes serious damage to the horse industry worldwide including in the
US. As a direct effect of the infection, horses suffer from respiratory disease, neurologic
disorders, abortions, and neonatal death. The infection also makes horses susceptible to other
secondary bacterial infections like Streptococcus equi subsp. zooepidemicus [16]. Even though
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horses may recover from the disease eventually, their productivity is compromised. Late term
abortions usually in the last trimester and neonatal death cause significant economic losses to
horse breeders and also set back the industry as whole. EHV-1 induced neurologic disease, also
known as equine herpes myeloencephalopathy (EHM) causes significant morbidity as well as
mortality. The restriction in the movement of horses nationally and internationally caused by
EHV-1 infection and the rescheduling of horse shows and races also impact the equine industry
negatively. Large amount of money are also spent on the care and management of horses infected
with EHV-1.

1.3 Classification of Herpesviruses:
The first organized classification of herpesviruses came in 1971 by the International
Committee on Taxonomy of Viruses (ICTV) [17] and the most recently updated classification
was adopted in 2009 by the ICTV [18]. Here the newly formed order Herpesvirales are
considered to have three distinct families: the Alloherpesviridae, the Malacoherpesviridae and the
Herpesviridae, the latter of which is also the largest amongst the groups. While the
Alloherpesviridae includes herpesviruses of fish and frogs and the Malacoherpesviridae includes
a bivalve virus, the revised family of Herpesviridae includes herpesviruses of mammals, reptiles
and birds [18]. The classifications of different herpesviruses into different families are largely
based on virion morphological criteria [19].
The members of the herpesviridae family have spherical virion morphology with four major
components: the core, the capsid, the tegument and the envelope (Figure 1.2). The core contains a
single copy of a linear, double-stranded deoxyribonucleic acid (DNA) molecule which is
arranged with unique long and unique short regions with terminal and internal repeats. The core
DNA molecule is encased within an icosahedral capsid with an external diameter of 125-130 nm
[18, 19]. The capsid is made of 162 capsomeres of which 12 are pentons and 150 are hexons [19].
This is surrounded by unstructured proteinaceous matrix, the tegument which consists of 30 or
4

more viral proteins [18]. The external lipid bilayer membrane, or envelope, surrounds the
tegument and a number of glycoproteins of both virus and host origin are embedded into the
envelope [19].

Figure 1.2: Basic Architecture of Herpesvirus Virion. All herpesviruses have four major
components, the core which consists of a dsDNA genome, capsid, tegument and envelope.
Several glycoproteins are embedded in the envelope.

Based on the biological criteria, the members of the herpesviridae family are categorized
into three subfamilies: Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae [20].
These subfamilies are further assigned into different genera based on molecular data; mainly
DNA sequence homology, genome size and structure and relatedness of viral proteins [14, 21].
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The members of the Alphaherpesvirinae subfamily are distinct from the other subfamilies
by their characteristic variable and wide host range, relatively short replication cycle (few hours),
rapid spread in cell culture with cytolysis and the capability to establish life-long latency in the
sensory ganglia of the central nervous system or in the lymphocytes of their hosts [22]. The
subfamily contains four different genera: Simplexvirus, Varicellovirus, Mardivirus and Iltovirus
[19]. Memebers of the Simplexvirus include Human herpesvirus-1, Human herpesvirus-2, Bovine
herpesvirus-2, Ateline herpesvirus-1 and Cercopithecine herpesvirus-1 [19]. Members of the
Varicellovirus include Bovine herpesvirus-1, Bovine herpesvirus-5, Suid herpesvirus-1, Equid
herpesvirus type-1, -3, -4, -6, -8 and -9, Caprine herpesvirus-1, Canid herpesvirus-1 and Human
herpesvirus-3 [19]. Members of the Mardivirus infect only birds and include Gallid herpesvirus-2
(Marek’s disease virus type-1), Gallid herpesvirus-3 (Marek’s disease virus type-2) and
Meleagrid herpesvirus-1 (Turkey herpesvirus) [18, 19]. Members of the Iltovirus include Gallid
herpesvirus-1 (Infectious laryngotracheitis virus) and Psittacid herpesvirus-1 (Pacheco’s disease
virus) [18].
The characteristic features of the members of the Betaherpesvirinae subfamily include
restricted host range, long reproductive cycle (lasts several days), slow growth in cell culture and
a characteristic cytomegalia of the infected cells with intranuclear inclusion bodies [14, 22]. In
many cases the virus causes no apparent clinical symptoms and can be latent in leucocytes, cells
of reticuloendothelial systems, salivary glands, kidneys and other tissues [23]. The subfamily
consists of three genera: Cytomegalovirus, Muromegalovirus and Roseolovirus [24].
Cytomegaloviruses have large genome size (>200 kbp) and cause characteristic enlargement of
the infected host cells [24]. Examples of this genus include Human cytomegalovirus and African
green monkey cytomegalovirus [24]. Muromegaloviruses which include two members, mouse
and rat cytomegalovirus, also have large genome size (>200 kbp). Roseoloviruses, on the other
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hand, have smaller (<200 kbp) genome size and infect primarily T cells and the two members of
this genus include Human herpesvirus-6 and Human herpesvirus-7 [24].
The members of the subfamily Gammaherpesvirinae infect T or B lymphocytes and have
variable replication cycle [22]. The gammaherpesviruses are very restricted in their host range
(restricted to the taxonomic family or order of their natural host) and are often found latent in the
lymphoid tissues [14]. This subfamily consists of four genera: Lymphocryptovirus, Rhadinovirus,
Macavirus and Percavirus [18]. The members of Lymphocryptovirus include the Epstein-Barr
virus and Gorilla herpesvirus and these viruses infect only primates [24]. The members of the
Rhadinovirus have more varied host range compared to other genera of this subfamily and
include Bovine herpesvirus-4, Macacine herpesvirus-5 and Human herpesvirus-8 [18]. The
members of the Macavirus genus are genetically very similar and include Caprine herpesvirus-2,
Alcelaphine herpesvirus-1 and Suid herpesvirus-3 [18]. Members of Percavirus include Equine
herpesvirus-2, Equine herpesvirus-5 and Mustelid herpesvirus-1 [18].

1.4 Herpesvirus Infections of Equids:
The equid herpesviruses are one of the most prevalent viral pathogens found among equids
causing a number of diseases. Equid herpesviruses belong to the order herpesvirales and family
herpesviridae but to date all the equid herpesviruses isolated are restricted to either
alphaherpesvirinae or gammaherpesvirinae subfamily. The members of the subfamily of
alphaherpesviruses of equids include equid herpesvirus-1 (EHV-1), equid herpesvirus-3 (EHV3), equid herpesvirus-4 (EHV-4), asinine herpesvirus-1 (AHV-1) , asinine herpesvirus-3 (AHV-3)
and Gazelle herpesvirus-1 (GHV-1) and all of these viruses belong to Varicellovirus [19]. The
members of the gammaherpesviruses of equids include equine herpesvirus-2 (EHV-2), equine
herpesvirus-5 (EHV-5) and asinine herpesvirus-2 (AHV-2). The most common equine
herpesviruses that infects a majority of world’s domestic horses (Equus caballus) are EHV-1 and
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EHV-4 that have been found for more than 70 years to be significant impediments to the success
of breeding, competition and recreational horse industries [25].

1.4.1 Equine Herpesvirus Infections:

1.4.1.1 EHV-1Infection:
EHV-1 infection causes respiratory disease characterized by fever (39.5-41.5 ˚C), malaise,
inappetence, serous nasal discharge, pharyngitis, coughing and submandibular or retropharyngeal
lymphadenopathy, neonatal death, ocular disease, epizootic abortion storms mainly in the late
trimester as well as sporadic abortions, and also a neurological disorder known as EHM [26].
Progressive secondary bacterial infection may lead to rhinopneumonitis [27]. Although horses of
any age group or breed or sex are susceptible to the viral infection, young horses are more
susceptible to the respiratory form of the disease and the older horses are more susceptible to the
development of EHM. Beside domestic horses, the virus has also been isolated from onagers
(Equus hemionus onager), zebras and gazelles (Gazella thomsoni) [28]. The virus can be latent in
lymphocytes (mainly CD8+ T lymphocytes) and also in sensory nerve cell bodies within the
trigeminal ganglia of the infected horse which then becomes a carrier for its lifetime [25].
1.4.1.2 EHV-2 Infection:
EHV-2 along with EHV-5 was originally described as ‘slowly cytopathic orphan’
herpesvirus of domestic horses and was also classified under cytomegalovirus like
betaherpesviruses [29-31]. With the availability of advanced biotechnological tools, complete
genomes of both the viruses have been sequenced and the data led EHV-2 and EHV-5 to be
incorporated under the subfamily of Gammaherpesvirinae and genus Percavirus [29, 32, 33].
Initially, the EHV-2 strain isolated in 1962 was a prototype LK strain from a foal suffering from
‘catarrh and coughing’ by Plummer and Waterson [34] and after that the virus has been isolated
in different parts of the globe [29, 35, 36]. The virus has a linear dsDNA of 184 kbp length and
57% G+C content genome which encodes 77 distinct proteins [29, 32]. Foals of young ages are
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more susceptible to EHV-2 infection [30, 37]. The virus can be shed persistently, intermittently or
continuously or even be latent with sporadic reactivation and this could be very significant
epidemiologically. It has been noticed that EHV-2 can be shed intermittently from the mucous
membranes of the respiratory tract of horses for up to 14 weeks [38, 39]. EHV-2 has been isolated
from peripheral blood leukocytes of 89% of the horses tested in the US and 90% in England [29,
40]. Moreover, the same animal can be infected with EHV-2 and EHV-5 at the same time [41].
Although endemic in the US, severe outbreaks of EHV-2 infections associated with respiratory
diseases have also been reported [42]. In the field conditions, horizontal transmission of the virus
is the most common route of spread to new animals [30]. Nasal mucosa, histiocytes and
Langerhans cells in conjunctiva, and peripheral blood lymphocytes have been shown to be
reservoirs and sources of excretion of EHV-2 in the environment [43-45].

Severe EHV-2

infections can show 100% morbidity with the symptoms of respiratory disease like increase in
body temperature (38.5-39.5 ˚C), dullness, malaise, enlarged lymph nodes, chronic pharyngitis,
coughing, serous to mucopurulent nasal discharge for several days and also keratoconjunctivitis
[42, 46-49]. EHV-2 has also been linked to the poor performance syndrome in young performing
horses and also to immunosuppression of the affected horses [49, 50]. In some isolated cases,
EHV-2 has also been associated with naturally occurring abortions of mares as well as
granulomatous dermatitis [51-53].
1.4.1.3 EHV-3 Infection:
EHV-3 is the causative agent of an infectious, mucocutaneous, venereal disease of mares
and stallions known as equine coital exanthema (ECE) which is characterized by the formation
of pock-like eruptions and erosions or ulcers on the external genitalia of mares and stallions [54,
55]. Although the virus is highly contagious, it does not normally cause any abortion or infertility
or any systemic illness [54, 56]. The virus is antigenically, genetically and pathogenetically
different from any other alpha or gamma equine herpesviruses and bearing only 2 to 5 per cent
homology with EHV-1 at DNA level [57]. Unlike EHV-1, EHV-3 has a restricted host range and
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grows in vitro only in the cells from equids. The virus grows optimally at 34 ˚C and an increase in
temperature up to 39 ˚C could reduce the infectious progeny virus 106 fold [56, 58, 59]. Latently
infected horses act as biological reservoirs and can shed the virus periodically, serving as a
potential source of infection for other animals within the population [54]. It has been estimated
that about 18-53% population of horses of breeding age possess EHV-3 specific antibodies [54,
60, 61]. Young and unbred horses are less susceptible to EHV-3 compared to older and breeding
horses [60, 61]. EHV-3 is principally transmitted by direct skin-to-skin contact during coitus from
an actively infected virus shedding horse but non-coital transmission by contact with virus
contaminated buckets, instruments, gloves, or examination sleeves used for the purpose of
breeding is also seen [54, 55]. After entry into a new horse, the replication of the virus is limited
within the stratified epithelium of the epidermis or mucocutaneous junctions of the nares, urethral
orifice, or female genital vestibule; and systemic dissemination of the virus has not been seen
[54]. Both virus-neutralizing (VN) antibodies and complement-fixing

(CF) antibodies are

detected in sera from EHV-3 infected horses where VN antibodies persist longer [61]. No
commercial vaccines are available which prevent ECE [54].
1.4.1.4 EHV-4 Infection:
After EHV-1, the most significant and ubiquitous alphaherpesvirus of equids is EHV-4 [25].
Unlike EHV-1, EHV-4 infection causes primarily respiratory disease and normally does not lead
to EHM. However, sporadic, single cases of abortion have been documented occasionally after
EHV-4 infection in horses [25, 37]. Although EHV-1 and EHV-4 are two distinct viruses, they
share a great deal of antigenic and genetic similarities. EHV-4 has a linear double stranded DNA
genome of 145.6 kbp with 50.5% GC content [25]. EHV-1 and EHV-4 share 55 to 84 per cent
nucleotide identity within the individual homologue genes and the degree of homology in amino
acid sequences ranges from 55 to 96 per cent [25, 62]. Because of the high degree of homology
between two viruses, they were considered to be different subtypes of EHV-1 (subtype-1 or S-1
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for EHV-1, subtype-2 or S-2 for EHV-4) until 1981 [63]. After that the DNA sequencing of
EHV-1 and EHV-4 confirmed the individual identity of the two viruses [62, 64].
1.4.1.5 EHV-5 Infection:
Along with EHV-2, EHV-5 is another widely distributed gammaherpesvirus of equines [29].
The virus was originally isolated from the nasal cavity of two horses from the UK in quarantine
in Australia in 1970 [42, 65] and since then EHV-5 had also been isolated from the peripheral
blood lymphocytes (PBL) of horses suffering from upper respiratory tract diseases or also from
apparently healthy horses in the US, Australia and Europe [32, 41, 66, 67]. EHV-5 has a linear
dsDNA genome of 179 kbp length and a G+C content of 52% [68]. Though the virus shares an
overall 60% homology with EHV-2 at the amino acid level, the two viruses are distinct entities
[29, 32]. Like EHV-2, EHV-5 has also been shown to exhibit a broad host range and a longer
replication cycle in vitro in cell culture [29, 69]. In the majority of the cases, EHV-5 infected
horses have shown inapparent or minimal signs. But recently, EHV-5 has been associated with
the development of characteristic equine multinodular pulmonary fibrosis (EMPF) and also to
secondary bacterial infection caused by Rhodococcus equi [42, 70, 71]. Williams et al have
described the progressive nodular fibrotic lung disease caused by EHV-5 and showed that the
lungs of the infected horses contained multiple nodules with marked interstitial fibrosis [70].
Histological studies found that the airways of the affected horses contained neutrophils and
macrophages containing the inclusion bodies which were confirmed to be ‘herpesviral-like
particles’ by transmission electron microscopy [70]. In another report, Wong et al have also
described EMPF in five horses with multifocal coalescing nodules of fibrosis in the lung
parenchyma [72]. In other studies Schwarz et al [73] also reported similar EMPF cases in five
horses in Hungary and Spelta et al [74] documented EMPF cases in three horses in Australia. In a
very recent study Williams et al infected horses with EHV-5 isolated from the spontaneous cases
of EPMF and have reproduced the signs of EMPF in the experimentally infected horses [75].
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1.4.2 Asinine Herpesvirus Infections:

1.4.2.1 AHV-1 Infection:
AHV-1 is another member of the subfamily alphaherpesvirinae and tentatively under
varicellovirus. The virus is also known as equine herpesvirus-6 (EHV-6). AHV-1 infection in
donkeys causes very similar skin lesions caused by EHV-3 infection of horses on keratinized
skin. Infected donkeys had erosive lesions on the muzzles and external genitalia as well as on the
udders [76, 77]. In spite of disease similarities caused by EHV-3 and AHV-1, the restriction
endonuclease and DNA hybridization analysis confirmed the distinct identity of AHV-1 [77].
1.4.2.2 AHV-2 Infection:
AHV-2 is a member of the subfamily gammaherpesvirinae and also tentatively known as
equine herpesvirus-7 (EHV-7) [42] . The virus has been isolated from the leucocytes of a
clinically normal donkey as well as also from nasal secretions of a mule [76, 78]. There is very
little information available on this virus but it is believed that AHV-2 is distantly similar to EHV2 and EHV-5 [76]. The characteristic disease symptoms caused by AHV-2 infections are not clear
and the virus yet needs to be unequivocally correlated with disease [76].
1.4.2.3 AHV-3 Infection:
Browning et al. isolated one alphaherpesvirus from the nasal cavity of donkeys after high
doses of corticosteroid treatment and the virus was named asinine herpesvirus-3 [76]. Although
the sequence analysis study of glycoprotein G gene of AHV-3 showed considerable similarities
(92% amino acid sequence similarity) with EHV-1, the restriction endonuclease fragment pattern
confirmed the virus to be a distinct member of alphaherpesvirinae subfamily and is also named
equid herpesvirus-8 (EHV-8) [76, 79, 80]. It is believed that donkeys are the primary hosts of
this virus, but horses can also be naturally infected with AHV-3 [80]. AHV-3 infection primarily
can cause afebrile rhinitis in donkeys but can also cause fever and rhinitis in horses [76, 80]. Like
other alphaherpesviruses, AHV-3 can also be latent and can recrudesce at any time [80]. AHV-3
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seronegative donkeys, when experimentally infected with the virus , showed afebrile rhinitis for 4
to 5 days, characterized by profuse serous nasal discharge which became mucopurulent later [76].
A complete genome sequence of a new strain of EHV-8, Wh by Liu et al revealed that the horse
strain of EHV-8 has eight nucleotide and two amino acid substitutions in the gG gene when
compared to other donkey strains of EHV-8 (AHV-3). Unlike EHV-1, AHV-3 has a restricted
host range and under laboratory conditions AHV-3 does not grow well in equine fetal kidney
(FEK) cells whereas EHV-1 grows rapidly producing high titers of infectious progeny virus [76].
Like EHV-1, AHV-3 also has 80 open reading frames which encode 76 unique proteins [80].

1.4.3 Gazelle Herpesvirus Infection:
While investigating the cause of death of eight Thomson’s gazelles from epizootic
encephalitis in a zoological garden in Japan, Fukushi et al. isolated a herpesvirus which was
serologically very similar to EHV-1 and EHV-4, and they named it Gazelle herpesvirus-1 (GHV1) [81]. Although, based on the nucleotide sequences of the conserved region of gB and gG
genes, the virus has about 95 per cent similarity with EHV-1 and EHV-8 and about 60 per cent
similarity with EHV-4, DNA fingerprinting proved its separate identity and hence, GHV-1 was
considered to be a new equine herpesvirus, equid herpesvirus-9 (EHV-9) [82]. In experimental
conditions it has been shown that dogs, cats, goats, cattle, horses, mice, hamsters, pigs and nonhuman primate common marmosets (Callithrix jacchus) could successfully be infected with
EHV-9 showing typical signs of fulminant encephalitis [82-84]. It is believed that equids
(domestic as well as wild) are the natural primary hosts of EHV-9, and natural infections have
been documented in equids such as Burchell’s zebras (Equus burchelli), Grevy’s zebras (Equus
grevyi) , Onagers, and other non-equid animals including cattle, deer, llamas, alpacas, gazelles,
giraffes, and polar bears (Ursus maritimus) [81, 84-88]. Although the reservoir of this virus is not
yet known completely, Burchell’s zebras and Grevy’s zebras have been shown to harbor the virus
[82, 84]. Compared to EHV-1, EHV-9 has a wide host range and unlike EHV-1, EHV-9 does not
cause encephalitis by vasculitis and hypoxic degeneration in adjacent neuronal tissues [82].
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Rather, cases of EHV-9 infections in wild equids and non-equids have shown that EHV-9 has
tropism for respiratory as well as neural tissues and the infection primarily causes nonsuppurative encephalitis characterized by neuronal degeneration with necrosis as well as
intranuclear inclusion bodies in neuronal cells [81, 82, 84, 87]. However, the severity of EHV-9
infection in domestic horses is mild and only limited to transient fever, interstitial pneumonia and
inapparent encephalitis [83].

1.5 Discovery of EHV-1
After the discovery of first virus, Tobacco Mosaic Virus in 1882, fifty years passed before
William Wallace Dimock and Philip Edwards in 1932 first described that other than bacteria,
different microorganisms could also cause epizootic abortion of mares [89]. In 1933 they first
noticed that no bacteria could be isolated from the aborted fetuses. It was further demonstrated
that bacteria-free tissue or body fluids from aborted fetuses could cause abortion in the pregnant
mares [90]. From that study Dimock and Edwards at Kentucky Agricultural Experiment Station,
University of Kentucky, Lexington, KY, concluded that a filterable agent was responsible for the
epizootic abortion storms of mares in Kentucky [89, 90]. Three years later in 1936 Dimock and
Edwards first documented few salient features that differentiated viral abortions from other
abortions caused by Streptococcus, Salmonella abortus-equi and they named this abortions as
‘equine viral abortions’ [91]. In 1940 findings of inclusion bodies in liver cells and lung epithelial
cells were considered to differentially diagnose ‘equine viral abortions’ from other abortions of
infectious and non-infectious origins [92]. In 1941 Manninger and Csontos in Hungary also
documented the same symptoms of viral abortions found in Kentucky along with additional
syndromes of respiratory diseases including mild fever [93]. Due to the respiratory symptoms
they first considered that ‘equine viral abortions’ were caused by ‘influenza’ virus [93]. Later, in
1942 Salyi described both macroscopic as well as microscopic lesions in aborted fetuses in
Hungary [94]. In the same year (1942), Dimock and Edwards also described the detailed clinical
features of the viral abortion and the gross pathological changes of aborted fetuses [95]. Since
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then, a number of animals including mice, guinea pigs, hamsters as well as different types cells
have been infected with EHV-1 under laboratory conditions to define the host range of this virus
[96-100]. In an experimental study by Doll et al it was shown that equine abortion virus from the
aborted fetuses can cause both respiratory disease and abortion in experimental mares [101]. Doll
et al named the ‘equine abortion virus’ as ‘equine rhinopneumonitis virus’ to differentiate it from
another virus, equine arteritis virus causing abortion [102, 103]. However, only in 1963 was the
virus visualized under electron microscope and determined to be a member of herpesvirus group
[34]. The rhinopneumonitis virus was then known as ‘equine herpesvirus type-1 (EHV-1)’.

1.6 Genome Organization Pattern of EHV-1:
After the complete genome sequencing of EHV-1 in 1992 by Telford et al information
regarding the genome organization has been available [64]. Like other herpesviruses, EHV-1 has
a linear dsDNA genome encapsidated in a thick-walled, spherical to pleomorphic, ~120 nm
diameter, icosahedral capsid with 162 capsomeres [104]. The genome is about 150.224 kbp in
length with an overall G+C content of 56.7 per cent and encodes 80 open reading frames (ORFs)
[64, 105]. The viral DNA consists of a long unique region (UL) of 112,870 bp length which is
flanked by two small inverted repeat sequences of 32 bp long, known as terminal repeats (TRL)
and internal repeats (IRL) (Figure 1.3) [64]. The UL region is covalently linked to a short unique
region (US) of 11,861 bp length which is also flanked by two large inverted repeat sequences of
12,714 bp lengths terminally and internally, known as terminal repeats (TRS) and internal repeats
(IRS) respectively [64].
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Figure 1.3: Genome Organization of EHV-1. The linear dsDNA genome of EHV-1 consists of
a unique long (UL) and a unique short (US) region of 112.87 kbp and 11.861 kbp respectively. UL
is flanked by a 32 bp long terminal repeats (TRL) and internal repeats (IRL) and US is also flanked
by terminal repeats (TRS) and internal repeats (IRS) of 12.714 kbp each. ORFs 64, 65, 66, 67 are
repeated inversely within the IRS and TRS and the two origin of replications (Oris) are located in
between ORF 64 and ORF 65. Another origin of replication (OriL) is located within UL regions
which encode ORFs 1 to 63. The US regions encode ORFs 68 to 76.

The US region of the genome can be oriented in two directions relative to the orientation of fixed
UL region and this makes the presence of two equimolar mixtures of different isomeric forms of
EHV-1 DNA [25].
The UL region encodes ORFs 1 to 63 and US region is predicted to encode ORFs 68 to 76
[64]. Four out of the eighty ORFs, ORF 64, ORF 65, ORF 66, and ORF 67 are duplicated
inversely in IRS and TRS regions and hence, EHV-1 is predicted to have at least 76 unique genes
[29, 64]. The ORFs are arranged compactly with little intervening sequences, without any
extensive ORF overlap and few occurrences of exon splicing [25]. Like other alphaherpesviruses,
the EHV-1 genome has 20 sets of short, tandemly reiterated DNA sequences, (8 in UL, 2 in US, 5
in each TRS and IRS) which are mostly present in the noncoding regions [29]. Beside the
significant homology in the genome organization patterns with other alphaherpesviruses like
HSV-1, VZV, pseudorabies virus (PrV) and BHV-1, EHV-1 is also assumed to have five unique
genes encoded by ORF 1, ORF 2, ORF 67, ORF 71 and ORF 75 which have not been found in
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any other herpesviruses to date [29]. Although the functions of these unique genes are unknown,
ORF-1 encoded protein, membrane protein UL56 with the help of other unidentified viral
protein(s) has been shown to down-regulate Major Histocompatibility Complex (MHC-I)
molecules [106]. These unique genes are believed to be the responsible factor(s) that make EHV1 distinct from other viruses of the same family [25].

1.7 EHV-1 Proteins:
EHV-1 has the capacity to encode 77 different types of proteins from 76 unique genes
because of the splicing of ORF64 [64]. The architecture of a purified EHV-1 virion is very
complex and comprises of at least thirty distinct polypeptides of which 6 polypeptides, encoded
by genes 22, 25, 35, 42, 43 and 56, form the nucleocapsid core. The tegument of the EHV-1
consists of a number of proteins encoded by genes 8, 11, 12, 13, 14, 15, 19, 23, 24, 40, 45, 46, 48,
49, 51 and 76 (table 1.1, 1.2, and 1.3). Most of these tegument proteins also take part in virion
morphogenesis, gene regulation and membrane fusion. The tegument proteins encoded by ORFs
19, 24 and 45 are also believed to degrade the host mRNA, help in capsid transport and in DNA
encapsidation, respectively [105, 108]. At least seven proteins encoded by the ORFs 22, 25, 35,
35.5, 37, 42, 43 and 56 are involved in the formation of the architecture of the core and the
nucleocapsid of the virion, of which the ORF 42 encoded major capsid protein is among the most
abundant proteins found in the EHV-1 virion [25, 105].
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Table 1.1: EHV-1 genes and their functionsϮ
EHV-1
GENE

START (Nt)

STOP
(Nt)

HSV
counterpart Gene Product

Functions

1

1298

1906

NA

Membrane protein UL56

Downregulate MHC-I expression,
vesicular trafficking

2

2562

1945

NA

Membrane protein VI

Unknown

3

2841

3614

NA

?

Unknown

4

4249

3647

UL55

Nuclear protein UL55

Unknown

5

5874

4462

UL54 (ICP27)

Multifunctional expression
regulator

Gene regulation, inhibits premRNA
splicing, post transcription
regulation of genes, exports viral
mRNA from nucleus

6

7042

6011

UL53

Glycoprotein K (gK)

Membrane fusion and virion
morphogenesis

7

10301

7056

UL52

DNA helicase-primase

DNA replication

8

10300

11037

UL51

Tegument protein UL51

Virion morphogenesis

9

12115

11135

UL50

Deoxyuridine triphosphatase

Nucleotide metabolism

10

12084

12386

UL49A

Glycoprotein N (gN)

Membrane fusion and virion
morphogenesis

11

12549

13463

UL49

Tegument protein VP22

Virion morphogenesis, possible
RNA transport in uninfected cells
Virion morphogenesis, gene
regulation by transactivating
immediate early genes

12

13595

14944

UL48

Transactivating tegument
protein VP16

13

15317

17932

UL47

Tegument protein VP13/14

Gene regulation by modulating
VP16

14

18083

20326

UL46

Tegument protein VP11/12

Gene regulation by modulating
VP16

15

21170

20487

UL45

Membrane protein UL45

Membrane fusion

16

22851

21445

UL44

Glycoprotein C (gC)

Binds to heperan sulphate for cell
attachment and also block
neutralization by binding to
complement factor c3b

17

24234

23029

UL43

Envelope protein UL43

Membrane fusion

18

25696

24479

UL42

DNA polymerase processivity
subunit

DNA replication

19

26262

27755

UL41

Tegument host shut-off protein

Cellular mRNA degradation

20

28859

27894

UL40

Ribonucleotide reductase
subunit 2

Nucleotide metabolism

21

31276

28904

UL39

Ribonucleotide reductase
subunit 1

Nucleotide metabolism

22

32916

31519

UL38

Capsid triplex subunit 1

Capsid morphogenesis

23

33292

UL37

36354 Tegument protein UL37

Virion morphogenesis

24

36588

46853

UL36

Tegument protein

Capsid transport

25

47311

46952

UL35

Capsid protein

Capsid morphogenesis and capsid
transport

26

48230

47403

UL34

Nuclear egress membrane
protein

Interacts with nuclear egress lamina
protein
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Table 1.2: EHV-1 genes and their functionsϮ (continued)
27

48791

48369

UL33

DNA packaging protein UL33

DNA encapsidation

28

48763

50625

UL32

DNA packaging protein UL32

DNA encapsidation and capsid
transport

29

50618

51598

UL31

Nuclear egress lamina protein

Interacts with nuclear egress
membrane protein

30

55184

51522

UL30

DNA polymerase catalytic
subunit

DNA replication

31

55453

59082

UL29

Single stranded DNA-binding
protein

DNA replication, gene regulation

32

59243

61570

UL28

DNA packaging terminase
subunit 2

DNA encapsidation

33

61432

64374

UL27

Glycoprotein B (gB)

Membrane fusion, cell entry, cellto-cell spread

34

64578

65060

NA

ProteinV32

35

67093

65153

UL26

Capsid maturation protease

Capsid morphogenesis

35.5

66142

65153

UL26.5

Capsid scaffold protein

Capsid morphogenesis

36

68975

67212

UL25

DNA packaging protein UL25

Possibly stabilizes the capsid and
retains the genome inside capsid

37

69897

69079

UL24

Nuclear protein UL24

Possible neuropathogenecity factor

38

69910

70968

UL23

Thymidine kinase

Nucleotide metabolism

39

71192

73738

UL22

Glycoprotein H (gH)

Cell entry and cell-to-cell spread of
virion

40

76224

74632

UL21

Tegument protein UL21

Virion morphogenesis, interacts
with microtubule

41

76793

77512

UL20

Envelope proteinUL20

Membrane fusion and virion
morphogenesis

42

77703

81832

UL19

Major capsid protein;

Capsid morphogenesis

43

82083

83027

UL18

Capsid triplex subunit 2

Capsid morphogenesis

44

84320

83148

UL15

DNA packaging terminase
subunit 1

DNA encapsidation

45

84480

86600

UL17

DNA packaging tegument
protein UL17

DNA encapsidation

46

86620

87732

UL16

Tegument protein UL16;

Possibly virion morphogenesis

47

88917

87886

NA

?

48

88947

89900

UL14

Tegument protein UL14

Virion morphogenesis

49

89369

91153

UL13

Tegument serine/threonine
protein kinase

Protein phosphorylation

50

91135

92832

UL12

Deoxyribonuclease

DNA processing

51

92784

93008

UL11

Myristylated tegument protein

Virion morphogenesis

52

94472

93120

UL10

Glycoprotein M (gM)

Virion morphogenesis and
membrane fusion

53

94390

97053

UL9

DNA replication origin-binding
protein

DNA replication

54

97069

99324

UL8

DNA helicase-primase subunit

DNA replication
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Table 1.3: EHV-1 genes and their functionsϮ (continued)
55

100332

99421

UL7

Tegument protein UL7

virion morphogenesis

56

102391

100130

UL6

Capsid portal protein

DNA encapsidation

57

102375

105020

UL5

DNA helicase-primase subunit

DNA replication

58

105070

105747

UL4

Nuclear protein UL4

59

106416

105877

NA

Protein V57

Possibly virion morphogenesis

60

107116

106478

UL3

Nuclear protein UL3

Unknown

61

108144

107206

UL2

Uracil-DNA glycosylase

DNA repair

62

108843

108147

UL1

Glycoprotein L (gL)

Cell entry, cell-to-cell spread

63
64

65

66

67

ᵮ

ᵮ

ᵮ

ᵮ

68

111985

110387

ICP0

Ubiquitin E3 ligase ICP0;

Proteasome mediated degradation
of cellular proteins like ND10, gene
regulation

118591

144569

ICP4

Transcriptional regulator ICP4 or
immediate early gene

gene regulation

114128

149032

121368

141792

US1

Regulatory protein ICP22

Gene regulation, expression of late
genes

122249

140911

122862

140298

US10

Virion protein US10

Unknown

123572

139588

125194

137966

NA

Virion protein V67

Colocalizes with nuclear lamin

124376

138784

126275

125019

US2

Virion protein US2

Interacts with cytokeratin 18
Nuclear egress, apoptosis and
protein ohosphorylation

69

126411

127559

US3

Serine/threonine protein kinase
US3

70

127681

128916

US4

Glycoprotein G (gG)

cell-to-cell spread of virion

71

129097

131490

US5

Glycoprotein J (gJ)

Unknown

72

131583

132791

US6

Glycoprotein D (gD)

Cell attachment

73

132899

134173

US7

Glycoprotein I (gI)

Cell-to-cell spread of virion

74

134406

136058

US8

Glycoprotein E (gE)

Cell-to-cell spread of virion

75

136055

136447

NA

Membrane protein US8A

Unknown

76

136783

137442

US9

Membrane protein US9

Axonal transport

Ϯ= Tables 1-3 are prepared on the basis of the data published in Allen et. al [25], Ma et. Al [106], Telford et. al [64],
Davison et. al [105] Kasem et. Al [107]. ᵮ= ORFs are duplicated in the US regions of the genome; NA= Not available.

The ORFs 6, 10, 16, 33, 39, 52, 62, 70, 71, 72, 73 and 74 encode envelope glycoprotein K
(gK), gN, gC, gB, gH, gM, gL, gG, gJ, gD, gI and gE respectively, homologues of which have
been identified in other alphaherpesviruss like HSV-1 [109-115]. These glycoproteins are
involved in different critical functions like attachment and entry of the virus into a cell, viral
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determinants of cell tropism, cell-to-cell spread, pathogenesis and immune responses [25, 109,
112]. However, EHV-1 also has three unique glycoproteins, gp2, gp10, and gp21/22a [110]. The
five glycoproteins, gB, gD, gH, gL and gK have been shown to be essential for viral replication
while some other glycoproteins including gC, gE, gG, gI, gM and gp300 have been found nonessential for viral replication but involved in virulence of the virus [25, 116]. Neubauer et al using
an EHV-1 mutant devoid of gB gene, have shown that gB is essential for the virus growth and
cell-to-cell spread [117] in viro. It has been suggested that gB plays a major role in the entry of
the virus by cell-to-cell fusion [118]. Monoclonal antibodies against gB protein have been shown
to prevent the typical alphaherpesviral syncytium or cell-to-cell fusion in vitro [119]. A number
of studies involving gB protein have documented its role as the most important immunogenic
protein of EHV-1 [120, 121]. gC, another transmembrane glycoprotein, is the major determinant
of virus attachment. gC of EHV-1 binds with the abundantly found glycosaminoglycans (GAG),
and heparan sulfate (HS) present on the host cell surface and this binding helps concentrate the
EHV-1 particles on the cell membrane which in turn potentiates the interaction with another
glycoprotein, gD [122, 123]. This interaction of gC with gD is followed by another interaction
with a specific cellular entry receptor that causes the stable attachment of the virus particle to the
host cell membrane [124]. gC of EHV-1 is a very immunogenic protein that has been shown to
induce high titers of neutralizing antibody and also cell mediated immune responses [125]. EHV1 gC can also bind to the complement factor, C3b and inactivate it eventually allowing the virus
to evade complement mediated lysis [126]. gD protein is absolutely necessary for the virus entry
as well as virus-induced cell-to-cell fusion [124]. Other glycoproteins, gH and gL, form a
heterodimer and gH is shown to be essential for direct fusion of the viral envelope with the host
cell membrane, virus entry and virus-induced cell-to-cell fusion [127, 128]. On the other hand,
the glycoprotein gE/gI complex is involved in the transmission of EHV-1 by cell-to-cell spread
within the same host [116].
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Like other herpesviruses, the gene expression pattern of EHV-1 is also temporally regulated
resulting in the sequential expression of immediate early (IE or α) gene first, followed by early
genes (E or β) and then the late genes (L or γ). Unlike HSV, EHV-1 has only one IE gene (ORF
64), the protein product of which is involved in the regulation of the expression of other genes of
EHV-1 [25, 129].
The gene products of ORFs 7, 9, 18, 20, 21, 27, 28, 30, 31, 32, 36, 44, 45, 50, 53, 54, 57 and
61 are either origin-binding proteins, DNA polymerase or DNA packaging proteins which are
involved in the replication and packaging of viral DNA [64, 105].

1.8 The Life Cycle of EHV-1:
EHV-1, during its life cycle, can undergo two different pathways- one for the lytic life cycle
and the other for latency. During the lytic stage of the life cycle, EHV-1 actively replicates within
the epithelial cells of the upper respiratory tract, endothelial cells of the blood vessels, and
leucocytes and as a result, the animal harboring the virus sheds EHV-1 through the nasal route
which can infect new horses [25]. New naive cells can be infected either by direct binding of
virus or by cell-to cell contact with infected cells [130]. The lytic replication cycle of EHV-1 is
depicted in the figure 1.4. After the attachment and entry into the cells, EHV-1 uncoats its
nucleocapsid which will be transported to nuclear pore complex. In the nucleus, the viral genes
are sequentially transcribed and eventually translated into different viral proteins, some of which
form new capsids. Once the genome replication is complete, new genomes are then encapsidated
within the nucleus and then transported into cytoplasm where the progeny virus is enveloped
from host cell membrane and buds out as progeny virion. The newly formed progeny virus can
infect new uninfected cells where it can either choose lytic replication cycle or latency.
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Progeny virus

EHV-1

Entry

Cytoplasm

Budding

Early Pr
Late Pr

IE Pr
NPC

Early mRNA

DNA
Replication

Nucleus

IE mRNA

New DNA

Viral gene expression and genome replication

Capsid Pr

Encapsidation

Figure 1.4: Lytic Life Cycle of EHV-1. EHV-1 enters into host cell by either direct membrane
fusion or endocytosis. After entry virus uncoats its nucleic acid in the cytoplasm which is then
transported to nucleus where viral gene expression starts. At the beginning IE gene (ORF64) will
be expressed, then IE (α) protein will help to express E (β) genes. IE (α) and E (β) proteins both
help in the expression of L (γ) genes. Viral genome replication starts within the nucleus
immediately after the translation of E (β) genes. Next, some of the L (γ) proteins will form the
capsid and the capsid assembly occurs within nucleus with the help of some chaperone proteins
like pre-VP22a. After the assembly of capsids, the viral DNA concatamers are cleaved into unit
length genomes by terminase enzyme with the additional help of pac1 and pac2 packaging
signals.The assembled virions will acquire an outer membrane from nucleus which is lost during
budding into cytoplasm where nucleocapsids acquire tegument proteins. Then it will get its
secondary envelope from cytoplasm or endosomic vesicle and will be transported into cell surface
and the nascent virus will be released by the fusion of vesicles with the plasma membrane.
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1.8.1 The Lytic Life Cycle of EHV-1:
1.8.1.1 Virus Attachment and Entry:
EHV-1 can enter into the host cells by two major pathways: either through the direct fusion
of the virus to the host cell membrane or through the cellular endocytosis or phagocytosis
pathways depending upon the cell types [131-133]. The first step in the entry process of EHV-1 is
the attachment to the host cell through receptor mediated binding. Multiple mechanisms and
proteins of EHV-1 are involved in the attachment with host cell membranes since deletion of one
particular protein cannot prevent virus attachment or replication completely [132, 134]. The
initial EHV-1 particle attachment occurs through the interaction of gB and gC and host cell GAG
proteoglycans. Glycoprotein C and also gB bind reversibly with heparan sulfate (HS),
ubiquitously present on the mammalian cell surface [123, 134]. Osterrieder et al using a gC
deletion mutant EHV-1 has shown that the virus can attach, enter and replicate both in non-equine
cells (RK-13) and primary equine cells in the absence of gC although the titer of the virus is
reduced to 5-10 fold for non-equine and 48-210 fold for primary equine cells [134]. A Study by
Sugahara et al [123] has shown that mutation in gC gives the protein increased affinity towards
HS and helps EHV-1 to adapt to different non-equine cells also. After the labile initial
attachment, gD binds to specific cell-surface receptors which causes a conformational change
allowing gD to interact with gH/gL and also gB, and this complex interaction makes the virus
attachment stable and triggers the viral fusion with the host cell membrane [124]. gD of
alphaherpesviruses has been shown to be indispensable for virus entry for HSV-1, PrV, and BHV
but not for Marek’s disease virus or VZV which do not encode a gD homologue [135-139]. By
studies involving CHO cells expressing EHV-1 gD or studies using monoclonal antibody against
EHV-1 gD, or using a gD deletion mutant of EHV-1 it has been shown that gD is essential both
for virus attachment and entry as well as for cell-to-cell fusion [124, 140, 141]. Unlike HSV-1,
no specific receptor for gD of EHV-1 has been identified to date; although it is postulated that
there is a novel entry receptor for EHV-1 gD other than HveA, HveB and HveC [142]. The
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protein gH or gH/gL heterodimer also plays a major role in the entry and spread of EHV-1 from
one infected to uninfected cells by cell-to-cell fusion and seems to be conserved among
alphaherpesviruses [127].
Beside the classical pathway of entry by membrane fusion, EHV-1 also enters into certain
cell types by endocytosis [132]. After the initial findings by Frampton Jr. et al studies by van de
Walle et al have documented that EHV-1 can utilize cellular integrins such as αVβ5 with the
ability to recognize the RSD motif [131, 132]. The interaction between the RSD motif present in
gD of EHV-1 and cellular integrins like αVβ5 triggers the endocytosis of EHV-1 [131]. It has
also been shown that EHV-1 enters into cells like PBMCs mainly by endocytic/phagocytic
pathways while the virus enters into the endothelial cells by direct membrane fusion [131].
1.8.1.2 Transport of EHV-1 Capsid to the Nucleus:
Following membrane fusion the de-enveloped virion particles are deposited in the cytosol.
In the case of endocytosis, the membrane of virion envelope fuses with the endosomal membrane
inside the cell and eventually the naked capsids are released into the cytoplasm [143]. During
this time some tegument proteins are dissociated from the capsid [14] and then the nucleocapsids
are transported into the nucleus of the cell through the nuclear pore complex (NPC) [143]. This
intracellular trafficking of viral nucleocapsids is achieved by the help of microtubules which are α
and β dimers of tubulins with a structural orientation of positive end towards the periphery of the
cell and the negative end towards the microtubule organizing center (MTOC) close to the nucleus
[143-145]. EHV-1 nucleocapsid and some tegument proteins will be transported into the nucleus
by the minus-end directed motor protein, dynein, along the microtubule. As has been shown by
Frampton Jr. et al that in the presence of dynein inhibitor but not kinesin inhibitor, the EHV-1
replication is severely compromised [143]. EHV-1 triggers the acetylation of microtubules which
causes its stabilization which is a primary requisite for dynein to transport the virion particles
[143].
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Whether by membrane fusion or endocytosis, in both cases, the cellular kinase Rho
associated coiled-coil kinase 1 (ROCK-1) must be activated for the effective intracellular
trafficking of nucleocapsid [132, 143] as inhibitors of ROCK-1 were shown to prevent the
nuclear transport of capsid [143]. It is assumed that ROCK-1 will either mediate the interaction
between virus and microtubules and/or other cytoskeletal components, or it can aid in the fusion
of viral envelope with cellular membrane [143]. Once the nucleocapsids reach the NPC, a
conformational change in NPC will allow the translocation of the viral genome as a densely
packaged, rod shaped structure into the nucleoplasm through the dilated NPC [14, 130] and the
empty capsids are then dissociated from NPCs and the genome transcription starts [146].
1.8.1.3 Expression of Viral Genes and Biosynthesis of Proteins:
Once the viral genome is in the nucleus of the host cell, the expression of EHV-1 genes,
DNA replication, capsid assembly and DNA packaging will occur. As discussed earlier,
expression of EHV-1 genes is temporally regulated and tightly coordinated. At the beginning, the
IE (α) gene is expressed which triggers the expression of the E (β) genes, followed by L (γ) genes
[129]. Six different regulatory proteins that control this cascade of gene expression are EHV-1 IE
protein, EHV-1 infected cell protein 0 (EICP0), EICP22 or also known as IR4, EICP27, IR2
protein (splice variants of IE gene) and EHV-1 α-gene transinducing factor (ETIF or VP16) [147152]. ETIF, the protein product of ORF12, is the only EHV-1 tegument associated late protein
(γ2) that can transactivate the sole IE gene (ORF64) transcription without the help of any other
proteins and this incident will trigger the EHV-1 gene transcription cascade. In HSV-1 the ETIF
homologue α-TIF (VP16) with the help of a protein, host cell factor, interacts with the cellular
transcription factor Oct-1 bound to the consensus sequence TAATGARAT (R= purine motif)
present in the promoter regions of all the IE genes. A similar consensus sequence is also located
within the EHV-1 IE promoter [147]. ETIF interacts with transcription factors TFIIB and
dTAF40 and the interaction may form a preinitiation complex that starts the transcription of
EHV-1 IE gene [147]. Structural analysis has shown that the IE protein has several domains
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essential for the transactivation of viral genes such as acidic transcriptional activation domain, a
serine rich tract that binds to the cellular EAP, nuclear localization signal and a DNA binding
domain [152]. Once the IE (α) gene is expressed, it transactivates the promoters of the early genes
EICP22 and EICP27 and enhances their transcription. EICP22 and EICP27 then synergistically
transactivate the expression of IE promoter and the gene products of all these 3 proteins together
synergistically transactivate the promoters of other early genes resulting in their enhanced
transcription [150, 151]. The IE protein together with either EICP22 or EICP27 can transactivate
the promoters of E (β) as well as L (γ) genes of EHV-1 [151]. The IE protein cannot transactivate
the promoter of any of the late genes (γ1 or γ2) independently including the ETIF gene [147]. In
contrast, EICP0 is a potent transactivator of all classes (α, β, and γ) of EHV-1 promoter and can
strongly transactivate the promoter of ETIF gene too [149]. Surprisingly, the IE protein will
repress the transactivation property of EICP0 genes [149, 153].

EICP0 and EICP27

synergistically can also transactivate the promoters of early and γ1 late genes while EICP0 and
EICP22 transactivate γ2 gene promoters [149].
The IE (α) gene, however, trans-represses its own expression through the consensus IE
protein binding site (5’-ATCGT-3’) near to the TATA box and transcription initiation site [154].
On the other hand, the IR2 protein which is a truncated form of IE protein (amino acid 323 to
1487) binds with the promoter regions of IE, EICP0, EICP22, EICP27, thymidine kinase and late
IR5 genes through the interaction with the transcription factor TATA box-binding protein (TBP)
and represses the transcription of those viral genes [152].
1.8.1.4 Replication of Viral Nucleic Acid:
From the work done with other alphaherpesviruses like HSV-1, it is known that once the
early proteins are synthesized, viral DNA replication will be started with the help of at least seven
early proteins including the gene products of UL5, UL8, UL9, UL29, UL30, UL42 and UL52
[105, 155, 156]. In fact, the late genes are only produced in appreciable amount after a few
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rounds of viral DNA replication [14]. After the viral DNA is deposited into the nucleus, it
becomes circularized by DNA ligase IV/XRCC4 [104]. Simultaneously, some of the newly
translated E (β) proteins which are essential for

Figure 1.5: Model for HSV-1 DNA Replication: In the nucleus, the linear genome is
circularized by DNA ligase IV/XRCC4 and the circular DNA serves as template for the viral
replication machinery. At the beginning theta-type replication is initiated at three redundant
origins of replication oriS and oriL and later proceeds towards the rolling circle replication
generating concatameric head-to-tail DNA. Lower figure shows the HSV-1 replication fork. The
figure is adapted from Muylaert et al [156] with permission.
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viral DNA replication, will bind to the template DNA to form the replication machinery and
initiate the DNA replication which continues on a rolling circle mechanism (Figure 1.5) resulting
in head-to-tail concatamers of viral DNA [157]. Although the mechanism of EHV-1 DNA
replication is not well studied, the analogous process of HSV-1 DNA replication has been
deciphered in much detail.
The viral DNA has 3 origins of replication, one in UL and two in US regions (Figure 1.3). It
is generally believed that at the beginning there will be bidirectional theta type of replication
which makes circular daughter DNA that eventually undergoes rolling circle type of DNA
replication, creating concatameric viral DNA [158]. The origin binding protein (product of UL9)
will recognize, bind and activate the origins of replication, OriS and OriL, and unwind the viral
DNA and this triggers other proteins to form a replisome consisting of DNA polymerase (protein
product of UL30 and UL42), trimeric helicase-primase (protein product of UL5, UL8 and UL52)
and ssDNA binding protein (protein product of UL29) [155, 159]. Besides the viral proteins,
many host proteins and enzymes including DNA polymerase α-primase, DNA ligase, and
topoisomerase II also play important roles in this process. The newly formed head-to-tail
concatamers will later be cleaved to be packaged into individual capsids [159].
1.8.1.5 Assembly of Capsid and Encapsidation of Viral DNA:
The capsid assembly process in HSV-1, EHV-1 and even in cytomegalovirus is very similar
[104] and takes place in the nucleus of the host cell [155]. The process starts only after the
replication of viral DNA and synthesis of new capsid proteins and it is initiated by the
oligomerization of the major capsid protein VP5.
Most of the proteins involved in the process are translocated into the nucleus themselves but VP5,
VP23, VP26 require the additional help of other proteins such as VP19C or scaffolding protein
pre-VP22a [155]. The capsid assembly continues as the oligomers of VP5 and pre-VP22a
interact each other and to the edges of the growing capsid which is secured by VP23 [159]. Once
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the viral DNA is packaged, the VP5-pre-VP22a complex is lost and then VP19C and VP23
proteins interact with each other to form partial capsids [155]. The triplex structures consisting of
one molecule of VP19C and two molecules of VP23 link the individual capsomeres [155, 160].
Twelve copies of UL6 proteins forming the portal complex are added to the nascent capsid chain
which becomes closed to form the procapsid [158, 160]. A series of structural transformations
will lead to the maturation of procapsid into capsid [161]. After the assembly of capsids, the viral
DNA concatamers are cleaved into unit length genomes by terminase enzyme with the additional
help of pac1 and pac2 packaging signals [162, 163]. The viral protease cleaves and removes the
scaffolding proteins VP21 and VP22a from inside the capsid and replaces them with newly
replicated DNA genome [161]. Several other proteins such as UL6, UL15, UL17, UL28, UL32,
UL33, UL36 and UL37 have also been implicated in the process of encapsidation of viral DNA
[164-166].
1.8.1.6 Egress:
After the encapsidation of the viral DNA, the nucleocapsids then undergo the process of
egress by the ‘envelopment-deenvelopment-reenvelopment pathways’ [167]. The newly formed
nucleocapsids will acquire primary envelope from the inner leaflet of the nuclear membrane and
bud out (Figure 1.6). The protein products of two conserved herpesvirus genes, UL31 and UL34,
genes have been shown to be involved in primary envelopment [168]. Eventually the primary
envelope will be lost (deenvelopment) and the nucleocapsids then move to the cytoplasm where
they acquire the tegument [169]. Herpesviruses like HSV-1 have at least 15 different types of
tegument proteins while VZV or CMV has been reported to have more than 15 tegument proteins
[169]. Tegument proteins UL36 and UL37 play a major role in the maturation of the virion as the
absence of those proteins abolishes the formation of the mature virion and its subsequent egress
[169]. UL36 protein interacts with the major capsid protein, UL19 and forms the first layer of
tegument around the icosahedral capsids [167, 169]. UL36 protein also interacts physically with
UL37 protein which forms the second layer of tegument [169, 170]. The tegument protein UL48
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(α-TIF) interacts with other proteins like UL41 and UL49 directly and also interacts with gB, gD,
gH directly or indirectly [169]. The absence of UL48 severely impairs the tegumentation and
affects

virion

morphogenesis

downstream

from

envelopment

and

probably

in

the

Figure 1.6: Summary of the Herpesvirus Egress Pathway. In the nucleus, the newly
synthesized herpesviral nucleocapsids will acquire primary envelopment by budding through the
inner nuclear membrane and then capsids will undergo de-envelopment during its translocation
towards cytoplasm where tegumentation occurs. Following to this, final envelopment occurs both
in the cytoplasm or vesices derived from trans-Golgi network (TGN) and at the endosome and
eventually be transported to cell surface and the mature virions will bud out of the plasma
membrane. The diagram is adapted from Mattenleiter [169] with permission.
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virus assembly in cytoplasm [169, 171]. Von Einem et al have shown that ETIF, the HSV-1
UL48 homologue in EHV-1 has an indispensable role in the replication cycle of EHV-1 and
besides its IE-gene transactivating property, it is also involved in secondary envelopment of the
virion [171]. Although some tegument proteins are indispensable for the virus maturation, it has
been noted that virion morphogenesis continues even in the absence of tegument proteins such as
UL13, US3, UL41, UL46, UL47, and UL49 [169].
After the final tegumentation in the cytoplasm, the nucleocapsids will acquire the secondary
envelope through protein-protein interactions occurring both in the cytoplasm or cytoplasmic
vesicles derived from the trans-Golgi network (TGN) as well as at the endosomal network (Figure
1.6) [167, 172]. The nascent virions are transported to the cell surface by utilizing the cellular
transport machinery and released by the fusion of vesicles with the plasma membrane (Fig 1.6)
[172].

1.8.2 The Latent Life Cycle of EHV-1:
The initial lytic replication of EHV-1 in the respiratory epithelium of horses after the
primary infection is followed by the onset of the latent stage of infection in which infected horses
show no clinical signs of disease, virus shedding or cell associated viremia [25, 130]. Although
the specific site of EHV-1 latency is not clear, it has been observed that the virus can remain
latent in the sensory nerve-cell bodies of the trigeminal ganglia and also in lymphocytes, both in
peripherally circulating lymphocytes as well as in lymphocytes found in draining lymph nodes
[173-177]. The principal sub-population of the lymphocytes that can harbor latent EHV-1 are
CD5+/CD8+ T lymphocytes (>80%) though a smaller sub-population of CD5+/CD8-/CD4- T
lymphocytes (20%) can also support latency of EHV-1 [178].
It is not clear what factors drive EHV-1 to enter into the latent cycle from the lytic one or
what mechanisms actually control latency. It is, however, known that absence or interference in
the activation of α-genes by VP16 protein can be related to the latency of HSV-1 [179]. Like
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other alphaherpesviruses, the transcription of the EHV-1 genome during the latent infection is
restricted, and only latency associated transcript (LAT) mRNA which is antisense to either the
regulatory β-gene ORF 63 or the α-gene ORF 64 is transcribed. Because none of the viral proteins
are expressed, the latently infected host cells escape immune surveillance and clearance [25, 130].
However, the latent horses become carriers for their lifetimes. These are potential reservoirs
of infection in which the viral lytic cycle can be reactivated at any time when given favorable
conditions like stress [16, 25]. It has been reported that in the field, stress induced by weaning,
transportation, re-housing, infection by other viruses like EHV-2, or corticosteroid treatments
have caused the reactivation of the EHV-1 from latency [25, 173, 176, 180]. Smith et al. have
shown that treatment with interleukin-2 (IL-2) or gonadotropin causes the reactivation of latent
EHV-1 from CD5+/CD8+ T lymphocytes through an indirect stimulation [178]. Viral factors also
may play a major role in the reactivation process. A mutant EHV-1 devoid of thymidine kinase
gene (TK-) was shown to possess impaired reactivation capacity although the same mutant virus
can achieve latency under experimental conditions [176]. During the reactivation process, the
latent EHV-1 genome in a small subset of lymphocytes starts active transcription resulting in the
expression of fusogenic viral glycoproteins on the cell surface, then cells undergo the transition
from latency towards the active lytic replication cycle [181]. However, for the assembly and
egress of infectious progeny virus following reactivation, lymphocytes carrying latent EHV-1
require fusion with permissive cells like endothelial cells [25]. Reactivation of latent EHV-1 from
lymphocytes or trigeminal ganglia may cause infectious virus to reach the nasopharyngeal
epithelium and result in viremia, abortion, or neurologic disease [25]. It is noteworthy that horses
with reactivated virus may become silent virus shedders as reactivation often fails to cause
apparent clinical signs of respiratory disease [25]. The cycle of latency and reactivation contribute
importantly to the epidemiology of EHV-1 abortions since a majority of natural EHV-1 abortion
have been documented even weeks or months after the cell-associated viremia ceases [25].
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1.9 Epidemiology and Transmission:
EHV-1 infection is ubiquitous in nature among equids around the world and about 80-90%
of horses have been estimated to get infected in the first two years of their life by either EHV-1 or
its close relative EHV-4 [16]. Young horses and horses with compromised immune systems are
more susceptible to EHV-1 infection [63]. Because of the capacity of EHV-1 to become latent,
horses recover from the primary infection but become carriers for their lifetime and frequently
shed infectious virus which helps to maintain the uninterrupted transmission cycle of EHV-1 to
other susceptible animals [25, 63]. More than 80 million horses around the world have latent
EHV-1 infection, which are the principal reservoir of infection and maintain the epidemiology of
EHV-1 infection [25]. Studies reveal that about 54% of central Kentucky broodmares carry latent
EHV-1 infection [182]. Although environmental contamination can cause indirect transmission,
the environment may not be the principal reservoir since the virus is unable to survive even 35
days in the environment outside horse body [130].
EHV-1 is a highly contagious virus and it can be transmitted from one infected animal to
others either by direct contact or indirectly [63]. Contact with virus-shedding horses with either
acute infection or reactivated EHV-1 infection from latency, or virus-laden aborted fetuses or
placenta are probably the major routes of EHV-1 transmission [63]. After contact of the horses
with virus containing respiratory secretions, fomites or aerosols, the virus enters into the host
initially through the upper respiratory tract epithelial cells [16, 25]. Naïve horses when exposed to
EHV-1 infection shed virus from the respiratory mucosa for longer durations (as long as 15 days)
compared to horses with experience of prior exposure or horses with reactivated EHV-1 from
latency (2 to 3 days) [183, 184]. It is also documented that semen could be a source of EHV-1
infection and the virus may be transmitted via the semen during mating or through artificial
insemination [185]. Most foals may get the infection for the first time during their first year of
life, either before or after weaning [25]. EHV-1 infection has even been documented from foals
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as young as 22 days old [186]. Unweaned foals probably get the infection from the reactivation of
latent EHV-1 in their dams [25].

1.10 Pathogenesis and Clinical Signs:
1.10.1 Respiratory Disease:
The incubation period of the respiratory form of EHV-1 disease is very short, usually 1 to 3
days. It can be up to 10 days depending on the strain of virus, infecting dosage and immune
condition of the host [25, 183, 187]. In the absence of mucosal antibody EHV-1 first infects and
replicates in the nasal and nasopharyngeal epithelial cells although the conjunctival epithelium
can also be infected after the direct contact with aerosol [25, 188]. In the case of intranasal
experimental infection, virus can be detected in the infected epithelial cells of the nasopharynx,
trachea and bronchi as early as 12 hours post infection [25, 189]. Subsequently, rounds of lytic
replication of the virus cause the necrosis of the epithelial cells resulting in the formation of
multiple erosions in the nasopharyngeal mucosa. These will cause the shedding of infectious virus
in the first week of infection [25, 130]. Shortly the virus infection reaches to the underlying layer
of lamina propria and infects the mononuclear leucocytes, which are drained into the draining
lymph nodes where the virus is amplified by more rounds of lytic replication [189]. These
infected leucocytes are transported to the circulatory system resulting in a cell-associated viremia
that spreads the virus to the endothelial lining of the pregnant uterus as well as the central nervous
system (CNS) causing abortion and neurologic disease, respectively [63, 190]. The identity of the
sub-populations of the leucocytes that support the replication of EHV-1 during the cell-associated
viremia is controversial [130]. Although primarily CD5+/CD8+ T lymphocytes are involved with
viremia, EHV-1 DNA has been identified in CD4+ T lymphocytes, monocytes, and B cells during
the acute phase of viremia [25, 130]. The cell-associated viremia, which is a prerequisite for
abortion, develops as early as 3 days post infection and can linger up to 22 days [25, 63].
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Figure 1.7: EHV-1 Pathogenesis. EHV-1 enters through the respiratory tract. It replicates in the
respiratory epithelium and spreads to lamina propria where it infects lymphocytes and other
immune cells. Infected cells are drained into lymph nodes where the virus is amplified by more
rounds of replication. Infected cells then enter into the circulation causing viremia through which
virus reaches to the blood vessels of uterus, brain and spinal cord where the virus replicates and
causes inflammatory pathology resulting in abortion and EHM.

The magnitude of EHV-1 viremia ranges from 1 in 104 to 1 in 107 infected leucocytes in horse
blood [63, 191]. However, in the case of the nasal and conjunctival routes of infection, the virus
will disseminate to the trigeminal ganglion within 48 hours of primary infection [176]. Within 213 days post infection the virus can be detected in pulmonary leucocytes, epithelial and
endothelial cells [189].
EHV-1 and EHV-4 infections principally cause disease of the upper respiratory tract which
include rhinopharyngitis and tracheobronchitis, although infection with EHV-1 can also result in
severe sequelae such as abortion, neonatal death, pulmonary vasculitis, ocular disease or
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neurologic disease [25]. Often the respiratory form of disease may be asymptomatic especially in
older horses with previous exposure to the virus or in the case of reactivation from latency [63].
In foals, EHV-1 infection involves bronchi and lungs making them vulnerable to secondary
bacterial pneumonia [16]. In young horses, the clinical signs include depression, anorexia, fever,
coughing, and initial bilateral nasal discharge. This is serous for first 2-3 days of infection and
then becomes mucopurulent with desquamated respiratory cells along with inflammatory cells, as
the condition progresses towards secondary bacterial infection [25, 63, 183]. In experimental
infections with the AB4 strain of EHV-1, foals showed a biphasic fever (39-42 ºC) with one peak
at 1-2 days post infection and another at 6-7 days post infection [183]. Other clinical signs
include neutropenia, lymphopenia, and progressive lymphadenopathy of submandibular lymph
nodes as well as of retropharyngeal lymph nodes [192]. When the virus reaches the lower
respiratory tract, the infected foals show the signs of bronchopneumonia [130]. The horse’s
immune system eliminates the virus from the respiratory tract within three weeks of the primary
infection and one to two weeks of the subsequent infection or after reactivation from latency
[183]. Even after clearing the infection from the respiratory tract, horses may develop some nonspecific symptoms like bronchial hypersensitivity, chronic obstructive pulmonary disease
syndrome or compromised athletic performance which is known as the ‘poor performance
syndrome’ [16, 183, 193].

1.10.2 Abortion, Neonatal Diseases and Diseases of Stallions:
Abortion caused by EHV-1 is the most common type of infectious abortion in horses and it
is estimated to be about 10% of all diagnosed abortions in thoroughbreds [194]. When viremia is
established and the virus reaches to the gravid uterus, it infects the endothelial cells of the small
arteriolar branches in the glandular layer of the endometrium at the base of microcotyledons,
resulting in multifocal vasculitis [195]. The inflammation in the affected blood-vessels leads to
thrombosis which further causes ischemic necrosis of the overlying microcotyledons and
intercotyledonary stroma followed by the anoxic death of the fetuses leading to its expulsion
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[195, 196]. The necrosis of the microcotyledons of the placenta sometimes causes the premature
separation of the placenta which thereafter is expelled. In some cases, fetuses may be born alive
even after the expulsion of placenta but shortly become affected with interstitial pneumonia
[197]. In most cases of EHV-1 induced abortions, virus can be isolated from the aborted fetuses,
yet, in some experimental abortions induced by EHV-1, the virus could not be isolated from the
fetuses [198-200]. Virus is consistently isolated from the endothelial cells of the aborted fetuses,
for which reason endothelial cells are thought to be the primary cells spreading EHV-1 to the
adjacent parenchymal cells [25]. The pathogenesis and the severity of the disease (abortion)
depends on a number of factors like the level of viremia, the strain of virus, immune status of the
animal and some host factors such as hormones. It has been shown by Mumford et al and others
that virulent strains of EHV-1, such as AB4 or Army 183 strains cause higher abortion rates
compared to less-virulent strains like V592 [201]. Even one neurovirulent strain, OH-03 or
Findley strain of EHV-1 produced a lower abortion rate when compared with AB4 (another
neurovirulent strain) in an intranasal experimental infection [202]. On the other hand, host factors
like prostaglandin hormone which is secreted at the uteroplacental interface are assumed to play
roles to initiate the abortion [25].
EHV-1 infected mares may abort without any previous symptoms within 9 days to 4 months
of infection although most abort within 21 days after infection [203]. EHV-1 induced abortions
could be sporadic as well as epidemic. The majority of the EHV-1 induced abortions occur in late
gestation usually during the last 4 months [204]. Normally the abortions do not compromise the
mare’s future reproductive capability and the mares can become pregnant very soon after the
abortion [63, 205]. Foals can be infected either within the uterus of the mare or can get the
infections from their mothers just after they are born but both the cases lead to pneumonia,
respiratory failure and death [206, 207]. Foals also suffer from gastrointestinal disease and
neurological signs [207]. Treatment is usually not effective against the foetal EHV-1 infections
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and most of the foals succumb to respiratory infection followed by secondary bacterial infection
[208].
Although not well-studied, the reproductive ability of stallions could also be compromised
by EHV-1 infections. Stallions have been reported to suffer from scrotal edema and loss of libido
[209, 210]. Tearle et al have documented that stallions experimentally infected with EHV-1
showed a significant number of morphologically abnormal sperm cells and there was also
evidence of shedding of infectious virus into the semen [211].

1.10.3 Neurologic Disease:
Although sporadic in nature the neurologic form of EHV-1 disease or equine herpesvirus
myeloencephalopathy (EHM) is the most severe form of the infection. However, there has been
an increase in the number of cases of EHM in recent years as has been documented in recent
outbreaks in riding schools, racetracks as well as veterinary hospitals all over North America and
Europe. This has caused the USDA-APHIS to list this disease as an emerging infectious disease
[212, 213]. Unlike pathologies caused by other alphaherpesviruses like HSV-1, EHV-1 induced
neurologic disease is developed as a result of the vasculitis of the blood vessels of the CNS. After
the entry of the virus, and subsequent development of viremia, EHV-1 reaches to the different
systems including the CNS where the virus establishes infection of endothelial cells of the
arterioles of the brain and spinal cord. This causes an acute inflammatory response resulting in
swelling, infiltration of inflammatory cells including lymphocytes releasing different types of
cytokines such as tumor necrosis factor (TNF) with resulting tissue damage, deposition of
immune complexes and formation of thrombi within the blood vessels. The vasculitis and thrombi
lead to hypoxic degeneration and malacia of the surrounding nervous tissues of both the white
and the grey matter with multifocal hemorrhages. The damage to the neural tissues also impairs
blood flow and nutrient supply to the surrounding nervous tissues of the spinal cord and brain,
aggravating the hypoxic degeneration leading to the death of neural cells. Although EHV-1 is an
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endotheliotropic virus, it has also been occasionally isolated from the neural tissues of EHV-1
infected horses.
Outbreaks of EHM can occur as a squeal to respiratory disease or abortion or it can occur
without the horse showing the signs of respiratory disease or abortion [214, 215]. There are
probably multiple factors contributing to the development of EHM. Host factors like immune
status of the animal, or vaccination frequency, virus factors like the strain of virus, and also
environmental factors have been reported to influence the development of EHM. Although
previously it appeared to be primarily a disease of pregnant and lactating mares, recent reports
suggested that the disease can affect horses of any age or sex as has been evidenced by reports of
outbreaks of EHM in foals, yearlings, geldings, mares and stallions [63].Younger foals can
develop the disease but older horses are more prone to develop EHM [216]. Allen (2008) reported
that in an experimental study older horses (>20 years of age) with reduced frequency of cytotoxic
T-lymphocyte (CTL) precursors were more susceptible to the development of EHM [217]. Some
researchers also suggested that the season may also influence horses to develop EHM as most
EHM outbreaks were reported to occur during late autumn, winter and spring [216]. A recent
study by Nugent et al has linked a single point mutation from the nucleotide adenine (A) to
guanine (G) in the DNA-polymerase gene of EHV-1 encoded by ORF30 at position 2254
(ORF30; A2254→G2254) to EHM [218]. This mutation changes the amino acid asparagine (N)
to aspartic acid (D) at position 752 (N752→D752) of EHV-1 DNA-polymerase protein and this
mutation enables the virus to cause high titer-viremia and develop EHM in horses [218]. It is
interesting to note that EHV-1 with A2254 also has been reported to cause EHM in several cases
while in other cases EHV-1 with G2254 has not produced any neurologic sign [219-221].
Moreover, a study by Kasem et al has suggested that the UL24 gene encoded by ORF37 is a
determining factor for development of neurologic disease in a mouse encephalitis model [107].
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These contradictory findings suggest that a single viral factor may not be responsible for
development of EHM; rather, the disease is a multifactorial one.
The onset of neurologic signs of EHM starts within 6-10 days after the beginning of the
respiratory tract infection; however, signs of EHM may appear as early as 24 hours following the
onset of fever. Clinical signs may vary and are dependent on the location and severity of the
lesions in the CNS [222]. The signs reach at peak within 48-72 hours after the onset of the
symptoms of EHM [25]. Usually there is high fever (41.1 ºC) before appearance of the signs of
the neurologic disorder such as temporary ataxia, proprioceptive deficiency, stiffness and
weakness of the limbs, swaying, stumbling and falling or complete paralysis [14, 25]. Although
paralysis of the hind limbs is usually seen, quadriplegia has also been frequently reported.
Normally the recumbency as a result of paralysis occurs within the first 24 hours of the onset of
the symptoms of hind limb paralysis. Horses tilt their heads, and lose the sensation and sensory
reflexes in the perineal area, inguinal areas and hind limbs although the appetite may remain
normal [214].Due to bladder dysfunction there may be urinary incontinence or retention of urine
and signs of vulvar or penile flaccidity with cystitis are also reported. Horses will be severely
depressed and the recovery time varies from several days to 18 months depending on the severity
of the neurologic symptoms [215]. In the United States, the morbidity rate related to EHV-1
infection causing EHM ranges from 1% to 90% whereas the case-fatality rate ranges from 0.5%
to as high as 40% [222].
Prognosis for the non-recumbent horses may be good but horses recumbent for more than
48 hours usually develop fatal complications like pneumonia, colic or bladder rupture, and
eventually die in coma or convulsion [25, 222]. In some cases, however, severely recumbent
horses also recover and the recurrence of the signs of neurologic disease from the recovered
horses has not been reported [222].
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1.10.4 Ocular Disease:
Hypervirulent strains of EHV-1 infection in foals may sometimes cause serious ocular
disease, primarily chorioretinitis resulting in the visual impairment [223]. Within 3-5 weeks after
respiratory tract infection by EHV-1, foals show the chorioretinal lesions which may be focal,
multifocal, or diffuse [25]. Uveitis may also be seen in some foals after the outbreak of EHM
[210]. Some reports also suggest that severe ocular infection can cause extensive retinal
destruction leading to blindness [223]. Evidences suggest that diffuse retinal lesions can cause
blindness while focal and multifocal lesions do not compromise the vision greatly [25].

1.11 Laboratory Diagnosis:
For the proper control of the disease, diagnosis at an early stage is of paramount importance. A
physical examination of the infected horses for the clinical signs along with proper history is very
important in the diagnosis of EHV-1 infection [16]. The respiratory form of the infection can be
diagnosed at a laboratory by virus isolation on a number of EHV-1 sensitive cell lines such as
rabbit kidney 13 (RK-13) cells, or baby hamster kidney cells (BHK) [214]. The level of EHV-1
specific serum antibody can be evaluated by enzyme linked immunosorbent assay (ELISA), or by
the serum neutralization test. Development of an EHV-1 specific ELISA which can distinguish
EHV-4 from EHV-1 has been very useful in the diagnosis of EHV-1 infection [224]. The most
sensitive diagnostic tool for the diagnosis of EHV-1 is probably the real-time RT-PCR. Recently
multiple real-time PCR assays have been developed not only to diagnose specifically EHV-1 but
also to differentiate between neuropathogenic and non-neuropathogenic strains of EHV-1 on the
basis of the presence of ‘G’ or ‘A’ nucleotide at 2254 position in DNA polymerase gene [225,
226]. Another important tool to diagnose EHV-1 is by immunofluorescence assay by using EHV1 specific monoclonal antibodies [16]. After necropsy, immunohistochemical staining of paraffin
embedded tissues is done to confirm the diagnosis of EHV-1 abortion as well as EHM cases
[214]. Although the diagnosis of EHM is more difficult, a proper physical examination for the
presence of neurological signs along with the history often helps tremendously. Clinical
42

specimens that are collected to diagnose EHM are nasal swabs, whole blood, cerebrospinal fluid,
acute and convalescent serum [222]. Macroscopically, on Post-mortem examination brain and
spinal cord may show a brownish patchy discoloration [214]. Microscopically, signs of vasculitis
with ischemic and hemorrhagic infarction, perivascular edema and necrosis of parenchyma are
seen [214].
However, differential diagnosis is often required from other similar infections like EHV-4
infection, equine influenza virus infection, or equine arteritis virus (EAV) infection for the
respiratory form of disease; EAV infection for abortion; West Nile virus infection, Sarcocystis
neurona infection for EHM in order to confirm EHV-1 infection.

1.12 Treatment and Supportive Care:
No specific treatment is available for EHV-1 induced diseases. However, supportive care
such as good management practices to limit the spread of the infection, symptomatic treatment of
infected horses, and use of antibiotics to control secondary bacterial infection can be very helpful
to deal with EHV-1 infections. During EHV-1 induced rhinopneumonitis, phenylbutazone at 3
mg/kg body wt (bwt), PO, q 12h to 24h or, flunixin meglumine at 1.1 mg/kg bwt, IM, q 12h to
24h are the drugs of choice [16]. Trimethoprim-sulfadiazine preparation at 30 mg/kg bwt, PO, q
24 h for 7-10 days is used to prevent secondary bacterial infection [16]. In severe bacterial
infections in young horses, broad-spectrum antimicrobials like amikacin, procaine Penicillin G,
Cetiofur, or Ceftazidine can be used [16]. Horses with anorexia may need fluid electrolyte
therapy. In case of paralytic EHV-1 infections, parenteral administration of corticosteroids (0.1
mg/kg bwt, IV, q, 24h) and nasogastric intubation of dimethyl sulfoxide (3 ml/kg bwt, q, 24h)
may be used to reduce the inflammation [16]. In some cases of EHM or neonatal foal infection,
nucleoside analogues such as acyclovir may also be used. Although use of acyclovir in vitro
showed an inhibition in EHV-1 replication [227] but in vivo use of acyclovir in neurologic
disease was not beneficial [228]. Beside acyclovir, valacyclovir also has been tried in
43

experimentally infected horses with EHV-1. Valacyclovir treatment, however, has not shown any
significant reduction in clinical signs, virus shedding, and viremia of EHV-1 infected horses
[229]. In case of EHM affected horses, cystitis is a common symptom which could be dealt with
careful catheterization with antibiotics [14]. Laterally recumbent horses may be considered for
euthanasia [16].

1.13 Prevention:
Complete elimination of EHV-1 infection from the herd is impractical because of the latent
reservoirs of carrier horses that remain a continuous threat. However, the prevention of EHV-1
infection can be done by prophylactic immunization and good management practices in the herd.

1.13.1 Vaccination:
For all horses at risk of EHV-1 infection, vaccination is advised as a preventive measure.
Maternally derived antibody through colostrum decreases with age and foals at the age of 5-6
months become maximally susceptible to infection [16]. Young foals at weaning should be
provided two intramuscular injections of vaccines at an interval of 3 months, with the subsequent
booster dose at every 3-6 months to prevent the respiratory form of disease [16]. Pregnant mares
should be vaccinated to reduce the risk of EHV-1 induced abortions [16]. No vaccine is available
to prevent either EHM or development of carrier state [230].
Both inactivated vaccines as well as modified live virus (MLV) vaccines are available and
the immune response elicited against EHV-1 vaccination depends on the type of vaccines [230,
231]. The MLV vaccine induces both CTL mediated immunity and humoral immunity and have
been found to reduce cell associated viremia [230]. On the other hand, inactivated vaccines have
been shown to induce virus neutralizing antibody and also reduce viremia and nasal shedding of
virus [231]. A DNA vaccine and also a recombinant vaccine using canarypox virus as vector
expressing EHV-1 glycoprotein gB, gC, and gD were shown to suppress initial virus replication
in the upper respiratory tract and the vaccines also induced neutralizing antibodies [232].
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However, the vaccines provided a partial protection and did not protect EHV-1 challenged horses
from cell-associated viremia [232]. In another study Soboll et al have observed that DNA
vaccines comprising of EHV-1 glycoproteins gB, gC, and gD provided partial protection [233]. In
spite of the promising results, none of the DNA vaccines targeting the glycoproteins provided
horses with complete protection from EHV-1 abortions or EHM. Very interestingly, a
recombinant vaccine consisting of IE gene of EHV-1 in modified live vaccinia virus vector
provided significant protection from clinical disease as well as cell-associated viremia to EHV-1
challenged horses [234]. The vaccine induced both humoral and CTL mediated immunity but a
compete protection from abortion and neurologic disease are yet to be achieved [234].

1.13.2 Management:
It has been reported that good managemental practices and sound vaccination strategy can reduce
75% of the EHV-1 induced abortions in the United States [235]. Management of herds should be
primarily done to reduce the spread of epidemics [63]. Horses should be divided into small
groups and segregated on the basis of distinct categories like weanlings, yearlings, new arrivals
and transients [16, 63]. Any new horse to be included in the small groups should first be kept in
quarantine or isolation for a period of 21 days [16]. Reduction of stress due to crowding, poor
nutritional state, heavy parasite infestation, disruption of established social groups or inclement
weather should be minimized [16]. Horses on prolonged transportation should also be kept for 21
days in isolation [16, 25]. Proper disinfection and hygienic practices must be followed to prevent
the spread of EHV-1 infection during an already present outbreak [63].

1.14 Host Immune Responses to EHV-1:
After the discovery of EHV-1 in the early 1930s there have been numerous efforts over the
decades by many scientists to characterize the protective immune responses against EHV-1 in
order to find a suitable vaccine [230, 236]. EHV-1 infection will induce a short-lived protective
immune response [237]. Both virus neutralizing (VN) as well as complement fixing (CF)
antibodies have been found in the sera of EHV-1 infected horses as early as 2 weeks after
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infection both in experimental as well as field conditions [27, 238]. VN antibody is EHV-1 type
specific and gives protection for longer (maximum 1yr) than CF antibody (maximum 3 months)
which cross reacts with EHV-4. Antibodies are directed principally against envelope
glycoproteins, gB, gC, gD, gH and gp2 of the virus [110, 124, 239, 240]. gC and gD proteins of
EHV-1 have been reported to have neutralizing epitopes [241, 242]. There is a controversy
whether the humoral immunity of horses can protect them from clinical disease by EHV-1. It is
however, true that the mucosal antibody, predominantly IgA, takes an important role in the
protective response to EHV-1 infection by neutralizing the cytolytically replicating EHV-1 to
reduce the nasopharyngeal virus shedding [243]. Re-infection with EHV-1 is very common in
horses and, interestingly, even the presence of virus-specific high antibody titers cannot prevent
horses from viremia during re-infection [243, 244]. Although VN antibody can reduce the signs
of EHV-1 induced respiratory disease, it cannot protect the horses from abortion as well as
neurologic disease, EHM [237].
As with other intracellular viruses, clearance of EHV-1 infection also depends on T
lymphocytes, primarily on the CD8+ cytotoxic T lymphocytes (CTLs) which are the major
effector arm of the cellular branch of the immune system [230, 233]. It has been demonstrated
that there is a direct correlation between the frequency of CTL precursors (CTLp) and the level of
protection in experimental EHV-1 infections [245]. Older ponies with high CTLp frequencies
showed reduced signs of clinical disease after experimental EHV-1 infection [246]. Kydd et al.
have reported that there is enhanced CTL activity and increased frequency of CTLp after
experimental EHV-1 infection [245]. Since the identification of the importance of CTL-mediated
immunity in the clearance of EHV-1, many attempts have been made to find the CTL target
epitopes. Studies have shown that the immediate early (IE) protein encoded by ORF64 of EHV-1
serves as the CTL epitope which induces the virus-specific CTL-mediated killing of infected cells
[233, 234, 247]. This CTL response to EHV-1 has been reported to be MHC class I serological
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haplotype A3/B2 restricted [230, 233, 234, 237]. In another study, beside the IE protein, some
glycoproteins such as gC, gD, gI, and gL were also shown to have CTL epitopes, although the
findings were only seen in individual horses [248]. However, studies by Soboll et al did not find
any significant EHV-1 specific lymphoproliferative or CTL responses when they challenged
ponies with EHV-1 after DNA vaccination expressing gB, gC or gD [233].

1.15 Immune Evasion Strategies of EHV-1 and Other herpesviruses:
Despite these protective immune responses, complete clearance of this pathogen from the
infected host is yet to be accomplished because of many impressive immune evasion strategies
that EHV-1 possesses. The virus can interfere with all 3 principal immune effector mechanisms,
namely antibody dependent lysis, CTL-mediated killing and NK cell mediated killing of infected
cells [237].

1.15.1 Evasion from Antibody Mediated Immunity:
Herpesviruses are known to have co-evolved with their hosts for a long time. During this
period of evolution the virus evolved a number of immunomodulatory mechanisms to escape
from host immune surveillance to assure its existence throughout the host’s lifetime. Antibody
(Ab) dependent humoral immunity gives protection against viruses either by neutralization of the
cell-free viruses, opsonization or antibody dependent cell cytotoxicity (ADCC). After the
infection of the host cells by EHV-1, viral glycoproteins are synthesized and transported to the
surface of the cell membrane. In general, the virus specific antibody recognizes these
glycoproteins or viral antigens and triggers the host effector arms such as complement,
phagocytic cells and NK cells which then clear the virus from the host. After the recognition of
viral antigens, the complement component C1q binds to the Fc region of the virus-specific
antibody and initiates the subsequent cascade of reactions resulting in the destruction of the virus
infected cells. Similarly, NK cells as well as phagocytic cells like macrophages also express Fc
receptors that recognize the Fc domain of the virus-specific antibody bound to virus infected cells
and subsequently causes the lysis of the infected cells.
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Although EHV-1 vaccination or infection induces a short-lived antibody responses, the
recognition of EHV-1 infected cells is however, not optimal. EHV-1 can hide its antigenic
proteins from being expressed on the surface of infected PBMCs as has been demonstrated by
van der Meulen et al [249, 250]. More than 98% of EHV-1 infected PBMCs did not express any
viral envelope proteins in their study even in the presence of cell-associated viremia. This
prevents the virus infected cells from antibody mediated clearance and is a potent immune
evasion mechanism adopted by EHV-1 [250]. Although late viral envelope glycoproteins were
undetectable inside the infected PBMCs, the IE protein and early proteins such as ICP22 were
detectable suggesting that viral replication in the PBMCs was restricted to the early phase [250].
It has, however, also been suggested that viral replication may not be restricted in PBMCs, but
instead infected PBMCs expressing viral envelope proteins may be selectively removed from the
circulation [250]. In both ways, interference in the expression of the envelope proteins on the
surface of PBMCs makes the infected PBMCs resistant to the neutralizing effect of the circulating
virus-specific antibodies. This helps the virus to escape from Ab-mediated killing of the infected
cells and the viremic PBMCs can spread to different organs and systems. Interestingly, these
infected PBMCs with restricted viral replication still have the capacity to transmit infectious
viruses to susceptible cells like endothelial cells by direct contact [250]. It is possible that direct
contact with susceptible cells may trigger yet unknown cell-signaling which initiates the onset of
transition of the viral replication cycle from early to late phase [250].
On the other hand, a few PBMCs still express the viral envelope proteins but more than
two-third of these cells cannot be cleared in the presence of complement and virus-specific Ab in
vitro [249]. This escape from complement mediated lysis of infected cells could be attributed to
the low efficiency of equine complement [251]. But this escape phenomenon may also be
attributed to viral proteins which actively interfere with complement mediated cell lysis. Indeed,
it has been shown that the envelope protein gC of EHV-1 binds to the C3 component of
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complement interfering with downstream cascade events and this causes the virus to be resistant
to complement mediated killing resulting in evasion of another major branch of the immune
system [126].

1.15.2 Evasion from CTL mediated Immunity:
Because herpesviruses are intracellular parasites and are able to thwart Ab-mediated
immunity, CD8+ cytotoxic T lymphocytes play a crucial role in clearing them from the host’s
system. The CD8+ CTL-mediated immune system exerts its effect via the recognition of viral
peptides presented by Major Histocompatibility Complex-I (MHC-I) molecules on the infected
cell surface. In general, after the infection of the host cells by virus, viral proteins will be
expressed and nascent proteins will be folded within the host cells. However, within the
cytoplasm some of the nascent viral proteins, mainly misfolded proteins, will be cleaved by the
host multi-subunit proteasome complex into smaller peptide fragments of 8-10 amino acids (aa)
in length in an ubiquitin-dependent manner [252, 253]. These cleaved peptides are then
transported into the endoplasmic reticulum (ER) via the Transporters associated with Antigen
Processing -1 and -2 (TAP1 and TAP-2) [254]. Meanwhile, the newly synthesized MHC class I α
chains will be transported into the ER for folding with the help of the chaperone protein, calnexin,
and then will associate with β2-microglobulin (β2m) to form a heterodimeric complex (α:β2m)
[253]. The short antigenic peptide fragments will then associate with the α:β2m heterodimer via
TAP with the help of tapasin, another chaperone protein, to form a stable peptide-MHC-I
complex which will finally be transported to the cell surface via the Golgi apparatus [254, 255]. It
is also important to note that if MHC-I molecules do not associate with antigenic peptides they
will be transported back to cytosol and be degraded by proteasome complexes in an ubiquitin
dependent manner [256]. The peptide antigens (Ag) presented by MHC-I molecules on the
infected cell surface will be recognized by the Ag-specific CD8+ T cells which will be
subsequently activated and converted to effector cells known as CTLs [253, 256]. These CTLs
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will then induce apoptosis in the infected cells, resulting in the clearance of the virus infected
cells from the host’s system [253].
Even in the presence of these intricate host mechanisms, herpesviruses are still able to
escape the host immune surveillance and co-exist with their hosts by adopting multiple immune
evasion strategies. Using different continuous cell lines, such as equine embryonic lung cells,
NBL-6 cells, or equine kidney primary fibroblasts, it has been shown that EHV-1 directly
downregulates the surface expression of the MHC-I molecules on the infected cells in vitro [257,
258]. Rappocciolo et al reported that EHV-1 interferes with the cellular antigen presentation
pathways by downregulating the cell surface expression of MHC-I molecules via the induction of
enhanced endocytosis by early viral proteins [257]. Many herpesviruses inhibit the transport of
peptides by interfering with the function of TAP, in order to interfere with the Ag presentation
pathways. EHV-1 proteins were found to interfere with the peptide transport activity of TAP,
causing the reduced availability of antigenic peptides in the ER for association with MHC-I
molecules, which in turn results in reduced maturation and thereby downregulation of the cell
surface expression of MHC-I molecules [237, 258]. Koppers-Lalic et al found that the EHV-1
protein pUL49.5 inhibits TAP and thus inhibits the expression of MHC-I molecules on the
surface of infected cells [259]. Kurtz et al however, argued about two possible mechanisms for
the downregulation of the surface expression of MHC-I molecules by early EHV-1 proteins
[260]. Because EHV-1 utilizes MHC-I as an entry receptor, they suggested that it is possible that
after EHV-1 binds to its receptor, that molecule will quickly be internalized along with the virus
[260]. Another possible mechanism is that EHV-1 utilizes its receptor to enter into the cells and
the MHC-I molecules are not internalized; rather, EHV-1 protein pUL49.5 suppresses further
expression of the molecules on the cell surface [260]. Like EHV-1, other members of the genus
Varicellovirus such as EHV-4, BHV-1 and PrV have been found to encode the novel TAP
inhibitor, pUL49.5 protein, but the mechanism of inhibition is different for different viruses of the
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same genus [261]. While pUL49.5 proteins of EHV-1 and EHV-4 interfere with the binding of
ATP to TAP, the same protein of BHV-1 is found to trigger TAP for proteasomal degradation
[261]. In a very recent study, it has been revealed that another novel EHV-1 phosphoprotein,
pUL56 encoded by the ORF1, directly inhibits the surface expression of MHC-I molecules in
vitro and this inhibition was independent of pUL49.5 mediated inhibition of TAP [106]. It has
been assumed that at the early stage of infection pUL56 will remove most of the MHC-I
molecules from the surface of the infected cells even before the loading of most viral peptides on
to the binding groove of MHC-I molecules [106]. However, in the later stage of the infection,
pUL56 will synergistically suppress MHC-I expression with pUL49.5 and interfere with the
presentation of viral antigenic peptides to the CTLs [106]. The mechanism of this pUL56
mediated suppression of the surface expression of MHC-I molecules is yet to be determined but
phosphorylation of pUL56 protein is not necessary for this action [106].
In vitro EHV-1 infection was found to decrease the expression of MHC-I significantly on
the surface of infected PBMCs [237, 250]. But in vivo, infected and non-infected PBMCs from
the same ponies experimentally infected with EHV-1 did not show a considerable difference in
the expression of MHC-I molecules [237]. It is possible that this apparent difference was because
of restricted EHV-1 replication in vivo compared to in vitro and also because only the absolute
percentage of MHC-I positive PBMCs was considered, and the amount of MHC-I expression per
infected PBMC was not considered in that particular study [237, 250].
Another strategy that herpesviruses could use to subvert the cell-mediated immunity is to
destroy lymphocytes directly, and indeed experimental EHV-1 infection by Kydd et al showed an
acute and transient reduction in the number of T lymphocytes, both CD4+ and CD8+ T
lymphocytes, but increased neutrophils in the lungs of infected horses at 2 days post infection
(d.p.i.) [237, 262]. This reduction of the lymphocyte numbers could be either due to direct
destruction of the lymphocytes, or selective migration of the immune cells causing overwhelming
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infiltration of the neutrophils into the lung resulting in the decline in the number of lymphocytes
[262]. Kydd et al also reported an increase in the number of CD8+ T lymphocytes at 21 d.p.i.
[262]. Another study by McCulloch et al argued that the lymphopenia after EHV-1 infection may
be either due to direct destruction of these lymphocytes by virus or partly may be due to the
selective migration of different inflammatory cells in different times after infection [192]. In fact,
there are multiple reports suggesting a decrease in the number of CD4+ as well as CD8+ T
lymphocytes in the blood of infected horses [192, 263]. Beside these, EHV-1 may possess many
other immune evasion strategies that are yet to be discovered to escape from CTL mediated
eradication from the host’s system.

1.15.3 Evasion from NK cell-mediated immunity:
NK cells are a type of cytotoxic lymphocyte and are considered to be cells of the innate
immune system. The cells have two types of receptors, activating and inhibitory receptors [264].
The activation of the NK cells depends on the intricate balance between these two types of
receptors [264, 265]. The inhibitory receptors can sense the self MHC-I molecules on the surface
of the antigen presenting cells and pass inhibitory signals to the cells [265]. But in general, during
viral infections expression of MHC-I molecules on the infected cell surface is reduced or altered
and that missing MHC-I molecules (known as ‘missing self’ hypothesis) triggers the activating
receptors which in turn activate the NK cells to kill the infected cells [265]. The NK cells are
considered to be evolved to supplement the function of CTLs which is inhibited by the reduced
surface expression of different types of MHC-I molecules [265].
Many viruses including herpesviruses have been shown to develop specific strategies to
evade NK cell-mediated immune surveillance [266]. Like other alphaherpesviruses, EHV-1 also
has been shown to selectively downregulate the surface expression of certain types of MHC-I
molecules while not affecting other types which indicates that the downregulation of MHC-I
molecules is allele specific [257]. If that selective downregulation of MHC-I alleles does not
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involve those molecules responsible for recognizing the inhibitory receptors, it is possible that the
virus may easily evade NK cell-mediated detection and removal from the host’s system [257,
265]. Thus by selectively reducing the surface expression of MHC-I molecules on the infected
cells, EHV-1 may escape both CTL as well as NK cell-mediated immunity.

1.15.4 Evasion from Cytokine Network:
Cytokines are small, hormone-like regulatory proteins (~25KDa) that are secreted from
various cells in the body in response to different stimuli and act in autocrine, paracrine as well as
endocrine manners via specific receptors present on various immune and non-immune cells.
Cytokines play a critical role in control of the innate and the adaptive immune systems by
controlling the development and expression of a broad array of immune responses [267].
Chemokines are pro-inflammatory cytokines that are chemoattractant in nature and are secreted in
the early phase of the infection inducing direct recruitment of inflammatory cells and
lymphocytes in adjacent cells [268]. Viruses have developed different strategies to evade the
cytokines responses such as mimicking host cytokines or cytokine receptors, induction of
inhibitory cytokines, or secretion of cytokine binding proteins [269]. Viral homologues of
cytokines (virokines) or viral homologues of cytokine receptors (viroceptors) compete with their
corresponding host cytokines or cytokine receptors respectively and modulate the host immune
response by cytokines [270].
Experimental EHV-1 infections of ponies were shown to induce an inhibitory circulating
cytokine, transforming growth factor β (TGF-β) that is reported to cause suppression of
lymphocyte proliferation in vitro [271]. The subsets of immune cells that secrete active TGF-β
after EHV-1 infection are alveolar macrophages, lymphocytes, and platelets [272]. Scientists also
documented similar reports of EHV-1 mediated suppression of lymphocytes but unlike other
studies, their reports did not find any circulating factor to be responsible for that
immunosuppression [273-275]. EHV-1 also alters cytokine functions of the host with its envelope
53

protein, gG which is a viral homologue of chemokine binding receptors. The glycoprotein gG
exists in two different forms, either in secreted soluble form or integrated into the cell membrane.
The secreted gG binds to a broad range of chemokines and blocks the interaction of cellular
cytokines with cellular receptors resulting in the suppression of chemokine mediated recruitment
of inflammatory cells [276]. It has also been suggested that gG protein inhibits equine IL-8
mediated migration of neutrophils in the lungs of EHV-1 infected horses [277]. Furthermore, gG
protein was also shown to suppress migration of murine macrophages by macrophage
inflammatory protein 1α (MIP-1α) [131]. Thus, EHV-1 has been found to interfere with all major
types of immunity of horses: cytokine-mediated immunity, Ab-mediated humoral immunity,
CTL-mediated cellular immunity, and NK cell-mediated immunity.

1.16 Type-I Interferon and Host Immune Response:
Interferons are a group of biological regulatory proteins also known as cytokines which act
as a first line of defense against many viral infections [278-280]. These cytokines are synthesized
and secreted by the virus infected host cells and inhibit virus replication in the infected cells as
well as nearby uninfected cells to induce a global antiviral state. While studying interference of
influenza virus replication, Isaacs and Lindenmann first reported that a secreted antiviral factor
induced by inactivated influenza virus could interfere with the replication of live influenza virus
and they named the factor ‘interferon’ [281]. To date three classes of interferons (IFN), namely
type-I, II and III, have been characterized on the basis of the amino acid sequences [279]. Type-I
IFN includes IFN-α (multiple subtypes), β, κ, ε, τ, and ω; type-II includes IFN-γ and type-III
includes λ1, λ2 and λ3 [278, 279]. Type-I and III IFNs are induced principally in viral infections
by different types of cells including epithelial, fibroblast and dendritic cells. On the other hand,
type-II IFN, which is also known as ‘immune IFN’, is expressed by the cells of the immune
system, principally by activated T cells, NK cells and macrophages [282]. Type-III IFN functions
by recruiting immune cells such as leucocytes, and macrophages to the site of inflammation and
also contributes to induction of an antiviral state inside the host cell [282]. However, type-II IFN
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is best known for its immune modulatory function rather than antiviral effect [278]. While type-I
IFNs signal through IFN receptor 1 and 2 (IFNAR1 and IFNAR2), and type-II through IFN
gamma receptor 1 and 2 (IFNGR1 and IFNGR2), type-III IFNs signal through IFN-λ receptor
1(IFN-λR1) and IL-10R2 [283].

Figure 1.8: IFN-β Induction Pathways: Viral PAMPs are recognized by different PRRs present
either in the cytoplasm or endosome or on the outer cell surface. This recognition triggers the
activation of different adapter proteins and kinases resulting in the activation of transcription
factors IRF-3, and NF-κB, which then are translocated into the nucleus and associate with the
promoter region of IFN-β gene. This causes an increased transcription of IFN-β gene which is
then translated in the cytoplasm. IFN-β then signals through JAK-STAT signaling pathways
resulting in the expression of IFN-α genes.
Type-I IFN induction by virus infected cells occurs in 3 phases- sensitization, induction and
amplification [284]. In the sensitization or first phase, the viral motifs known as pathogen
associated molecular patterns (PAMPs) are detected by the pattern recognition receptors (PRRs)
present in the cells resulting in the signal transduction. These signals will converge to coordinate
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activation of transcription factors like interferon regulatory factor 3 (IRF-3), and NF-κβ which
induce IFN-β at a very low level [280, 285] (Figure 1.8). Two families of PRRs that play the
major role in sensing the viral motifs are toll-like receptors (TLRs) and retinoic acid inducible
gene-I (RIG-I) like receptors (RLRs). Among these PRRs, TLR-3, 7, 8 and 9, which are localized
in endosomes and RLRs like melanoma differentiation-associated gene-5 (MDA-5), and
Laboratory of Genetics and Physiology 2 (LGP2), which are localized into cytoplasm, are mostly
engaged in viral PAMP detection. Most of the known PRRs signal through activation of IRF-3 by
phosphorylation which forms dimers and translocates into nucleus, binds to the promoter of IFNβ and induces the transcription of IFN-β [284].
In the induction or second phase, the secreted IFN-β binds to its cognate receptors (IFNAR1
and IFNAR2) present ubiquitously on the cell surface (Figure 1.9). On binding of IFNs to their
receptor subunits, there is heterodimerization and subsequent phosphorylation of tyrosine
residues in the receptors [286]. This in turn triggers the activation of proteins in the receptor
associated Janus kinase (JAK) family, such as JAK-1 and Tyk-2, by phosphorylation [286].
Activated JAKs phosphorylate signal transducer and activator of transcription-1 (STAT-1) and
STAT-2 at tyrosine residues. These phosphorylated STATs associate with interferon regulatory
factor 9 (IRF-9) forming a heterocomplex known as ISGF3 [287] (Figure 1.9). ISGF3
translocates into the nucleus where it binds to the interferon stimulated response elements (ISRE)
of different IFN inducible genes including IRF-7 causing their enhanced transcription [287].
Activated IRF-3 forms a heterodimer with IRF-7, translocates into the nucleus and binds to the
promoter of IFN-α genes causing their increased transcription [285].
In the amplification or third phase, the synergistic effect of IFN-α and IFN-β induces
enhanced transcription of a diverse set of genes known as interferon stimulated genes (ISGs)
which create a global antiviral environment within the host cell (Figure 1.9).
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Figure 1.9: Type-I IFN signaling pathways. Type-I IFNs bind to their cognate receptors
IFNAR1 and IFNAR2 causing the receptor dimerization which triggers activation of the JAK-1
and Tyk-2 protein kinases. The kinases then phosphorylate STAT-1 and STAT-2 molecules
which then form a dimer and then translocate into the nucleus from the cytoplasm. Subsequently,
the dimers associate with another protein, IRF-9 forming a trimeric complex, ISGF3, that binds to
the interferon sensitive response elements (ISRE) to enhance the transcription of a number of
ISGs.

1.17 Antiviral Immunity by Interferon Stimulated Genes:
IFNs exert their antiviral effects through direct functioning of ISGs (Figure 1.9) which
interfere with transcription and translation of viral genes, or promote apoptosis of the infected
cells [284, 288]. Among more than 300 known ISGs, the most characterized type-I IFN induced
genes are dsRNA dependent protein kinase R (PKR), 2’-5’-oligoadenylate synthetase (OAS),
ISG-15, ISG54 and ISG-56 [280]. PKR activation requires binding to dsRNA, which is a
byproduct derived during the replication of both DNA and RNA viruses. Activated PKR
autophosphorylates, homodimerizes and then phosphorylates the eukaryotic translation initiation
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factor, eIF-2α, inhibiting further translation of host cell proteins. In addition to this, PKR can
induce NF-κB activation by phosphorylating IκB [289]. OAS activation also requires binding to
dsRNA. This in turn converts ATP to 2’-5’-oligoadenylate which then activates a cytoplasmic
enzyme, RNase L, leading to degradation of viral as well as cellular mRNAs and thus OAS
inhibits virus replication [290].
ISG15 is, on the other hand, an antiviral protein that is upregulated dramatically in response
to type-I IFN. ISG15 is an ubiquitin-like protein which covalently associates with many cellular
proteins and ubiquitinylate those proteins for proteasome mediated degradation [291].
Another very important ISG of antiviral importance is ISG56 which happens to be the first
IFN inducible gene to be discovered and cloned subsequently [292]. The ISG56 family of
proteins includes ISG54 (p54), ISG56 (p56), ISG58 (p58) and ISG60 (p60) [293]. Human ISG54
and ISG56 have been reported to interact with translation initiation factor, eIF3 complex, and
subsequently inhibit its ability to stabilize the ternary complex, eIF2-GTP-Met-tRNAi formed
during the initial step of translation [293, 294]. Furthermore, recently it became known that
ISG56 can also directly bind to viral proteins and inhibit replication of that virus. For example,
ISG56 protein interacts with a key human papillomavirus (HPV) protein, E1 helicase and
inactivates it [295].
Very recently one IFN inducible gene was identified while studying the genes induced by
human cytomegalovirus (HCMV) infection and was named viperin (‘virus inhibitory protein,
endoplasmic reticulum-associated, interferon-inducible’) [296, 297]. Viperin is a multidomain,
multifunctional protein with 3 distinct domains: an N-terminal domain containing an amphipathic
α helix, a central domain containing three cysteine residues organized in a CXXXCXXC motif
and a C-terminal conserved domain. Viperin is also known as radical S-adenosylmethionine
domain containing 2 or RSAD2. The protein is induced in a variety of cell types by a number of
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stimuli such as different DNA or RNA viruses, type-I, -II, -III IFNs, polyinosinic-poly cytidylic
acid (poly I:C), or lipopolysaccharide (LPS) [297]. Viperin has been reported to interfere with the
replication of a broad spectrum of DNA and RNA viruses such as HCMV, West Nile Virus,
Dengue virus, and Influenza A virus through diverse mechanisms. It has been found that
overexpression of viperin in fibroblasts interferes with the expression of HCMV structural
proteins like gB, pp65, and pp28 that are required for viral maturation and assembly and thus
inhibits replication of HCMV [296]. Viperin has also been found to bind and inactivate an
enzyme, farnesyl diphosphate synthase

required for the synthesis of cholesterol and other

isoprenoid derived lipids [297]. As a result it can disrupt the lipid rafts present in the cell
membrane and it can play a major role in the replication of viruses that use lipid rafts. It has
indeed been found that overexpression of viperin inhibits the replication of influenza A virus by
disrupting the membrane lipid rafts [298]. In addition to its antiviral property, viperin has also
been suggested to be involved as a mediator in the intracellular signaling pathways that control
immune responses. In plasmacytoid dendritic cells (pDC), viperin has been shown to mediate
TLR7 and TLR9 mediated production of type-I IFN by recruiting signaling mediators IRAK1 and
TRAF6 to lipid droplets [299].
Beside the ISG mediated innate immune response, type-I IFN also regulate adaptive immune
responses [285]. IFN-α/β has been shown to upregulate monocyte derived dendritic cell (MoDC)
maturation markers like MHC-I, MHC-II, CD80, CD86, CD40 and CD83 in vitro [300]. It has
even been reported that monocytes cultured in GM-CSF + IFN-α/β rather than GM-CSF + IL-4
differentiate more quickly into DC suggesting a significant role of IFN- α/β in priming of T cells
[300, 301].
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1.18 Evasion of Type-I Interferon Response by Alphaherpesviruses:
As successful pathogens, viruses will always try to modulate the antiviral responses
provided by type-I IFN. Multiple viruses have been reported to possess diverse mechanisms to
evade the IFN-response. Some viruses interfere with global protein synthesis of the host cell;
some viruses limit IFN induction by interfering with the production of viral PAMPs or their
availability to PRRs; others inhibit IFN signaling pathways at multiple levels or interfere with the
function of ISGs; or some viruses even develop replication strategies that are insensitive to IFN
[279]. Herpesviruses are the master regulators of modulating host immune responses to their
benefit. Because of their large coding capacity, herpesviruses have evolved multiple proteins to
interfere with the type-I IFN response. Alphaherpesviruses like bovine herpesvirus-1 (BHV-1)
and herpes simplex virus-1 (HSV-1) encode an IE protein in the infected cells known as ICP0
which has been shown to interfere at multiple steps of the type-I IFN response. ICP0 has a zinc
RING finger domain at its amino-terminus which has E3-ubiquitin ligase activity [302, 303]. An
intact zinc RING finger domain is necessary for the activity of ICP0 protein in most cases [285,
303]. Bovine ICP0 (bICP0) degrades IRF3 through its RING finger domain and it also interferes
with IRF7 resulting in inhibition of IFN-β promoter activity as well as ISG promoters [302-304].
In contrary to BHV-1, HSV-1 ICP0 does not degrade IRF3 but sequesters IRF3 from binding to
promoters of type-I IFN and ISGs [305, 306]. A variety of other mechanisms adopted by HSV-1
ICP0 have been reported by different researchers including inhibition of IRF7 mediated ISG
induction as reported by Lin et al [307] and interference with STAT-1 activation as reported by
Halford et al [308].
HSV-1 ICP27 is another multifunctional IE protein that has been shown to be involved at
multiple steps in the viral lifecycle including viral gene expression and export of viral mRNAs
[309-311]. The protein is also involved in repressing host transcription as well as mRNA stability
leading to host shut off of protein synthesis [310]. Studies by Melchjorsen et al have revealed that
ICP27 inhibits IRF3 activation leading to inhibition of IFN-β induction [306, 312]. ICP27 has
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also been reported to inhibit STAT-1 activation and its nuclear translocation during wild type
(WT) HSV-1 lytic infection, further establishing its role in interfering with type-I IFN response
[313, 314]. HSV-1 infection to Vero cells causes secretion of a heat stable, IFN-antigonizing
protein that inhibits nuclear translocation of STAT-1 in the infected as well as uninfected
bystander cells [314]. Very interestingly mere expression of ICP27 protein of HSV-1 induces the
cell to secrete the same antiviral protein with the ability to inhibit STAT1 activation as well as
nuclear translocation [314].
A late protein of HSV-1, known as virion host shut off protein (Vhs), has been shown to be
involved in inhibiting protein synthesis by degrading both host as well as viral mRNA[315]. Vhs
is thought to interfere with the induction phase of the IFN response where IFN mRNA may be
degraded by Vhs [316]. A Vhs-deleted HSV-1 has been reported to induce greater amounts of
type-I IFN and ISGs in murine embryonic fibroblasts (MEF) compared to WT HSV-1 [317]. Vhs
is also involved in the inhibition of the phosphorylation of STAT-1 [318, 319] and in the
degradation of ISG transcripts [307, 320].
Another late protein, US3 (a serine threonine kinase) of HSV-1, is also involved in the
evasion of the type-I IFN response by interfering with the TLR3 mediated immune response
[321]. Peri et al found an increased induction of IFN-β mRNA and ISGs due to infection to
monocytic cells with US3-deleted HSV-1, compared to decreased TLR3 mRNA and decreased
dimerization of IRF3 in WT HSV-1 infection [322].
UL13 protein, which is also a serine threonine kinase of HSV-1, has also been reported to
be involved in evading the type-I IFN response although the mechanism is not well characterized
[323]. Besides, ICP34.5 and US11 have also been shown to be involved in interfering with the
type-I IFN response [324, 325].
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Some of the homologue proteins of HSV-1 and BHV-1 involving the type-I IFN-response
have also been found in EHV-1 but their functions in the equine host in regard to the type-I IFN
response are yet to be identified.

1.19 Statement of Problem and Hypothesis
EHV-1 continues to be a very important viral pathogen causing significant economic loss to
the equine industry all over the world including the United States. As stated earlier, no existing
vaccine can completely protect horses from abortion, EHM or reinfection. Moreover, within the
past decade, the number of cases of EHM in EHV-1 outbreaks has been unusually high [212]
which made this pathogen a great concern for the equine industry.
Most of the research characterizing the immune response to EHV-1 infection is focused on
the adaptive immune system. Unfortunately, the interaction of EHV-1 with the innate immune
system has not been well characterized. As that there is a strong correlation between neurologic
symptoms and level of viremia [182, 226, 234, 326], the effective control of EHV-1-induced
abortion and neurologic disease requires control of viremia [234]. Antibodies are inefficient in
controlling the cell-associated viremia and even the CTL-mediated immune responses cannot
clear the virus completely from the host [327]. To cause an abortion or EHM, infection of
endothelial cells of the blood vessels of the uterus and nervous system by EHV-1 followed by
lytic replication of EHV-1 in those cells is required. Characterization of the interaction of EHV-1
with the innate immune system may provide information about the mechanisms that EHV-1
employs in order to establish infection in endothelial cells, bypassing host innate immunity. This
knowledge could be useful for designing of novel antiviral therapies against EHV-1 abortion or
EHM. The innate immune responses to EHV-1 infection in endothelial cells are not well
characterized and our current knowledge is rudimentary in this regard.
The most important mediator of the innate immune system that plays a major role in
mediating potent antiviral responses to restrict viral replication irrespective of virus specificity is
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IFN, especially type-I IFN. Type-I IFN are even capable of limiting some viral infections in the
absence of adaptive immunity [328]. Although, most viruses like herpesviruses (alpha, beta and
gamma), influenza viruses, and paramyxoviruses stimulate the induction of type-I IFN [285, 303,
305, 328, 329], viruses like porcine arterivirus and dengue inhibit its induction as a potential
immune evasion mechanism [330, 331]. The type-I IFN response to EHV-1 infection has not
been well-studied. Very few published reports are available [332] describing the type-I IFN
response to EHV-1 infection. Edington et al reported the increased presence of type-I IFN [332]
in the serum as well as increased production by cultured PBMC from the EHV-1 infected horses
[332]. EHV-1 infection shows many distinct patterns of type-I IFN response compared to other
herpesviruses. For example, pretreatment of fibroblasts with type-I IFNs cause reduction in the
replication of alphaherpesviruses like HSV-1 in vitro [333]. Additionally, a combination of typeI and II IFN causes a greater reduction in HSV-1 replication in infected cells in vitro [329].
Again, in the cases of HSV infection in mice and humans and herpes zoster in man [332, 334,
335], low levels of type-I IFN correlate with higher spread of disease. On the other hand,
Edington et al have observed that during EHV-1 infection in vivo, serum IFN levels are at their
peak when viral pathogenicity is highest suggesting that high levels of serum IFN correlate with
the severity of clinical disease [332]. Edington’s group also has demonstrated that EHV-1 is not
susceptible to the action of type-I IFN [336]. Contrary to that report, Steinbach et al showed a
marked reduction in the replication of EHV-1 due to the treatment of IFN-α [337]. This typical
IFN response pattern raises some questions: does EHV-1 stimulate or inhibit type-I IFN
production in vitro in cell culture and does this correlate with the in vivo findings of Edington et
al [332]? If it stimulates the production of IFN, then how does the virus multiply in the presence
of IFNs and why does the virus titer remains highest when serum level of IFN is highest? There
are no detailed reports of the nature of the type-I IFN response against EHV-1 infection in vitro.
Given the importance of the innate immune system in viral infection, it is important to
characterize the EHV-1 interaction with the innate immune system, and especially the role of the
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type-I IFN response in detail in equine endothelial cells (EECs). Finding the role of host innate
factors in the pathogenesis of EHV-1 could also provide new and effective ways to control this
pathogen.
The central premise of this work is that EHV-1 has mechanisms to evade the antiviral effects of
type-I IFN response of the horse. It is apparent from the work of Edington et al that EHV-1
induces a type-I IFN induction in horses but the virus resists the antiviral effects of type-I IFN. A
neuropathognic strain of EHV-1, T953 will be used as a model virus for this study. The type-I
response will be studied in EECs. Because,EECs will be considered to provide in vitro analogue
of cellular responses responsible for EHV-1 abortion and EHM. As reviewed above that for the
pathogenesis of EHV-1-induced abortion and EHM, replication of the virus in endothelial cells in
horse is a key step [338]. To elucidate the mechanisms the sub-hypotheses of this study are
H1. EHV-1 infection will cause suppression of type-I IFN induction compared to uninfected
cells, when treated with known type-I IFN inducer.
H2. EHV-1 will show reduced sensitivity to the antiviral effects of exogenous equine type-I IFN
(rEqIFN-α) compared to VSV.
To test these hypotheses, the specific aims are
A1. To measure the induction of type-I IFNs in EECs infected with either T953 virus in the
presence of known IFN-stimuli such as polyinosinic-polycytidylic acid (poly I:C) or absence of
stimuli.
A2. To determine the effect of rEqIFN-α on the replication of EHV-1 in vitro in EECs compared
to IFN-sensitive virus VSV.
The preliminary results from this study suggested an evasion of type-I IFN response by EHV-1 in
vitro. Based upon those results, additional aims were also included to elucidate the mechanism of
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suppression of type-I IFN response along with the viral genes responsible for that suppression in
T953 infected EECs. The additional specific aims are
A3. To identify EHV-1 genes involved in the evasion of type-I IFN mediated immune response
A4. To identify the mechanism(s) used by EHV-1 to modulate the type-I IFN mediated immune
response
The experimental approaches that will be taken to evaluate the specific aims are as follows:
In specific aim A1, EECs will be infected with T953 or Sendai virus (SeV) at a multiplicity of
infection (MOI) of 5 or co-infected with T953+SeV or T953+poly I:C and at different time points
type-I IFN production will be evaluated by real-time RT-PCR as well as type-I IFN bioassay. The
viral infection and replication will also be evaluated by indirect immunofluorescence assay (IFA)
and plaque assay respectively. In the specific aim A2, equine cells will be pre-treated with
rEqIFN-α to induce antiviral ISGs in those cells and then cells will be challenged with T953 virus
at low MOI to see if the virus can evade the ISG mediated response. Virus replication in the IFNtreated cells will be the criterion to determine if the virus can evade type-I IFN response. In the
specific aim A3, viral DNA polymerase will be inactivated using phosphonoacetic acid which in
turn will block viral late gene expression and then the effect of late gene blocking on type-I IFN
production will be evaluated in EECs. In the specific aim A4, EECs will be infected with T953
and different signaling pathways for IFN production such as IRF-3 and NF-κB signaling
pathways will be studied to know if the virus is interfering with the activation process of those
signaling pathways to suppress type-I IFN response. The signaling pathways by which type-I IFN
functions (JAK-STAT signaling pathways) will also be investigated. In addition to this, role of
T953 on the expression of different antiviral molecules induced by type-I interferon signaling will
be elucidated in this study.

Copyright © Sanjay Sarkar 2014
65

CHAPTER II: MATERIALS AND METHODS
2.1 Antibodies, Cytokines and Other Reagents
All the antibodies that were used in this study for immunofluorescence assay (IFA) and
Western blot (WB) have been listed Table 2.1.

Table 2.1: Antibodies used in this study
Working
Dilution/Concentration

Name of Ab

Source

Anti-rabbit IRF-3 (D6I4C
XP)
Anti-rabbit IRF-3

Anti-rabbit β-actin
Anti-rabbit lamin A/C
Anti-rabbbit viperin

Cell Signaling Technology, Danver,
MA
Santa Cruz Biotechnology, Dallas, TX
Cell Signaling Technology, Danver,
MA
Santa Cruz Biotechnology, Dallas, TX
Origene, Rockville, MD
Cell Signaling Technology, Danver,
MA
Cell Signaling Technology, Danver,
MA
GenScript USA Inc., Picataway, NJ
Abcam, Cambridge, MA

Anti-rabbit ISG56
Anti-rabbit IκBα

Pierce through Thermo Fisher
Scientific, Rockford, IL
Santa Cruz Biotechnology, Dallas, TX

Anti-rabbit IE1

Dr. Dennis O'Callaghan [339]

Anti-mouse gC

Dr. George P. Allen [110, 241]

1:2000 (WB)
1:500 (WB)
1:1500 (IFA), 1:3000
(WB)
1:100 (IFA), 1:1000
(WB)

Goat anti-rabbit IgG
conjugated to HRP

Cell Signaling Technology, Danver,
MA

1:3000 (WB)

Goat anti-mouse IgG
conjugated to HRP

Cell Signaling Technology, Danver,
MA

1:3000 (WB)

Goat anti-rabbit IgG (H+L)
conjugated to FITC

Santa Cruz Biotechnology, Dallas, TX

1:300 (IFA)

Texas Red goat anti-mouse
IgG (H+L)

Life Technologies, Grand Island, NY,

1:400 (IFA)

Anti-rabbit phospho-IRF-3
Anti-rabbit STAT-1 Ab
Anti-rabbit STAT-1 Ab
Anti-rabbit phospho-STAT-1

1:200 (IFA), 1:1000
(WB)
1:500 (WB)
1:1000 (WB)
1:500 (WB)
1:100 (IFA)
1:1000 (WB)
1:1000 (WB)
0.5 μg/ml
3 μg/ml

For the detection of EHV-1 infection, anti-rabbit IE1 mAb (1:1500 for IFA, 1:3000 for WB)
was received as a kind gift from Dr. Dennis O’Callaghan, Louisiana State University.Anti-mouse
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For the detection of EHV-1 infection, anti-rabbit IE1 mAb (1:1500 for IFA, 1:3000 for WB)
was received as a kind gift from Dr. Dennis O’Callaghan, Louisiana State University.Anti-mouse
EHV-1 gC mAb was developed by the late Dr. George P. Allen at Maxwell H. Gluck Equine
Research Center, University of Kentucky, Lexington, KY 40503 and was kindly provided by Dr.
Udeni B.R. Balasuriya, Maxwell H. Gluck Equine Research Center, University of Kentucky,
Lexington, KY 40503. Polyinosinic-polycytidylic acid (poly I:C), was purchased from InvivoGen
(CA, USA) and phosphonoacetic acid (PAA) was purchased from Thermo Fisher Scientific,
Rockford, IL, USA. Recombinant equine IFN-α (rEqIFN-α) was purchased from Kingfisher
Biotech, Saint Paul, MN, USA.

2.2 Culture of Cells
All the cell culture medium and reagents used in this study are enlisted in the table 2.2.
Table 2.2: List of cell culture reagents used in this study

Cell culture reagents

Source

Eagle’s Minimum Essential Medium (EMEM)
Minimum Essential Media (MEM)
Dulbecco’s Modified Eagle’s Medium (DMEM)
Dulbecco’s Phosphate-Buffered Salaine (D-PBS),
pH 7.4
Fetal Calf Serum (FCS)
Fetal Bovine Serum (FBS)
Penicillin-Streptomycin
Sodium Pyruvate
Sodium Bicarbonate
L-glutamine
Non-essential Amino Acids
Trypsin-EDTA
Rabbit Kidney-13 (RK-13) Cells
Madin-Darby Bovine Kidney (MDBK) Cells
African Green Monkey Kidney Cells (Vero Cells)

Mediatech Inc.,Manassas, VA
Invitrogen, Carlsbad, CA
Mediatech Inc.,Manassas, VA
Mediatech Inc.,Manassas, VA
Hyclone Laboratories Inc., Logan, UT
Hyclone Laboratories Inc., Logan UT
Gibco, Carlsbad, CA
Gibco, Carlsbad, CA
Gibco, Carlsbad, CA
Gibco, Carlsbad, CA
Gibco, Carlsbad, CA
Mediatech Inc., Manassas, VA
ATCC, CCL37, Manassas, VA
ATCC, CCL22, Manassas, VA
ATCC, CCL81, Manassas, VA

Equine endothelial cells (EECs) from pulmonary artery [340] were kindly provided by Dr. Udeni
B.R. Balasuriya at Maxwell H. Gluck Equine Research Center, University of Kentucky,
Lexington, KY, USA. EECs were maintained as confluent monolayers in 150-cm2 cell culture
flasks in Eagle’s Minimal Essential Medium (EMEM) with 10% fetal calf serum, 100 U/ml
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penicillin-streptomycin, 1 mM sodium pyruvate, 200 mM L-glutamine and sodium bicarbonate
(0.6 g/L) at 37°C in the absence of CO2. When confluent, the cell monolayer was washed 2x with
30 ml D-PBS and then trypsinized with 2 ml Trypsin-EDTA at 37 oC for 2-3 min. Cells from one
150-cm2 cell culture flasks were then resuspended in 100 ml enriched DMEM containing 10%
fetal calf serum, 100 U/ml penicillin-streptomycin, 0.1 mM non-essential amino acid and 200
mM L-glutamine and were propagated into four 6-well plates. When needed (such as for
immunofluorescence study) EECs were also grown onto cover slips in 24-well cell culture plates
in DMEM containing 10% fetal calf serum, 100 U/ml penicillin-streptomycin, 0.1 mM nonessential amino acid, and 200 mM L-glutamine.
Rabbit kidney-13 cells (RK-13 cells), African Green Monkey Kidney cells (Vero cells) and
Madin-Darby bovine kidney cells (MDBK cells) were maintained in 75-cm2 cell culture flasks in
EMEM supplemented with 10% fetal bovine serum, 100 U/ml Penicillin-streptomycin, 1 mM
sodium pyruvate and 200 mM L-glutamine.

2.3 Virus Strains
The equine herpesvirus used in this study was the neurovirulent T953 strain of EHV-1
(also known as Findlay strain or OH’03 strain of EHV-1). The virus was originally isolated from
the nasopharyngeal swab of a horse suffering from EHV-1 induced quadriplegia during the
extensive neurologic disease outbreaks that occurred at the Veterinary Medical Teaching
Hospital, at The University of Findlay, Ohio, USA in January, 2003. [213]. The virus was
isolated and archived by the late Dr. George P. Allen and it was kindly provided by Dr. Udeni
B.R. Balasuriya at the Maxwell H. Gluck Equine Research Center, University of Kentucky,
Lexington, KY. The neurovirulence phenotype of EHV-1 T953 strain was further confirmed by
experimental inoculation of horses with low passaged EHV-1 T953 strain by the late Dr. George
P. Allen [217]. The virus was originally isolated and propagated on the equine fibroblast cell line
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at a low MOI. For this study, the virus was amplified in EECs and passage 3 (P3) of this virus
was used.
Another neuropathogenic strain of EHV-1, Ab4 was isolated from a mare suffering from
paresis in England in 1980 [341]. The recombinant Ab4 mutant virus which was generated by
deleting ORF1 and ORF2 genes (Ab4ΔORF1/2) and WT Ab4 [342] were kindly provided by Dr.
Nikolaus Osterrieder, Institut für Virologie, Freie Universität Berlin, Berlin, Germany. Sendai
virus (ATCC VR907, Cantell Strain) was purchased from Charles River Laboratories
International Inc., Wilmington, MA, USA. The recombinant vesicular stomatitis virus expressing
green fluorescent protein (VSV-GFP) was kindly provided by Dr. Adolfo García-Sastre (Mount
Sinai School of Medicine, NY, USA).

2.4 Preparation of Viruses
To prepare a stock of EHV-1 virus, EECs in 175 cm2 cell culture flasks were infected with
EHV-1 T953 at an MOI of 0.1. When nearly 100% cytopathic effect (CPE) was shown, viruses
were harvested by three cycles of freeze-thaw of the infected flasks. The viruses were clarified at
2000 g for 30 min at 4̊C, filtered through 0.45 μm cellulose acetate membrane filter (Thermo
Fisher Scientific, Pittsburgh, PA) and the tissue culture fluids (TCFs) containing the virus was
aliquoted and preserved at -80 °C as stock virus. From this stock, the virus was again amplified in
EECs and clarified as stated and TCFs were further purified by ultracentrifugation at 100,000 x g
for 4 h at 4oC through a 20% sucrose (in D-PBS) cushion using L7 Ultracentrifuge machine
(Beckman Coulter, CA, USA). To maximize the titer of the virus, each pellet was then
resuspended in minimum volume (100-200 μl) of sterile DMEM with 2% FBS, sonicated briefly
(30 sec x 3 cycles, with 1 min rest in between a cycle) and aliquoted at 100 μl each in 1.5 ml
eppendorf tubes to save at -80 ̊C. The viruses were titrated on RK-13 cells by plaque assay. Ab4
wild type (WT) and Ab4ΔORF1/2 viruses were propagated and amplified on EECs and purified
in the same manner as T953 was done.
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UV inactivation of EHV-1 T953 strain was achieved by using UV Stratalinker 1800
(Stratagene).
Briefly, 1 ml of TCF containing the T953 virus was placed in a 35 mm petridish and was exposed
to the ultra-violet rays with a wavelength of 254 nm for 30 min on ice from a distance of 10 cm
from the UV bulb. After the UV treatment, the virus was propagated on a monolayer of RK-13
cells to confirm the inactivation.
Sendai virus was inoculated into the allantoic cavities of ten day old specific pathogen free
embryonated hen eggs, which were incubated at 37°C for 72 h. Allantoic fluids were harvested
and clarified at 2000 x g for 30 min at 4̊C and then purified by ultracentrifugation at 100,000 x g
for 4 h at 4 °C through a 20% sucrose (in D-PBS) cushion using L7 Ultracentrifuge machine
(Beckman Coulter, CA, USA). The pellet was resuspended in calcium-magnesium free D-PBS,
and aliquoted at 100 μl each in 1.5 ml eppendorf tubes and saved at -80 °C for future use. The
virus was titrated by plaque assay on Vero cells.
VSV-GFP was amplified in MDBK cells by infecting confluent layers of MDBK cells in
800 cm2 Corning roller bottles (Sigma Aldrich, St. Louis, MO, USA) at an MOI of 0.5. When
approximately 100% CPE was shown, viruses were harvested by three cycles of freeze-thaw of
the infected roller bottles. The viruses were then clarified at 2000 g for 30 min at 4 °C, filtered
through a 0.45 μm cellulose acetate membrane filter, and TCFs containing the virus were
aliquoted and saved at -80 °C as stock virus. This stock virus was again amplified in MDBK cells
and clarified as stated and TCFs were further purified by ultracentrifugation at 100,000 x g for 4 h
at 4 °C through a 20% sucrose (in D-PBS) cushion using L7 Ultracentrifuge machine (Beckman
Coulter, CA, USA). The pellets were then resuspended in minimum volume (100-200 μl) of
sterile MEM, sonicated briefly (30 sec x 3 cycles with 1 min rest between each cycle) and
aliquoted at 100 μl each in 1.5 ml eppendorf tubes to save at -80 °C. The virus was titrated on
MDBK cells by plaque assay.
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2.5 Virus Infection of EECs
EECs were cultured in 175 cm2 tissue culture flasks and were propagated in either 6-well or
24-well plates before infection. At confluency, EECs were washed twice with sterile D-PBS and
then infected with either T953, SeV or combination of both of the virus at an MOI of 5. During
infection in a 6-well plate, virus was added in a total volume of 200 μl and in case of 24-well
plate virus was added in a total volume of 100 μl. The virus was adsorbed onto the EECs for 1 h
at 37 ˚C, 5% CO2 with an intermittent gentle mixing of the plates at every 10 min interval. Cells
were mock infected with virus diluent (DMEM+2% FBS). After the incubation, the plates were
washed again with D-PBS and the growth medium was added. The infected plates were then
incubated at 37 ˚C with 5% CO2 in a humidified chamber for the indicated time points and
different assays were performed as will be described below.

2.6 Plaque Assay
The virus was titrated by plaque assay as described by McCollum et al with little
modification [343]. Briefly, RK-13 cells or MDBK cells or Vero cells were propagated in 6-well
plates. Then the confluent monolayers were washed twice with D-PBS and infected with 10 fold
serial dilutions (10-1, 10-2, 10-3, 10-4, 10-5, 10-6, 10-7, 10-8, 10-9, and 10-10) of cell culture
supernatants containing virus. 10 fold serial dilutions of virus were made by adding 100 μl of
virus to 900 μl of sterile MEM. For each dilution of the virus, duplicate wells were infected. The
virus was let to adsorb for 1 h with intermittent shaking at 10 min interval at 37°C inside an
incubator in presence of 5% CO2. Next, the plates were washed twice with PBS (pH 7.4) to
remove the unadsorbed viruses and the growth medium (enriched EMEM with 10% FBS) with
0.75% carboxy-methyl cellulose (CMC) (Sigma Aldrich, St. Louis, MO) were added and the
plates were further incubated for 96 h at 37oC, 5% CO2. Then the growth medium was removed
and the plates were stained with 1% crystal violet solution in buffered formalin (10%) for
visualization of plaques.
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The titers were calculated by counting the number of plaques and multiplying by the dilution
factors. Finally, the titers of the viruses were expressed in plaque forming units/ml (PFU/ml).

2.7 Infectious Center Assay
The infectious center assay (ICA) is normally used to calculate the proportion of cells
within a culture of sensitive cells which are infected with virus. This assay was performed in this
study to know if rEqIFN-α treatment of EECs makes the cells resistant to virus entry following
infection with T953 virus. During the early phase of the infection or eclipse phase, there is no free
virus and as a result no CPE is found within the indicator cells.
EECs were propagated into 6-well plates and at about 90% confluency, the cells were
treated with rEqIFN-α at 1000 IU/ml for 24. One group of EECs was also left untreated. After
IFN-treatment the cells were washed 2X with D-PBS and challenged with T953 at an MOI of 0.5
and incubated at 37 °C for 1 h in presence of 5% CO2. After virus adsorption, the cells were
washed 2X with D-PBS, trypsinized and resuspended as single cell suspensions in growth media.
Cells were then counted and equal numbers of cells (2x105 cells in total volume of 200 ul) were
plated in duplicate wells for each dilution onto confluent monolayers of RK-13 cells (indicator
cells). The cells were then overlaid with 0.75% CMC in EMEM complete growth media and
incubated at 37 °C with 5% CO2 for 96 h. After that the growth medium was removed and the
plates were stained with 1% crystal violet in buffered formalin for 2 h at RT. The plates were
washed under running tap water and the plaque numbers were counted. The number of plaques
which were formed on the indicator cells indicated the number of EECs that were originally
infected with T953. Then the infected cell numbers per 2 million EECs that were originally
infected with the virus were determined.
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2.8 RNA Extraction and Real-Time RT-PCR Assay
Total cellular RNA was extracted from mock or T953 infected or otherwise coninfected
(T953+SeV or T953+poly I:C or T953+EqIFN-α) EEC samples from 3 h, 6 h, 12 h and 18 h post
infection (p.i.) using the RNeasy Mini Kit (Qiagen, Valencia,CA) following the manufacturer’s
protocol. The possible genomic DNA contamination was removed by in-column treatment of
RNA with DNase-I (RNase free DNase set, Qiagen, Valencia, CA). The quality and the quantity
of the RNA were assessed by measuring the absorbance ratio of RNA at optical density (OD)
values at 260 nm and 280 nm (OD260/OD280) and OD260 value respectively by NanoDrop (Thermo
Scientific, Wilmington, DE). One microgram of total cellular RNA was brought to a volume of
41.5 μl using nuclease free water (Qiagen, Valencia, CA) and reverse transcribed in a 80 μl total
volume reaction using 38.5 ul reverse transcription master mix containing 0.5 μl [20 U/μl] avian
myeloblastosis virus [AMV] reverse transcriptase [Promega, Madison, WI], 1 μl oligo dT primer
[0.5 μg/μl, Promega], 1 μl RNasin plus RNase inhibitor [40 U/μl, Promega], 4 μl dNTP [10 mM,
Promega], 16 μl AMV buffer [Promega], and 16 μl MgCl2 [25 mM, Promega]) as described by
Coombs et al. [344]. The reaction mixture was incubated at 42 °C for 15 min followed by 95 °C
for 5 min in a thermocycler. The cDNA was then diluted 1:1 with sterile nuclease-free water
(Qiagen, Valencia, CA). Equal amounts of cDNA were used for the gene expression analysis of
different cytokines by TaqMan real-time PCR using an Applied Biosystems 7500 Fast Real-Time
PCR system (Applied Biosystems, Foster City, CA). The sequences of specific primers and
probes used in this study targeting specific genes are provided in Table 2.3. In each PCR reaction
in 384-well plates, 5 μl master mix (SensiMixTM II Probe Kit, Bioline), 0.5 μl 20X primer-probe
mix (Applied Biosystems) and 4.5 μl template cDNA were added and incubated at 95 °C for 10
min, followed by 40 cycles for 15 sec each, and 60 °C for 1 min.
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Table 2.3: Primers and probes for real-time RT-PCR used in this study
Target
gene
EqRPLP0

EqIFN-β

EqISG56

EqViperin

Sequences (5’ to 3’)/ Information

References

Fwd: CTGATTACACCTTCCCACTTGCT
Rev: AGCCACAAATGCAGATGGATCA
Probe: FAM-AAGGCCTTGACCTTTTC-NFQ
5’-AATGGCCCTCCTGCTGTGT-3’
5’-CCGAAGCAAGTCATAGTTCACAGA-3’
FAM-CTCCACCACGGCTC-NFQ
Fwd: AGCCCATTCAGCTAAACAAAAC
Rev: CAGTGTCTTCAATTAGCAAATCCC
Probe: 5'- /56-FAM/TCC AGC CTG /ZEN/TCC TTG
ATG TGA TCTTC/3IABkFQ/ -3'

Boliar et al [345]

Fwd: CGCCAGTGCAATTACAAGTG
Rev: TCTCCGCCCGAAAAGTTTATC
Probe: 5'- /56-FAM/CTT CCA CAC /ZEN/GGC CAA
GAC TTCCT/3IABkFQ/ -3'

Sarkar et al from this
study

Horohov et al [346]

Sarkar et al from this
study

All reactions were performed in duplicate. The quantitative real-time PCR (qPCR) data were
normalized to mRNA levels of equine ribosomal protein large P0 (RPLP0) as endogenous
controls. Initially, several house-keeping genes [RPLPO, β glucuronidase (β-GUS),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β2-microglobulin, β-actin and eukaryotic
18s rRNA] were tested and the expression level of RPLPO was found to be the most stable during
EHV-1 infection. As a result, RPLPO was used to normalize the qPCR data. PCR efficiency for
all reactions was assessed by LinReg software [347]. Fold changes in the gene expression were
calculated by the relative quantitation method described by Livak et al [348] which assumes that
the relative concentration of target mRNA is equal to 2 –ΔΔCt where ΔΔCt = [(Avg. Ct of gene of
interest – Avg. Ct of RPLP0)

sample

– (Avg. Ct of gene of interest – Avg. Ct of RPLP0) calibrator].

The average ΔCt value of mock infected samples for each individual gene was used as the
calibrator.
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2.9 Type-I Interferon Bioassay
For interferon bioassays, EECs were either mock infected or EHV-1 infected or treated as
specified and the supernatants were harvested at different times post infection. The supernatants
were filtered through Vivaspin 2 (Sartorius Stedim North America Inc., Bohemia, NY) to remove
virus particles. Filtered supernatants were added on to a monolayer of MDBK cells at 100 μl/well
in duplicate wells and incubated for 24 h at 37oC, 5% CO2. The efficiency of the Vivaspin 2 filter
to remove virus particles from TCF was confirmed by the absence of CPE when looked under an
inverted light microscope. MDBK cells were then grown in 96-well plates and at 80 %
confluency the cells were treated with 100 μl/well of serially two fold diluted filtered
supernatants. After 24 h of incubation, the cells were washed twice with warm D-PBS and
challenged with VSV-GFP at an MOI of 0.1. At 18 h post challenge, the growth medium was
discarded and cells were then stained with 1 % crystal violet with buffered formalin. The results
were expressed as laboratory unit (LU)/ml. The dilution in which 50% of a well was protected
after VSV-GFP challenge was considered to have one LU of type-I interferons.

2.10 Immunofluorescence Assay
EECs were grown on poly L-lysine-coated coverslips (Fisher Scientific, Waltham, MA) in
24-well plates and treated as specified. At indicated time points, the cells were washed with ice
cold PBS (pH 7.4) and fixed with 4 % PFA at room temperature (RT) for 30 min. After washing
3X with PBS-glycine (10mM glycine in PBS), cells were permeabilized with 0.1 % Triton X-100
in D-PBS (pH 7.4) for 10 min at RT, washed again 3X times with PBS-glycine (10 mM) and then
blocked with 5 % goat serum in PBS for 30 min at RT. The coverslips were then washed again
3X with PBS-glycine and incubated with primary antibodies at RT for 50 min. The name of the
antibodies and their dilutions used in this study are enlisted in table 2.1. Next, the unbound
primary antibodies were washed off with PBS-glycine and then the coverslips were incubated
with corresponding secondary antibodies conjugated with either fluorescein isothiocyanate
(FITC) or tetramethyl rhodamine isothiocyanate (TRITC) for 50 min at RT. Finally, the
75

coverslips were washed and mounted in VECTASHIELD Mounting Medium containing 4’, 6’diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA) and observed under an
inverted fluorescence microscope (Nikon ECLIPSE Ti, Melville, NY, USA).

2.11 Western Blot Analysis
EECs were grown on 6-well plates and treated with T953 or as described. At indicated time
points the cells were washed in cold PBS (pH 7.4) and harvested in cell lysis buffer containing 20
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM ethylene glycol tetraacetic acid
(EGTA; Sigma), 1% Triton X-100 (Sigma), 2.5 mM sodium pyrophosphate, 1 mM βglycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, 1mM phenylmethylsulfonyl fluoride
(PMSF; Fisher Scientific) enriched with protease and phosphatase inhibitors (Halt Protease and
Phosphatase Inhibitor Cocktails, Thermo Scientific, Rockford, IL) on ice. The lysates were
briefly sonicated and centrifuged at 14,000 g for 10 min at 4 °C. These protein samples were
mixed with 5X reducing sample buffer (Lane Marker Reducing Sample Buffer, Thermo
Scientific,) containing proprietary pink tracking dye in 0.3M Tris-HCl, 5% sodium dodecyl
sulfate (SDS), 50% glycerol, 100mM dithiothreitol (DTT), boiled at 95 °C for 5 min and cooled
immediately. Denatured proteins were separated onto 10 % SDS polyacrylamide resolving gels
and 5 % stacking gels at 200 V for 40 min. After that, proteins were transferred onto a
polyvinylidene difluoride (PVDF, Bio-Rad Laboratories, CA) membranes at 100 V for 50 min to
75 min (depending upon the molecular weight of the protein of interest) and blocked with 5 %
non-fat dry milk (Bio-Rad) in Tris-buffered saline (TBST) for 1 h at RT. Following blocking, the
membranes were incubated overnight with primary antibodies either in blocking buffer or 5 %
bovine serum albumin (BSA) in TBST at 4 °C. The unbound primary antibodies were removed
by washing the membranes 3X with TBST, with 10 min each washing. The membranes were then
incubated with corresponding secondary antibodies for 1 h at RT followed by 3X washing with
TBST (10 min each wash) and then developed by using the enhanced chemiluminescence
(SuperSignal West Pico Chemiluminescent Substrate Kit, Thermo Scientific) detection method.
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The protein bands in the membrane were visualized by Fluorche E System (Cell Biosciences, San
Jose, CA).

2.12 Separation of Cytoplasmic and Nuclear Proteins
EECs were maintained in T150 flasks in complete growth media and infected with T953 at
an MOI of 5 or left uninfected. At indicated time points the cells were lysed and cytoplasmic as
well as nuclear proteins were separated by cell fractionation by NE-PER® Nuclear and
Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific, Rockford, IL, USA) as per
manufacturer’s protocol. Briefly the cells were washed two times with D-PBS (pH 7.4) and
harvested with trypsin-EDTA and centrifuged at 500 x g for 5 min. The pellet was washed again
by suspending it in D-PBS and pelleted again by centrifugation at 500 x g for 3 min. The
supernatants were removed very carefully leaving the pellet as dry as possible. Next, an
appropriate volume of cytoplasmic extraction reagent I (CER I) solution was added to resuspend
the pellet with vigorous vortexing. The volume of CER I was dependent on the volume of cell
pellet following the chart supplied with the kit. The tube was incubated on ice for 10 min and
then ice cold CER II was added followed by vortexing. It was then incubated on ice for 1 min and
vortexed again and centrifuged at 16000 x g for 5 min at 4 °C. Immediately after that the
supernatant containing the cytoplasmic proteins were transferred into pre-chilled tubes and stored
at -80 °C until further use. The insoluble pellet containing nuclei was resuspended again using ice
cold nuclear extraction reagent (NER) by vortexing briefly and was incubated on ice for 40 min
with 15 seconds vortexing at 10 min intervals. The tubes were then centrifuged at 16000 x g for
10 min at 4 °C and the supernatant containing the nuclear proteins was separated and stored at -80
°C. The cytoplasmic and nuclear protein lysates were mixed with 5X sample buffer for separation

by SDS-PAGE in a 10% bis-crosslinked polyacrylamide gel as described earlier. After separation,
proteins were transferred onto a PVDF membrane and blotted with corresponding primary and
secondary antibodies and developed as described earlier.
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2.13 Quantification of Band Intensity
The relative intensity of the expression level of different protein bands in the western blot
images was quantified by densitometric analysis using ImageJ software, National Institute of
Health (NIH), USA following the manufacturer’s instructions. The

2.14 Statistical Analysis
All the experiments were repeated 3 times if not otherwise stated. The data were analyzed
either by Student’s t test or analysis of variance (ANOVA) and Pairwise Multiple Comparison
Procedures by Holm-Sidak Method using statistical analysis software Sigmaplot 12.3 (Systat
Software Inc. San Jose, CA). In the case when only two groups were compared (as in the case of
real-time PCR data in ISG mRNA induction experiment), Student’s t test was performed. In all
other cases, data were analyzed by ANOVA. P values of less than 0.05 % were considered as
statistically significant.

Copyright © Sanjay Sarkar 2014

78

CHAPTER III: RESULTS

3.1 Standardization of EHV-1 Infection in EECs
To determine the MOI to be used for the study, EECs were grown on 6-well plates and were
infected with a neuropathogenic strain of EHV-1, T953 at an MOI of either 0.5, 5 or 10. At 12 h
post infection, cells were fixed with 4% PFA and the virus infection was evaluated by IFA using
EHV-1 IE1 specific antibody. It was found that >95% cells were IE1 positive at an MOI of 5
(Figure 3.1) and hence, this MOI was selected, unless otherwise stated.

Figure 3.1: Immunofluorescence images showing the infection of EECs with T953: EECs
were infected with T953 at an MOI of 5 and at 12 h.p.i. the cells were fixed and stained with antirabbit IE1 antibody. Mock treated EECs stained with DAPI for nucleus (A), anti-rabbit IE1 Ab
conjugated with FITC (B), and merged images of A and B (C). T953 infected EECs stained with
DAPI (D), anti-rabbit IE1 Ab conjugated with FITC (E), and merged images of D and E (F).
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3.2 Replication of T953 in EEC:
To evaluate whether T953 can replicate and produce infectious progeny virus in EECs,
monolayers of EECs were infected at an MOI of 5 and virus titers in the supernatants of infected
cells collected at various time post-infection (3, 6, 12 and 18 h.p.i.) were determined by plaque
assay. Results showed that T953 can successfully replicate in the EECs producing progeny virus.

Figure 3.2: Replication of T953 in EECs: EECs were infected with T953 at an MOI of 5 and at
3, 6, 12 and 18 h.p.i. supernatants from the infected cells were collected and titrated for virus. At
18 h.p.i. highest titer of the virus were seen. Data represents mean with standard deviation from 3
independent experiments.
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3.3 Effect of T953 Virus Infection on IFN-β Gene Transcription in EECs
T953, a neuropathogenic strain of EHV-1, is an endotheliotropic virus which replicates in the
endothelial cells of blood vessels, causing ischemic damage which results in the neurologic
disease, EHM. One of the sub-hypotheses was that T953 virus suppresses type-I IFN induction in
the infected endothelial cells making the microenvironment more conducive for enhanced viral
replication which adds to the severity of the disease. Previously, it has been shown that EHV-1
infections of PBMCs induce significant amounts of type-I IFN both in vivo and in vitro [332,
349], but there is no report whether EHV-1 has the ability to interfere with type-I IFN immune
responses of horse. Here, EECs were infected with T953 at an MOI of 5. SeV and poly I:C served
as positive controls for the type-I IFN induction. Virus diluent (DMEM + 2% FBS) treated EECs
were used as negative controls. At 3, 6, 12 and 18 h.p.i. IFN-β gene expression was evaluated by
real-time RT-PCR assay. T953 infection of EECs induced a significant amount of IFN-β mRNA
transcription (p<0.001) at early times post infection (3 and 6 h.p.i.) [Fig 3.3A] but at later time
points (12 and 18 h.p.i.) there was no significant amount of IFN-β mRNA induction (Fig 3.3A).
There was also a gradual decrease in the transcription of the IFN-β gene from 3 to 6 h.p.i. On the
other hand, UV inactivated T953 virus did not induce any IFN-β mRNA either at early or late
stage of the infections (Figure 3.3A).
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Figure 3.3: T953 suppresses IFN-β mRNA induction. EECs were either mock infected or
infected with different viruses separately or together or treated with chemicals as indicated. At
indicated time points equine IFN-β mRNA was quantified by real-time RT-PCR and data were
normalized to endogenous control equine RPLP0. T953 infection inhibited IFN-β mRNA at later
time points (12 h onwards) after an initial induction at early time points (3 h) [Fig 3.3A]. T953
virus also suppressed IFN-β mRNA induced by SeV [Fig 3.3B] and poly I:C [Fig 3.3C]. Data
represents mean with standard deviation from 3 independent experiments. *** = p<0.001, ** =
p<0.01 and * = p<0.05 were considered significant.
To identify if T953 virus can inhibit the IFN-β mRNA induction by other known stimuli,
EECs were coinfected with SeV at an MOI of 5 or co-treated with poly I:C and T953 virus for
indicated time periods. It was observed that from 6 h.p.i. onwards, T953 and SeV coinfected
EECs had significant decreases (p<0.01, p<0.001, p<0.001 at 6, 12 and 18 h.p.i respectively) in
the IFN-β mRNA induction compared to only SeV infected EECs (Fig 3.3B). T953 virus
infection also significantly suppressed the poly I:C induced IFN-β mRNA transcription at 12 h.p.i
onwards (p<0.001) [Fig 3.3 C].
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3.4 Effect of T953 Virus Infection on Type-I IFN Production in EECs
To evaluate the effect of T953 virus on type-I IFN induction at the translational level, a
type-I IFN bioassay using a recombinant VSV-GFP virus was performed on the saved
supernatants from the previously infected EECs for real-time RT-PCR assay. It was seen that
T953 infection of EECs induced a significant amount of type-I IFN activity at 3 and 6 h.p.i. when
compared to mock infected EECs (p<0.05) [Fig 3.4 𝐴]. The virus infection also induced type-I
IFN activity in the later time points (12 and 18 h.p.i.) [Fig 3.4 A], although there was a gradual

decrease in the type-I IFN activity. As with IFN-β mRNA transcription, UV-inactivated T953
virus did not induce any significant amount of type-I IFN activity.
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Figure 3.4: T953 suppresses type-I IFN activity. EECs were either mock infected or infected
with different viruses separately or together or treated with chemicals as indicated. At indicated
time points cell supernatants were collected and type-I IFN activity was quantitated by interferon
bioassay using VSV-GFP. Type-I IFN bioassay is performed by incubating IFN-sensitive cells
with serially diluted samples containing IFN and then challenging those cells with IFN-sensitive
virus VSV-GFP. The well of a 96 well plate at which 50% of the cells were protected from VSVGFP CPE was considered as 1 laboratory unit (LU). Data represents mean with standard error
from 3 independent experiments. ** = p<0.01 and * = p<0.05 were considered significant. T953
infection to EECs induced type-I IFN activity at all time points (Fig 3.4A). But, T953 inhibited
type-I IFN activity induced by SeV at 6 h, 12 h and 18 h (Fig 3.4B). The virus also suppressed
poly I:C induced type-I IFN activity at 12 h and 18 h(Fig 3.4C).
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To determine whether T953 virus could inhibit production of type-I IFN induced by other known
stimuli at translational level, EECs were coinfected with T953 and SeV or T953 and poly I:C for
different periods of time. It was observed that T953 coinfected with SeV induced significantly
decreased type-I IFN activity at 6 h.p.i (p<0.05), 12 h.p.i. (p<0.01) and 18 h.p.i (p<0.01)
compared to only SeV induced type-I IFN activity (Fig 3.4B). Data also suggested that T953
virus could suppress the type-I IFN activity induced by poly I:C significantly (p<0.05) at later
times post infection (12 and 18 h.p.i.) [Fig 3.4C]. The results of these studies involving IFN-β
gene expression kinetics also suggested that the longer the virus was incubated the more was the
IFN-inhibitory effect. This suggested that expression of late viral genes might be responsible for
the suppression of type-I IFN production.

3.5 The T953 Strain of EHV-1 Actively Suppresses IFN-β Gene Expression Induced
by Sendai Virus
In the coinfection model of the previous experiment, EECs were infected with SeV and
T953 together and were incubated for same period of time. It was possible that decreased IFN-β
induction at later time points were due to the normal IFN kinetics or due to the absence of stimuli
at late stage of the infection. To assure that T953 virus but no other reasons can actively suppress
the type-I IFN production, a coinfection study was done where first T953 or SeV was allowed to
express its genes for some time (3 h), then the same cells were infected with the other virus and
were incubated for another 6 h. At 9th hour after first infection, IFN-β mRNA production was
compared between coinfected EECs and EECs infected with only SeV.
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Figure 3.5: T953 actively suppresses SeV induced INF-β mRNA transcription. EECs were
either infected with SeV or T953 and at 3 h.p.i. cells were re-infected with T953 or SeV
respectively for another 6 h. At 9 h.p.i. cells were lysed for total cellular RNA and IFN-β mRNA
were quantitated from the reverse transcribed cDNA by real-time qPCR assay. Data were
normalized to endogenous control equine RPLP0. Data represents mean with standard deviation
from 3 independent experiments. T953 infection to EECs actively suppressed the transcription of
IFN-β mRNA induced by SeV. Data were significant at p<0.001 (***).

When EECs were first infected with T953 virus and allowed to express its genes for 3 h, then
infected the same cells with SeV for another 6 h, it was found that coinfected EECs produced a
significantly lower amount of IFN-β mRNA (p<0.001) compared to only SeV infected cells for 6
h (Fig 3.5). Even when EECs were first stimulated with SeV for 3 h and then same cells were
infected with T953 for another 6 h, there was a significant (p<0.001) decrease of IFN-β mRNA
compared to only SeV infected cells for 9 h (Fig 3.5). These data suggested that T953 virus
actively suppressed the type-I IFN induction capability induced by another known virus stimulus
(SeV).
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actively suppressed the type-I IFN induction capability induced by another known virus stimulus
(SeV).

3.6 T953 Virus Actively Suppresses IFN-β Gene Expression Chemically Induced by
Poly I:C
In the above coinfection experiment, it was considered possible that one virus infection to a
cell could restrict the entry of another virus into the same cell. If so, it was possible that decreased
IFN-β mRNA production by Sev and T953 coninfected EECs was due to the interference of SeV
entry into the coinfected EECs by T953. To rule out that explanation for the suppression of IFN-β
mRNA induction, EECs were first infected with T953 virus and allowed to express viral genes for
different time periods (0, 3, 6 and 12 h) and then same infected cells were stimulated with the
chemical inducer, poly I:C at 80 μg/ml for 12 h. IFN-β mRNA transcription was evaluated by
real-time RT-PCR assay. The results showed that T953 infected EECs produced significantly
lower amount of IFN-β mRNA when co-stimulated with poly I:C compared to only poly I:C
treated cells (Fig 3.6) in all time points.
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Figure 3.6: T953 actively inhibits poly I:C induced IFN-β mRNA transcription. EECs were
infected with T953 virus and at 0, 3, 6 and 12 h.p.i. infected cells were stimulated with poly I:C at
80 μg/ml for an additional 12 h. Cells were then lysed for total cellular RNA which was reverse
transcribed and IFN-β mRNA transcripts were quantitated by real-time qPCR assays. Equine
RPLP0 was used as endogenous control to normalize the data. Data represents mean with
standard deviation from 3 independent experiments. IFN-β mRNA transcription of T953 + poly
I:C coinfected EECs was compared with only poly I:C treated cells. T953 actively inhibited
transcription of chemically induced IFN-β mRNA by poly I:C. a, b, c are significantly different
from each other at p<0.001.

From these data it was also evident that the longer the virus was allowed to express its genes, the
greater the suppressive effect. By 12 h.p.i., T953 infected EECs stimulated with poly I:C were no
longer able to make significant amounts of IFN-β mRNA. This supports the hypothesis that T953
can actively suppress type-I IFN induction by known exogenous stimuli including poly I:C and
SeV.
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can actively suppress type-I IFN induction by known exogenous stimuli including poly I:C and
SeV.

3.7 Effect of Late Gene Blocking of EHV-1 on Type-I IFN Production
The preceding results show that T953 infection suppresses IFN-β responses and indicated a
possible link of EHV-1 late genes with the reduced IFN-β mRNA at later time points. The next
goal of this study was to block the late gene expression of T953 virus. EECs were infected with
T953 virus in presence of a chemical inhibitor, phosphonoacetic acid (PAA) which is known to
inactivate the herpes viral DNA polymerase [350]. The late gene expression of T953 virus at
protein level was evaluated at 18 h.p.i. by an immunofluorescence study using a monoclonal
antibody against the late gene, gC. A titration on PAA concentration was done to find the right
concentration to be used without host cell toxicity. PAA at a concentration of 300 μg/ml of
growth media during T953 infection to EECs, prevented the majority of viral late gene, gC
expression (Fig.3.7). In addition to blocking of L (γ) genes, it was also evaluated whether PAA
had any effect on IE gene expression by using another antibody (α-IE1 Ab) specific to IR1
protein (IE gene product). The results showed that IE gene expression was unaffected by PAA
treatment (Fig 3.7). This confirms that PAA blocks the late gene expression of herpesvirus
including EHV-1 but it does not interfere with the expression of IE gene and thus allowed for the
evaluation of the effect of IE (α) and E (β) genes on the suppression of the type-I IFN both at
mRNA and protein levels. EECs were infected with T953 in the presence or absence of PAA for
3, 6, 12 and 18 h. EECs treated only with PAA in virus diluent medium were used as negative
controls. At indicated time points type-I IFN production was evaluated by measuring the
transcription of IFN-β mRNA by real-time RT-PCR assay as well as type-I IFN activity by
interferon bioassay.

90

Figure 3.7: PAA blocks late gene expression but not IE gene expression. EECs were infected
with T953 in the presence or absence of PAA at 300 μg/ml. At 18 h.p.i. viral gene expression was
evaluated by IFA using EHV-1 late gene gC specific Ab (anti-gC Ab) and IE gene specific Ab
(anti-IE1 Ab).Upper panel shows the staining of mock infected EECs treated with PAA. Middle
panel shows that in the presence of PAA, T953 infected EECs showed no gC expression but
showed IE gene expression. The lower panel shows that in the absence of PAA, T953 infected
EECs showed expression of both the late gene, gC and the sole IE gene.
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Figure 3.8 A: Late gene blocking induces robust IFN-β mRNA transcription at later time
points. EECs were infected with T953 in the presence or absence of PAA and at indicated time
points cells were harvested to extract total cellular RNA. Transcription of IFN-β mRNA was
quantitated by real-time RT-PCR assay. Data were normalized to the endogenous control equine
RPLP0. Data represents mean with standard deviation from 3 independent experiments. Late gene
blocking of T953 by use of PAA induced more IFN-β mRNA in EECs compared to only T953
infected EECs without PAA at 12 and 18 h.p.i. Data are significantly different from each other at
p value of <0.01 (**).

Significant differences (p<0.01) were observed in the IFN-β mRNA transcription starting at 12
h.p.i. and at 18 h.p.i. T953 infected EECs in the presence of PAA caused a robust IFN-β mRNA
production compared to T953 infected EECs in the absence of PAA (Fig. 3.8 A). It was further
investigated whether blocking of viral late genes had the same type-I IFN inducing effect at the
level of translation. Results of the type-I IFN bioassay performed on the infected cell supernatants
showed that T953 virus infected EECs produced significantly higher levels of type-I IFN activity
at 12 and 18 h.p.i. when expression of viral late genes was blocked by PAA treatment compared
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to T953 infected EECs in the absence of PAA treatment (p<0.05 and p<0.001, Fig 3.8 B). It is
interesting to note that the same effect was even more evident at 24 h.p.i.(data not shown).

Figure 3.8 B: Late gene blocking induces robust type-I IFN activity at later time points.
EECs were infected with T953 in the presence or absence of PAA and at indicated time points
cell supernatants were collected and titrated for type-I IFNs by interferon bioassay. Data
represents mean with standard deviation from 3 independent experiments. Late gene blocking of
T953 by use of PAA induced significantly more type-I IFN activity in EECs compared to only
T953 infected EECs at 12 and 18 h.p.i. Data were considered significant at p value of <0.01 (**)
and p<0.05 (*).

These data suggest that EHV-1 has mechanisms which actively inhibit type-I IFN immune
responses and viral late genes but not IE or E genes play a major role in this suppression.
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3.8 Effect of T953 Virus Infection on the Stability of IRF-3
It is well established that for the production of type-I IFN, triggering of either IRF-3/7, AP1 or NF-κB transcription factors is necessary. As reviewed above, different viruses may target
different transcription factors to interfere with production of this important host antiviral
cytokine. Like BHV-1 IE protein bICP0 or HSV-1 it seemed plausible that EHV-1 protein(s)
directly degrade the most important transcription factor, IRF-3 in the type-I IFN production
pathways. To elucidate the mechanisms, EECs were either infected with T953 or mock infected.
At 3, 6, and 12 h.p.i. cells were lysed to prepare total cell lysates and were analyzed by Western
blot using anti-IRF-3 antibody.
The Western blot analyses on T953 infected cell lysates showed that virus infection of
EECs indeed caused down-regulation of the endogenous level of IRF-3 proteins (Fig 3.9 A) as
early as at 6 h.p.i. At 12 h.p.i. the majority of the endogenous IRF-3 level was down-regulated
when compared to mock infected cell lysates. Western blot image also suggested that the
intensity of IRF-3 down-regulation increased with the increased expression of viral late gene, gC
(Fig 3.9 C). Densitometric analyses of the Western blot images suggested about 3.4 X and 105 X
decreased level of total endogenous IRF-3 protein in the T953 infected EECs at 6 and 12 h.p.i.
respectively when compared to mock infected EECs (Fig 3.9 D).
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Figure 3.9: T953 causes down-regulation of IRF-3. EECs were infected with either T953 or
mock infected. At indicated time points whole-cell lysates were prepared and equal amounts (40
μg) of lysates were separated by 10% SDS-PAGE and blotted with (A) anti-IRF-3, (B) anti-βactin and (C) EHV-1 late protein gC antibodies. β-actin was used as endogenous loading control.
(D) Densitometric analyses were done by NIH ImageJ software and the IRF-3 band intensity was
normalized to β-actin band intensity. T953 infected cell lysates showed a decrease in relative fold
intensity of IRF-3 compared to mock infected cells. The Western blot images were representative
of 3 independent experiments. T953 induced down-regulation of IRF-3 at later time points (6 h
and 12 h) in EECs when compared to mock infected EECs. Level of IRF-3 protein was reduced
with the increase in late protein gC.
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3.9 Role of T953 Virus in the Activation of IRF-3
It was evident from results of our previous experiments that, among possible mechanisms
for interference with host type-I IFN production pathways, T953 directly or indirectly targeted
transcription factor IRF-3 for its down-regulation. It was however, important to know if T953
virus also interfered with other steps in the activation of IRF-3 signaling pathways including
phosphorylation of IRF-3 or nuclear translocation of phosphorylated IRF-3 (pIRF-3) from
cytoplasm. Therefore, EECs were either mock infected or infected with T953. At 3 and 12 h.p.i.,
cells were lysed and nuclear and cytoplasmic fractions of total proteins were separated by
subcellular fractionation. SeV infection of EECs for 12 h was considered as positive control.
Protein fractions were analyzed by Western blot using anti-pIRF-3, anti-IRF-3 and anti-lamin
A/C Abs.
Western blot analyses (Fig 3.10) of the subcellular protein fractions of infected cell lysates
showed that total (cytoplasmic plus nuclear) level of pIRF-3 in T953 infected EECs was downregulated from early (3 h) time points to later (12 h) time points. It was also evident that at 3 h
T953 infection induced activation of IRF-3 molecules by phosphorylation and majority of the
pIRF-3 was translocated into the nucleus from the cytoplasm (Fig 3.10 A). On the other hand, at
12 h.p.i. the virus induced phosphorylation was greatly reduced and there was down-regulation in
the nuclear accumulation of the activated pIRF-3 when compared with 3 h.p.i. (Fig 3.10 A).
When membranes were blotted with anti-IRF-3 Abs

which detected total IRF-3 (both

phosphorylated as well as unphosphorylated IRF-3) it was also observed that at early time points,
the majority of the total IRF-3 molecules were translocated into the nucleus when compared with
cytoplasmic IRF-3 (Fig 3.10 B, C). At later time points, however, the majority of the total IRF-3
molecules were in the cytoplasm (Fig 3.10 B, C). Since, IRF-3 molecules in general translocate
into the nucleus only after activation by phosphorylation, the down-regulation in the amount of
total nuclear IRF-3 at later time points also indirectly suggests a down-regulation in the activation
of IRF-3 molecules at those time points. It was noted that IRF-3 Ab (FL-425) from Santa Cruz
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Biotechnology detected a nonspecific band in the mock infected nuclear lysates which was not
detected when membranes were blotted with IRF-3 mAb (D6I4C) from Cell Signaling
Technology (Fig 3.10 C). Densitometric analyses of the Western blot images showed that the
fraction of total nuclear IRF-3 that was phosphorylated (pIRF-3/IRF-3) decreased over time when
compared between nuclear lysates from 3 h.p.i. and 12 h.p.i. (Fig 3.10 J). Interestingly, the ratio
of pIRF-3/IRF-3 in the cytoplasmic lysates increased over time when compared between 3 h.p.i.
and 12 h.p.i. This increased cytoplasmic pIRF-3 fraction at later time points suggested that T953
infection either prevented further translocation of pIRF-3 into the nucleus from cytoplasm at 12
h.p.i. or the virus infection triggered nuclear pIRF-3 to translocate back into cytoplasm. In both
cases, however, there was a down-regulation in the activation of IRF-3 at later time points. The
data suggest that the transcription factor IRF-3 gets normally activated and translocated into the
nucleus of the infected cells at early time points but at later time points IRF-3 signaling pathways
are blocked either by inhibiting the translocation of pIRF-3 from cytoplasm to nucleus or
stimulating pIRF-3 to translocate back into the cytoplasm from the nucleus or preventing IFR-3
phosphorylation by degrading endogenous IRF-3 making IRF-3 unavailable for phosphorylation.
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Figure 3.10: T953 prevents activation of IRF-3. EECs were infected with either T953 or mock
infected. At indicated time points cells were lysed and nuclear and cytoplasmic protein lysates
were separated. Equal amounts (20 μg) of lysates were separated by 10% SDS-PAGE and blotted
with (A) anti-pIRF-3, (B, C) anti-IRF-3 and (D) anti-lamin A/C antibodies. Lamin A/C was used
as nuclear loading control. Protein fractions of SeV infected cell lysates analyzed with (E) antipIRF-3, (F) anti-IRF-3 (FL-425) and (G) anti-lamin A/C Abs were used as positive control. (H-K)
Densitometric analyses were done by NIH ImageJ software and the fraction of IRF-3 that was
phosphorylated was determined by the ratio of pIRF-3 to IRF-3 band intensity. The Western blot
images were representative of 2 independent experiments.

98

Figure 3.10: T953 prevents activation of IRF-3. EECs were infected with either T953 or mock
infected. At indicated time points cells were lysed and nuclear and cytoplasmic protein lysates
were separated. Equal amounts (20 μg) of lysates were separated by 10% SDS-PAGE and blotted
with (A) anti-pIRF-3, (B, C) anti-IRF-3 and (D) anti-lamin A/C antibodies. Lamin A/C was used
as nuclear loading control. Protein fractions of SeV infected cell lysates analyzed with (E) antipIRF-3, (F) anti-IRF-3 (FL-425) and (G) anti-lamin A/C Abs were used as positive control. (H-K)
Densitometric analyses were done by NIH ImageJ software and the fraction of IRF-3 that was
phosphorylated was determined by the ratio of pIRF-3 to IRF-3 band intensity. The Western blot
images were representative of 2 independent experiments.

As reviewed earlier activation of IRF-3 by phosphorylation followed by translocation from
cytoplasm to nucleus is a key step in the IRF-3 signaling pathways. Studies were designed to
confirm whether T953 virus was able to block the IRF-3 activation pathways by preventing
nuclear accumulation of IRF-3.
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Indirect immunofluorescence images of EECs that were either mock infected or infected with
T953 virus for 1, 3, 6 and 12 h. (Fig 3.11) clearly showed that in the mock infected EECs at all
time points (1, 3, 6, and 12 h.p.i.) the transcription factor IRF-3 was mainly cytoplasmic (Fig
3.11.II, 3.11.III, 3.11.IV, 3.11V); but when activated by a known stimulus, poly I:C, the majority
of the IRF-3 molecules translocated into the nucleus (Fig 3.11.I).

Figure 3.11.I: Poly I:C induces nuclear accumulation of IRF-3. EECs were stimulated with
poly I:C and at indicated time points cells were fixed in 4% PFA and analyzed by IFA. Panels
show EECs that were poly I:C treated for 3 h were stained with anti-IRF-3 and anti-EHV-1 gC
Abs. (A) Nuclear stain DAPI (blue), (B) IRF-3 (green), (C) EHV-1 gC (red) and (D) merged
images. Long white arrows indicate magnified cells. Poly I:C stimulated EECs showed nuclear
localization of IRF-3.
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Figure 3.11.II: T953 prevents nuclear accumulation of IRF-3. EECs were infected with T953
or mock infected and at indicated time points cells were fixed in 4% PFA and analyzed by IFA.
Panels show EECs that were mock infected for 1 h (upper panel) and T953 infected for 1 h
(lower panel) were stained with anti-IRF-3 and anti-EHV-1 gC Abs. (A) Nuclear stain DAPI
(blue), (B) IRF-3 (green), (C) EHV-1 gC (red) and (D) merged images. Long white arrows
indicate magnified cells. T953 infected EECs showed both cytoplasmic and nuclear IRF-3 while
mock infected cells showed cytoplasmic IRF-3.

101

Figure 3.11.III: T953 prevents nuclear accumulation of IRF-3. EECs were infected with T953
or mock infected and at indicated time points cells were fixed in 4% PFA and analyzed by IFA.
Panels show EECs that were mock infected for 3 h (upper panel) and T953 infected for 3 h
(lower panel) were stained with anti-IRF-3 and anti-EHV-1 gC Abs. (A) Nuclear stain DAPI
(blue), (B) IRF-3 (green), (C) EHV-1 gC (red) and (D) merged images. Long white arrows
indicate magnified cells. Majority of the T953 infected EECs showed nuclear IRF-3 while mock
infected cells showed cytoplasmic IRF-3.
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Figure 3.11.IV: T953 prevents nuclear accumulation of IRF-3. EECs were infected with T953
or mock infected and at indicated time points cells were fixed in 4% PFA and analyzed by IFA.
Panels show EECs that were mock infected (upper panel) and T953 infected for 6 h (lower
panel) were stained with anti-IRF-3 and anti-EHV-1 gC Abs. (A) Nuclear stain DAPI (blue), (B)
IRF-3 (green), (C) EHV-1 gC (red) and (D) merged images. Long white arrows indicate
magnified cells. T953 infected EECs showed both cytoplasmic and nuclear IRF-3 while mock
infected cells showed cytoplasmic IRF-3.
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Figure 3.11.V: T953 prevents nuclear accumulation of IRF-3. EECs were infected with T953
or mock infected and at indicated time points cells were fixed in 4% PFA and analyzed by IFA.
Panels show EECs that were mock infected (upper panel) and T953 infected for 12 h (lower
panel) were stained with anti-IRF-3 and anti-EHV-1 gC Abs. (A) Nuclear stain DAPI (blue), (B)
IRF-3 (green), (C) EHV-1 gC (red) and (D) merged images. Long white arrows indicate
magnified cells. The majority of the IRF-3 molecules were cytoplasmic both in T953 as well as
mock infected EECs.
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In the T953 infected EECs, IRF-3 molecules started to become activated and translocated from
cytoplasm into nucleus as early as 1 h.p.i. when the majority of IRF-3 molecules were still in the
cytoplasm (Fig 3.11.II). At 3 h.p.i., however, the majority of the IRF-3 molecules were found to
have translocated from the cytoplasm and accumulated in the nucleus (Fig 3.11.III). At 6 h.p.i.
IRF-3 was found both in the cytoplasm as well as in the nucleus of virus infected EECs although
the majority of the IRF-3 molecules were still in the nucleus (Fig 3.11.IV). At 12 h.p.i. the
majority of the IRF-3 molecules were in the cytoplasm of the T953 infected EECs (Fig 3.11.V).
These data supported the findings of the Western blot images (3.10) that after an initial activation
followed by nuclear accumulation of IRF-3 at early times post infection, T953 virus induced a
gradual decrease in the nuclear accumulation of activated IRF-3 in EECs in vitro which could be
responsible for suppressing type-I IFN production at later times.

3.10 Effect of T953 Infection on NF-κB Signaling Pathways
In addition to the IRF-3 signaling pathways, NF-κB signaling pathways also play an
important role in the production of type-I IFNs. To determine whether the virus was able to
suppress the NF-κB mediated signaling pathways to inhibit type-I IFN induction, EECs were
either infected with T953 or mock infected. At 3, 6, and 12 h.p.i., cells were lysed for total
cellular lysates and were analyzed by Western blot with anti-IκBα, anti-β-actin and anti-IE1 Abs.
Normally in the absence of stimuli, NF-κB transcription factors remains sequestered by
associating with another inhibitory protein IκBα in the cytoplasm. When induced by a stimulus,
IκBα is phosphorylated and degraded by cellular proteasome and subunits of NF-κB are released
and activated [351]. These activated NF-κB subunits then enter into the nucleus and bind to the
DNA of the cell regulating the transcription of a number of genes including IFN-β (Fig 1.8). The
results showed that T953 infection caused a down-regulation of the endogenous level of NF-κB
inhibitory protein, IκBα (Fig 3.12.I) suggesting an activation of the NF-κB signaling pathways at
later time points (12 h.p.i.).
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Figure 3.12.I: T953 infection induces degradation of IκBα. EECs were infected with either
T953 or mock infected. At indicated time points whole-cell lysates were prepared and equal
amounts (40 μg) of lysates were separated by 10% SDS-PAGE and blotted with (A) anti-IκBα,
(B) anti-β-actin and (C) EHV-1 IE1 antibodies. T953 induced degradation of IκBα at later time
points (12 h) in EECs when compared to mock infected EECs. (D) Densitometric analyses were
done by NIH ImageJ software and IκBα band intensity was normalized to β-actin band intensity.
T953 infected cell lysates showed a decrease in relative fold intensity of IκBα compared to mock
infected cells. The Western blot images were representative of 3 independent experiments.

Additionally, NF-κB signaling pathways were also studied directly by IFA using NF-κB
p50 specific Ab (Fig 3.12.II). EECs were either mock infected (negative control) or infected with
T953 for indicated time points. Mock infected EECs stimulated with TNF-α at 45 ng/ml of media
for 45 min were the positive control. Infected or TNF-α treated cells were then stained with NFκB p50 specific primary Ab. It was observed that in mock infected cells in the absence of TNF-α
treatment, the majority of the p50 subunit was located in the cytoplasm (Figure 3.12.II i, and
3.12.II.ii).
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Figure 3.12.II.i: T953 infection does not activate NF-κB signaling pathways at early time
points. EECs were mock infected (upper panel) or infected with T953 (lower panel) for 3h. Cells
were then fixed in 4% PFA and analyzed with IFA using anti-NF-κB p50 and anti-EHV-1 gC
Abs. Figure shows (A) Nuclear stain DAPI (blue), (B) NF-κB p50 (green), (C) EHV-1 gC (red)
and (D) merged images. Long white arrows indicate magnified field. Majority of the NF-κB p50
molecules were cytoplasmic both in T953 as well as mock infected EECs.
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Figure 3.12.II.ii: T953 infection activates NF-κB signaling pathways at later time points.
EECs were mock infected (upper panel) or infected with T953 (lower panel) for 12h. Cells were
then fixed in 4% PFA and analyzed with IFA using anti-NF-κB p50 and anti-EHV-1 gC Abs.
Figure shows (A) Nuclear stain DAPI (blue), (B) NF-κB p50 (green), (C) EHV-1 gC (red) and
(D) merged images. Long white arrows indicate magnified field.In T953 infected EECs, the
majority of the NF-κB p50 molecules were located in the nucleus while in mock infected cells,
NF-κB p50 were in the cytoplasm.
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Figure 3.12.II.iii: TNF-α causes activation of NF-κB p50 signaling pathways. EECs were
stimulated with TNF-α at 45 ng/ml for 45 min. Then the treated cells were fixed in 4% PFA and
analyzed with IFA using anti-NF-κB p50 and anti-EHV-1 gC Abs. Figure shows (A) Nuclear
stain DAPI (blue), (B) NF-κB p50 (green), (C) EHV-1 gC (red) and (D) merged images. Long
white arrows indicate magnified field. TNF-α stimulation caused nuclear translocation of NF-κB
p50 suggesting an activation of NF-κB signaling pathways.

But in the mock infected EECs treated with TNF-α, the majority of the p50 subunit was
translocated into the nucleus (Fig 3.12.II.iii). At early time points (3 h) after T953 infection, the
majority of the cells showed p50 subunit located in the cytoplasm indicating that NF-κB signaling
pathways were not activated (Fig 3.12.II i). On the other hand, at later time points after T953
infection (12 h), the majority of the infected EECs were observed to possess p50 subunit in the
nucleus (Fig 3.12.II.ii) indicating that NF-κB signaling pathways were activated. In summary, the
results thus show that at the beginning of infection, NF-κB signaling pathways were not activated
while at later time points of the virus infection the pathways were activated. These important
findings also suggest that inhibition of type-I IFN by T953 infection in EECs at later time points
was probably not due to the inhibition of NF-κB signaling pathways.
Altogether, the results shown in Figures 3.9, 3.10, 3.11 and 3.12 reveal that T953 virus
inhibited type-I IFN production in EECs at later time points by a mechanism which includes
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inhibiting IRF-3 signaling pathways through multiple strategies such as inducing degradation of
IRF-3 and also preventing nuclear accumulation of IRF-3.

3.11 Effect of Exogenous rEqIFN-α on the Replication of T953
The previous results support that EHV-1 has mechanisms to inhibit type-I IFN response at
the production level by interfering with IRF-3 signaling pathways. But it was not clear whether
the virus can also interfere with the effect of type-I IFN as there were contradictory reports
regarding the antiviral effect of type-I IFN against EHV-1. Therefore, it was important to
determine the effect of type-I IFN on the replication of T953 virus in vitro. For this, EECs were
pre-treated for 24 h either with rEqIFN-α at a concentration of 1000 IU/ml of growth media or
with equal volume of MEM in growth media and then the cells were challenged with T953 at a
low MOI (MOI=0.5). At indicated time points (3, 6, 12, 24, 36 and 48 h.p.i.) cell supernatants
were collected and titrated for the presence of T953 virus by plaque assay (Fig 3.13). The results
of the plaque assay showed that exogenous treatment of the rEqIFN-α had very little inhibitory
effect (less than 10 fold) on T953 virus replication at 12 and 24 h.p.i. At 36 and 48 h.p.i. this
inhibitory effect was even less. In all the time points, however, no statistically significant
differences in T953 titers were found between the rEqIFN-α treated and untreated EECs (Fig
3.13).
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Figure 3.13: rEqIFN-α cannot block the replication of T953 in EECs. Cells were pre-treated
for 24 h with rEqIFN-α at 1000 IU/ml of media and were challenged with T953 at an MOI of 0.5.
At indicated time points cell supernatants were collected and T953 virus titers were determined
by plaque assay. Bars show the means with standard errors from 3 independent experiments.
rEqIFN-α treatment did not inhibit T953 replication.

Figure 3.14: rEqIFN-α inhibits replication of VSV-GFP. (A) EECs were either pre-treated
with rEqIFN-α at 1000 IU/ml of media or left untreated for 24 h and then challenged with VSVGFP at an MOI of 0.5 for another 24 h. VSV-GFP replication was evaluated by determining the
expression of GFP under inverted fluorescent microscope. (A) rEqIFN-α treatment completely
inhibited expression of GFP (B) EECs untreated with rEqIFN-α could not suppress the expression
of GFP. The images were representative of 3 independent experiments. rEqIFN-α treatment
completely inhibited VSV-GFP replication.
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As a positive control EECs were either pre-treated with rEqIFN-α for 24 h or left untreated
and then challenged with an interferon sensitive virus, VSV-GFP at an MOI of 0.5. At 24 h.p.i.
effect of rEqIFN-α on replication of the VSV-GFP virus was determined by evaluating the
expression of GFP under an inverted fluorescent microscope. No GFP expression was observed in
the VSV-GFP infected EECs pre-treated with rEqIFN-α at 1000 IU/ml of media (Fig 3.14 A). On
the other hand, EECs which were not treated with rEqIFN-α showed expression of GFP (Fig 3.14
B). VSV is known to be a type-I IFN-sensitive virus. The inhibition of VSV-GFP replication by
rEqIFN-α in EECs confirmed that VSV is IFN-sensitive and also confirmed that EECs were IFNcompetent cells.

3.12 Effect of rEqIFN-α on the Infection Process of T953 Virus in EECs
In the previous experiment (Fig 3.13), although rEqIFN-α had a little inhibitory effect (not
statistically significant) at 12 and 24 h.p.i., even this minor inhibitory effect was further reduced
by 36 and 48 h.p.i. It was possible that rEqIFN-α treatment would induce antiviral proteins or
ISGs and would make the majority of cells resistant to T953 virus infection but few cells were
still susceptible. When those few cells were infected, they produced progeny viruses which
eventually amplified in numbers by more rounds of replication. By 24 h.p.i. these amplified
progeny viruses could overpower the cellular antiviral immunity induced by ISGs and infect more
nearby uninfected cells. These caused increase in the titer of the virus by 48 h which were not
different when compared with the virus titer from the IFN-untreated cells. Alternatively, it could
also be possible that rEqIFN-α treatment would cause all the cells equally resistant or susceptible
to T953 infection. When challenged with T953 virus, equal number of cells were infected from
IFN-treated and untreated cells. It is possible that antiviral immunity in the IFN-treated cell might
prolong the multi-cycle infection process of the virus till 24 h.p.i. but did not completely block it.
As a result, in spite of an initial little difference between virus titers (12 h and 24 h) between IFN-
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treated and untreated infected cells, there was no significant difference later (36 h and 48 h). To
differentiate that, an infectious center assay was performed to elucidate whether IFN-treatment
caused a difference in the number of infectious centers or a difference in the infected cell
numbers or the IFN treatment prolonged the multi-cycle infection process.

Figure 3.15: rEqIFN-α does not inhibit replication of T953 virus. EECs were either pretreated with rEqIFN-α at 1000 IU/ml of media or left untreated. At 24 h cells were infected with
T953 at an MOI of 0.5. After the adsorption of virus at 37 o C for 1 h, cells were trypsinized and
single cell suspensions were made and equal number of cells were added to the confluent layer of
another permissive cell, RK-13 in 6-well plates and were allowed to adhere for 30 min. Cells
were overlaid with 0.75% CMC in growth medium and incubated at 37 o C for 96 h. 6-well plates
were then washed and stained with 1% crystal violet in 10% buffered formalin. Numbers of
plaques were counted and infected cell numbers in total cell suspension were determined. The
data represent means with standard errors from 3 independent experiments. rEqIFN-α treatment
did not alter the cell numbers infected with T953 when compared with the cells not treated with
IFN.
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The infectious center assay showed no statistically significant differences in the infected cell
numbers between rEqIFN-α treated and untreated EECs (Fig 3.15). Results from 3.13 and 3.15
suggest that exogenous rEqIFN-α treatment of EECs neither blocked viral replication in those
cells nor hindered the entry of the virus reducing the infection rate. Rather, the results support the
hypothesis that rEqIFN-α pre-treatment prolonged the multi-cycle infection process of the virus
resulting in reduced numbers of progeny viruses at the beginning which increased at later time
points (48 h.p.i.).

3.13 Effect of T953 Infection on the Type-I IFN Signaling Pathways
Because T953 virus was very resistant to the inhibitory effect of exogenous rEqIFN-α, this
raises the question whether the virus was interfering with the type-I IFN mediated JAK-STAT
signaling. It is common for different herpesviruses to target JAK-STAT signaling to subvert host
interferon responses. To elucidate whether T953 interferes with JAK-STAT signaling, EECs were
infected with T953 and, at 30 min before the indicated time points, cells were stimulated with
exogenous rEqIFN-α at a concentration of 1000 IU/ml of media. Mock infected EECs treated
with rEqIFN-α were used as positive control. At the indicated time points, cells were lysed to
prepare whole cell lysate and equal amounts (30 μg) of protein lysates were analyzed by Western
blot using anti-pSTAT-1, anti-STAT-1, anti-β-actin and anti-IE1 antibodies. The results showed
that T953 virus did not prevent exogenous rEqIFN-α induced STAT-1 phosphorylation at early
time points (3 h) but the virus down-regulated STAT-1 phosphorylation at late time points (12 h)
(Fig 3.16 A).
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Figure 3.16: T953 downregulates STAT-1 phosphorylation. EECs were infected with T953 at
MOI of 5 and cells were either left untreated or treated with rEqIFN-α at 1000 IU/ml of media for
30 min before lysis at indicated time points. Equal amounts (30 μg) of whole-cell lysates were
separated on 10% bis-cross-linked polyacrylamide gels and subjected to Western blot analysis
using (A) pSTAT-1, (B) STAT-1, (C) β-actin, and (E) EHV-1 IE1 antibodies. T953
downregulated the phosphorylation of STAT-1 at later time points but did not alter the level of
endogenous STAT-1 level. (D) Densitometric analyses were done to normalize the pSTAT-1 and
STAT-1 levels against β-actin by NIH ImageJ software. The Western blot images were
representative of 3 different blots from independent experiments.
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But this down-regulation of pSTAT-1 at later time points were not due to the down-regulation of
endogenous level of STAT-1 since the virus did not alter the endogenous level of STAT-1 (Fig
3.16 B). T953 infection to EECs was confirmed by the expression of EHV-1 IE1 protein (Fig
3.16 E).

3.14 Role of T953 Infection in the Translocation of STAT-1 in EECs
The Western blot findings of T953 mediated interference with JAK-STAT signaling pathways by
down-regulating the phosphorylation of STAT-1 molecule was further studied by indirect
immunofluorescence assays. EECs were infected with T953 for 12 h, and at 30 min prior to
fixation in 4% PFA, infected cells were either treated with rEqIFN-α (1000 IU/ml of media) or
with MEM. Mock infected EECs treated with rEqIFN-α were used as positive control. When cells
were stained with anti-STAT-1 Ab, the majority of STAT-1 molecules were in the cytoplasm of
the mock infected EECs (Fig 3.17.I). But when mock cells were stimulated with IFN the majority
of the STAT-1 molecules were translocated into nucleus (Fig 3.17.I). On the other hand, in the
absence of rEqIFN-α treatment the majority of the STAT-1 molecules were present in the
cytoplasm of T953 infected EECs (Fig 3.17.II). Cytoplasmic STAT-1 in T953 infected EECs
indicated that T953 did not activate STAT-1 molecules and thus did not activate JAK-STAT
signaling pathways.

116

Figure 3.17.I: rEqIFN-α induces nuclear translocation of STAT-1. Mock infected EECs were
either stimulated with rEqIFN-α at 1000 IU/ml or equal volume of MEM for 30 min prior to
fixation in 4% PFA at 12 h.p.i. Cells were then stained with anti-STAT-1, and anti-gC (EHV-1)
Abs. A, B, C, and D shows nuclear stain DAPI (blue), STAT-1 (green), EHV-1 gC (red) and
merged images respectively. Mock infected EECs in the absence of rEqIFN-α (upper panel)
shows cytoplasmic STAT-1 while rEqIFN-α treated mock cells (lower panel) showed nuclear
STAT-1.
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Figure 3.17.II: T953 infection inhibits nuclear translocation of STAT-1. T953 infected EECs
were either stimulated with rEqIFN-α at 1000 IU/ml or equal volume of MEM for 30 min prior to
fixation in 4% PFA at 12 h.p.i. Cells were then stained with anti-STAT-1, and anti-gC (EHV-1)
Abs. A, B, C, and D shows DAPI nuclear stain (blue), STAT-1 (green), EHV-1 gC (red) and
merged images respectively. Both in the absence (upper panel) or presence (lower panel) of
rEqIFN-α treatment, the majority of the STAT-1 molecules in the T953 infected EECs were
cytoplasmic.
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Moreover, T953 infection also prevented rEqIFN-α induced nuclear translocation of STAT-1 (Fig
3.17.II). These findings from the IFA study corroborated the results of the western blot data in the
previous section that T953 interfered with JAK-STAT signaling pathways.

3.15 Role of Viral Gene Expression on Type-I IFN Signaling Pathways
It was clear that T953 infection could suppress the activation of STAT-1 molecules and also
prevented the nuclear translocation of STAT-1, but it was not evident whether viral gene
expression was necessary to exert that effect. Studies were designed to evaluate the role of viral
gene expression in JAK-STAT signaling pathways. EECs were infected with WT T953 or UV
inactivated T953 (UV T953) and stimulated with rEqIFN-α for 30 min before harvesting cells for
total cellular lysates at 18 h.p.i. In the previous results (Fig 3.16) T953 infection for 12 h caused a
down-regulation in the STAT-1 phosphorylation but the study was not continued beyond that
time points. Protein lysates were analyzed by Western blotting using anti-pSTAT-1, anti-STAT-1
and anti-β-actin Abs. Mock infected cells treated with rEqIFN-α was included as positive
controls. Besides showing the role of viral gene expression in suppressing STAT-1 activation,
this study also showed whether the suppression effect was continued beyond 12 h.p.i.
The results showed that WT T953 infection suppressed STAT-1 phosphorylation at 18 h.p.i.
just as shown above at 12 h.p.i. UV T953, however, did not inhibit rEqIFN-α induced STAT-1
phosphorylation (Fig 3.18). Neither WT T953 nor UV T953 degraded STAT-1 from its
endogenous level. These findings suggest that viral gene expression which is absent in UV-T953
infected cells, was necessary to interfere with STAT-1 activation.
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Figure 3.18: UV inactivated T953 cannot prevent rEqIFN-α induced STAT-1
phosphorylation. EECs were mock infected or infected with wild type (WT) T953 or UV
inactivated T953 or left untreated. Cells were then either induced with exogenous rEqIFN-α at
1000 IU/ml of media or left untreated 30 min before lysis at 18 h.p.i. Equal amounts (30 μg) of
whole-cell lysates were loaded into each well of 10% bis-cross-linked polyacrylamide gel and
electrophoresed and blotted using (A) anti-pSTAT-1, (B) cocktail of anti-STAT-1 and anti-βactin antibodies. The Western blot images were representative of 2 different blots from
independent experiments.
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3.16 Effect of ORF1/2 Deletion on STAT-1 Phosphorylation
ORF1/2 of EHV-1 are the early genes of EHV-1 and have been shown to be involved in
host immune responses by modulating cytokine responses such as IFN-γ [342]. ORF1 of the
neuropathogenic EHV-1 Ab4 strain has been shown to down-regulate the expression of MHC-I
molecules which might interfere with the antigen presentation resulting into the interference of Tcell mediated immune responses [106]. Hence, considering the importance of ORF1 and ORF2,
its effect on the activation of JAK-STAT signaling pathways was evaluated using ORF1and
ORF2 deletion mutants of neuropathogenic strain Ab4 (Δ1/2 Ab4). EECs were infected with WT
Ab4 virus, or Δ1/2 Ab4 mutant virus at low MOI (MOI=1) for 18 h. Before lysis cells were
induced with rEqIFN-α for 30 min. Western blot analyses showed that Δ1/2 Ab4 virus infected
EECs could not prevent rEqIFN-α induced phosphorylation of STAT-1 when compared with
rEqIFN-α stimulated mock infected EECs (Fig 3.19 A). On the other hand, WT Ab4 infected
EECs suppressed STAT-1 phosphorylation when stimulated with exogenous rEqIFN-α (Fig 3.19
A). Neither WT Ab4 nor Δ1/2 Ab4 infection down-regulated the endogenous level of STAT-1
(Fig 3.19 B). The membranes were also blotted with EHV-1 IE1 Ab to check that WT as well as
mutants of Ab4 viruses successfully infected EECs (Fig 3.19 E). The results indicate that EHV-1
genes encoded by ORF1 and ORF2 suppressed exogenous rEqIFN-α induced STAT1phosphorylation.

121

Figure 3.19: Δ1/2 Ab4 mutant virus cannot prevent STAT-1 phosphorylation. EECs were
infected with another EHV-1 neuropathogenic strain Ab4 WT, or with an ORF1/2 deletion
mutants of Ab4 (Δ1/2 Ab4) at MOI of 1 and cells were either left untreated or treated with
rEqIFN-α at 1000 IU/ml of media for 30 min before lysis at 18 h.p.i. Equal amounts (30 μg) of
protein lysates were separated on 10% bis-cross-linked polyacrylamide gels and subjected to
Western blot analysis using (A) anti-pSTAT-1, (B) anti-STAT-1, (C, F) anti-β-actin and (E) antiEHV-1 IE1 antibodies. (D) Densitometric analyses were done to normalize the pSTAT-1 and
STAT-1 levels against β-actin by NIH ImageJ software. The Western blot images were
representative of 3 different blots from independent experiments.
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3.17 Deletion of ORFs 1 and 2 Does Not Interfere with the Entry and Gene
Expression of Mutant Δ1/2 Ab4 virus
The mutant virus Δ1/2 Ab4 was characterized by Soboll Hussey et al. [342] earlier in detail and a
growth curve was made on NBL-6 cells. It was shown that deletion of ORF 1 and 2 does not
lower the infectivity of the mutant virus when compared to its WT Ab4 virus. However, in this
study also it was evaluated whether the Δ1/2 Ab4 mutants were able to infect and express its
genes in the EECs by IFA study using antibodies against EHV-1 IE1 protein and also EHV-1 late
protein gC. The IFA data showing the expression of IE1 protein indicated that Δ1/2 Ab4 mutant
was able to enter into EECs successfully like its parental virus Ab4 (Fig 3.20). The expression of
late protein gC also confirmed that the mutant virus was able to infect and express its genes in
EECs like WT Ab4 (Fig 3.20).
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Figure 3.20: ORF1/2 deletion does not affect the capacity of Δ1/2 Ab4 mutant virus to infect EECs.
Panels show images of i) mock infected EECs, ii) Ab4 WT infected EECs and iii) Δ1/2 Ab4 infected EECs.
A, B, C and D represents DAPI (nuclear stain) stained images, anti-IE1 Ab (green) stained images, anti-gC
Ab (Red) stained images and (D) Merged images of A, B, and C respectively.
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3.18 Effect of T953 Infection on the Expression of Viperin in EECs
Type-I IFNs exerts their antiviral effects through the induction of ISGs. As EHV-1 T953
interfered with the activation of STAT-1 molecules, which is important for downstream ISG
induction, it was imperative to know if the virus was able to inhibit ISG induction partially or
completely. Studies were designed to find out if T953 infection of EECs induced expression of a
recently discovered IFN induced antiviral protein, viperin. As reviewed earlier that viperin has
been found to inhibit many DNA as well as RNA viruses such as HCMV, HCV, dengue virus,
influenza virus and many others. EECs were infected with T953, or treated as indicated (Fig
3.21). At 3 and 12 h.p.i whole cell lysates were prepared and equal amounts of protein lysates
were subjected to Western blot analysis using anti-viperin and anti-β-actin Abs. Results indicate
that T953 infection did not induce viperin protein at either early (3 h) or later (12 h) time points
(Fig 3.21. Interestingly, T953 infection at later time points also suppressed poly I:C induced
viperin expression. The results also indicated that T953 infection for 3 h did not prevent poly I:C
induced viperin expression. The Western blot image also showed that late gene blocking of T953
by PAA treatment permitted viperin protein expression compared to T953 infected EECs without
PAA. In summary, T953 virus infection of EECs suppressed viperin expression and the virus also
had the ability to inhibit other stimuli that induce viperin expression.
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Figure 3.21: T953 infection suppresses viperin expression. EECs were infected with T953, or
treated with poly I:C, or coinfected as indicated. At indicated time points whole cell lysates were
prepared and equal amounts (30 μg) of proteins were separated on 10% SDS-PAGE and analyzed
by Western blotting using anti-viperin and anti-β-actin Abs.(A) At 3 h.p.i. T953 neither induced
viperin expression nor completely prevented poly I:C induced viperin expression. (B) At 12 h.p.i.
T953 prevented poly I:C induced viperin expression.
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3.19 T953 Infection Interferes with Exogenous IFN-α induced ISGs Viperin and
ISG56 Expression
Because T953 infection did not induce any viperin protein either at early and later time
points and viperin could be induced by both IFN-dependent as well as IFN-independent
pathways, further studies were designed to determine whether the virus was able to inhibit
exogenous rEqIFN-α -induced viperin expression both at mRNA and protein level. In addition to
viperin, ISG56 was also evaluated in this study.
EECs were infected with T953 and at 6 h.p.i. stimulated with rEqIFN-α for another 1 or 6 h.
Mock infected EECs were also stimulated with rEqIFN-α for 1 and 6 h. At the indicated time
points transcription of viperin and ISG56 mRNA were evaluated by real-time RT-PCR assay.
Results indicate that T953 infection of EECs for 6 h reduced transcription of rEqIFN-α-induced
viperin mRNA significantly (Fig 3.22 A). The virus infection of EECs for 6 h also downregulated rEqIFN-α-induced ISG56 mRNA significantly (Fig 3.22 B).

127

Figure 3.22: T953 inhibits interferon induction of ISGs at the transcriptional level. EECs
were either mock infected or infected with T953 at an MOI of 5. At 6 h.p.i., infected EECs were
stimulated with exogenous rEqIFN-α (1000 IU/ml of media) for either 1 h or 6 h. One group of
mock as well as virus infected cells was left untreated. At indicated time points, cells were lysed
for total cellular RNA and mRNA transcripts of ISGs were quantitated by real-time RT-PCR
assays. T953 inhibited exogenous rEqIFN-α induced viperin (A) as well as ISG56 (B) mRNA
transcription significantly (***= p<0.001 and *= p<0.05). Data represent means with standard
errors from 3 independent experiments.

The suppression of viperin and ISG56 transcription was confirmed by Western blot analyses of
the T953 infected cell lysates (Fig 3.23).
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Figure 3.23: T953 inhibits interferon induced ISGs induction at translational level. EECs
were either mock infected or infected with T953 for 6 h. Cells were then either stimulated with
exogenous EqIFN-α (1000 IU/ml of media) or left unstimulated for another 6 h. Whole-cell
lysates were prepared and equal amounts of lysates were subjected to Western blot analysis by
using (A) anti-viperin, (B) anti-ISG56 and (C) anti-β-actin Abs. T953 downregulated protein
level of viperin and also reduced ISG56 protein translation induced by EqIFN-α. Images are
representative of 3 independent experiments.
EECs were infected with T953 for 6 h and stimulated with rEqIFN-α for another 6 h. Whole
cell lysates were prepared and equal amounts (30 μg protein) of lysates were subjected to Western
blot analyses using anti-viperin, anti-ISG56 and anti-βactin Abs. The results showed that T953
infection down-regulated rEqIFN-α induced viperin protein expression by more than half (3.23
A). On the other hand, T953 infection to EECs suppressed rEqIFN-α induced ISG56 completely
(3.23 B). Altogether, these data indicate that T953 infection suppressed rEqIFN-α induced ISGs
such as viperin and ISG56 both at the transcriptional as well as translational levels.
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CHAPTER IV: DISCUSSION

The first line of defense against infectious agents is mounted by the host’s innate immune
system which was thought to be very simple [352] as until recently it was presumed that the
adaptive immune system played the central role in the clearance of viral infections. It is now
believed that innate immune system plays the crucial roles in acute infections especially in viral
infections [353]. Generally, in microbial infections, innate immune system exerts its action by
recognizing pathogens through different innate immune receptors (TLRs, RLRs and NLRs) and
then secreting different types of cytokines to eliminate that infection from the host. Failing to do
so, innate immune system recruits the adaptive immune system to eventually clear the infection
[352]. It is now well documented that the type-I IFNs, namely IFN-α and IFN-β act as
nonspecific antiviral agents against many viruses, including herpesviruses [314]. Besides
inhibiting virus replication directly, type-I IFNs have also been reported to modulate adaptive
immune responses by enhancing CD8+ T cell activation, regulating migration of immune cells,
helping in the maturation of DC and also inducing apoptosis [300, 354, 355].

4.1 Suppression of Type-I IFN by EHV-1 T953 Strain After an Initial Transient
Induction
Because effective replication of EHV-1 in endothelial cells is thought to be necessary for
the development of EHM as well as also for abortions, control of virus replication in endothelial
cells could be an effective way to control EHV-1 abortions and EHM. The central hypothesis of
this research was that EHV-1 has mechanisms to evade the antiviral effects of type-I IFN
response of the horse. The suppression of type-I IFN responses at either IFN induction or IFN
signaling or both could make the microenvironment conducive for efficient lytic replication of
EHV-1 leading to the inflammatory damage to the blood vessel and surrounding tissues. To date,
there have been no detailed reports of type-I IFN responses to EHV-1 infection in endothelial
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there have been no detailed reports of type-I IFN responses to EHV-1 infection in endothelial
cells. Herpes viruses like HSV-1, BHV-1, VZV have been shown to inhibit type-I IFN production
in fibroblast cells [303, 305, 356]. In contrast to this, HSV-1 has also been shown to induce the
production of type-I IFN mainly by pDC indicating that induction of interferon responses is cell
type specific [357]. In this study the type-I IFN responses to EHV-1 infection were investigated
in EECs, as a model for simulating the infection in horses.
EHV-1 infection of EECs caused a transient induction of IFN-β mRNA at an early stage of
infection (3 h.p.i.) but soon after that the virus started suppressing further induction of IFN-β
mRNA and by 12 h.p.i., the virus shut off the transcription of IFN-β gene to a basal level when
compared to mock infected cells. However, when measured at protein level by type-I IFN
bioassay, it was observed that the virus infection showed type-I IFN activity in infected cell
supernatants both at 3 h and at 12 h although reduced activity at later time points (12 h). The
type-I IFN activity at protein level found in the later time points could be due to the accumulating
effect of type-I IFNs that were secreted in 3 and 6 h.p.i. In contrast to this study, Edington et al.
[332] observed that in vivo EHV-1 infection of horses induced high level of EqIFN in serum.
Also, low levels of EqIFN were secreted by explanted mononuclear cells infected with EHV-1. In
another in vitro study, Wagner et al. [349] found that EHV-1 infected PBMCs induced type-I IFN
(IFN-α) and chemokines like CCL5, CXCL9 and CXCL10 but suppressed CCL2 and CCL3
production. Although, the data from this study appears contradictory to the previous studies, upon
careful evaluation it should be clear that the current results showed that EHV-1 was capable of
inducing type-I IFN (IFN-β) gene expression (both at mRNA and protein level) in the endothelial
cells. Furthermore, the kinetic analyses of type-I IFN production by EHV-1 infected EECs
indicated that the virus also had the ability to interfere with later type-I IFN production, i.e., after
an initial phase of induction. On the other hand, the previous studies, either in vivo (horse) or in
vitro (equine PBMCs) did not address whether EHV-1 could also inhibit IFN-α/β production. The
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apparent differences in EHV-1 induced type-I IFNs could be attributed to a number of factors. In
the case of in vivo infection, a number of different cell types both immune cells (pDC, mDC and
PBMCs) as well as non-immune cells (epithelial, endothelial and fibroblast cells) are present in
the body and which specific cell type(s) produced the IFN response in the serum of EHV-1
infected horses was not specified. Research has shown that type-I IFN induction is cell type
specific and immune cells like DCs could respond differently than non-immune cells to a virus
infection [358, 359]. Indeed, Le et al. [360] and others [359] reported that mouse
cytomegalovirus (MCMV) infected pDC produced a significant amount of type-I IFNs, but nonimmune cells like fibroblasts did not. By inhibiting type-I IFN production in fibroblasts, MCMV
made an ‘intracellular milieu’ or ‘virus factory’ which was optimized for viral genome replication
[360]. pDCs have been reported to be the cells that primarily produce type-I IFNs in response to
infectious agents [361]. It is entirely possible that during in vivo EHV-1 infection, pDCs along
with other cells like mDCs and other mononuclear cells are activated to produce IFN-α/β which
was detected by Edington’s group. Wagner’s group also found IFN-α in EHV-1 infected PBMCs
(immune cells). Difference due to virus strains could not be ruled out since Wagner’s group used
different strains of EHV-1 (Ab4, NY03 and RacL11) than the strain used in this study (T953).
The relation of type-I IFN production to the strain differences needs to be further investigated.

4.2 T953 Virus Mediated Shut-down of Type-I IFN Induction by SeV or Poly I:C
Next, it was important to determine if the virus actively shut down type-I IFN production in
the host cells or the suppression of IFN-α/β at later time points was due to normal IFN production
kinetics. To address that issue, a co-infection study was designed where EECs were infected
either with T953 and SeV together or T953 and poly I:C together for different periods of time. In
both cases results showed that T953 suppressed the SeV or poly I:C induced type-I IFN by EECs
(Fig 3.3 and 3.4).
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Interestingly, when poly I:C treated EECs were taken as positive control, a biphasic
induction of IFN-β gene transcription was found. After a peak of IFN-β mRNA at 3 h there was a
downregulation of IFN-β mRNA at 6 h and again at 12 h there was increase in the IFN-β gene
transcription (Fig 3.3). This phenomenon was also seen at the translation level (Fig 3.4). This
biphasic induction of IFN-β was probably due to a positive feedback loop. Using an IFN-β-GFP
reporter system, Hwang et al. [362] showed that synthetic dsRNA analogue, poly I:C causes a
biphasic expression of IFN-β in the HepG2 cell line in a positive feedback loop. Poly I:C also has
been found to induce STAT-1 phosphorylation in a biphasic manner [363]. Type-I IFNs have
been shown to induce the expression of a number of ISGs, some of which like RIG-I and MDA-5
are also involved in sensing foreign dsRNA [362, 364-366]. For example, secreted IFN-β
stimulates the RLRs like RIG-I and MDA5 which stimulates autocrine feedback loop producing
more IFN-β. IFN-β induction through RLRs involves a number of positive feedback loops which
also involve multiple ISGs. IFN-β also stimulates LGP2 which competes with RLRs for binding
of foreign cytosolic RNA to activate MAVS/IPS-1 in mitochondria to produce more type-I IFNs
in a positive feedback manner [365]. The transcription factor IRF-7 which is an ISG plays an
important role in the production of type-I IFNs [367]. It has been reported earlier that IFN-β
induces the production of IRF-7 which in turn transactivates the transcription of more type-I IFNs
resulting in a positive feedback loop [367]. Another reason for the biphasic expression of IFN-β
could be the stochastic chromatin states before initiation of transcription, resulting in differential
gene expression as has been found in the bimodal expression of IL-4 [362]. It has been shown
that the biphasic expression of IL-4 due to the heterogeneous state of the chromatin in Th cells
was not controlled by a positive feedback loop [362, 368]. However, chromatin state has not been
found to be the principal reason for biphasic IFN-β gene expression since, blocking of IFN-β
secretion disrupted this pattern indicating a positive feedback loop by secreted IFN-β [362]. If
this bimodality was due to the heterogeneous status of the chromatin at IFN-β gene locus,
blocking of IFN-β-loop would not have any effect. In the present study biphasic IFN-β gene
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expression induced by poly I:C probably involved a positive feedback loop which caused a
second peak at 12 h.
To verify that EHV-1 gene expression actively shut down the type-IFN production, another
co-infection study was designed. In the earlier co-infection studies (Fig 3.3, 3.4) combinations of
viruses (T953 and SeV) or combinations of virus and chemical (T953 and poly I:C) were added to
cells at the same time and incubated for same duration. But in this co-infection experiment cells
were pre-infected with T953 and the virus was allowed to express its genes for some time (6h)
before the cells were coinfected with SeV to induce IFN-β induction and the results indicated that
EHV-1 gene expression actively suppressed the ability of SeV for IFN-β mRNA induction (Fig
3.5) . Sometimes, when a virus infected cells are co-infected with another different virus, entry of
the second virus may be interfered. It could be argued that inhibition of SeV induced IFN-β gene
transcription was due to the interference of SeV entry by T953. To test this another co-infection
was done where cells were infected with T953 for different time periods (0 h, 3 h, 6 h and 12 h)
and then induced with poly I:C for IFN-β gene expression (Fig 3.6). The inhibition of both SeV
and poly I:C (Fig 3.5, 3.6) induced IFN-β gene transcription by T953 virus confirmed that the
T953 virus not only suppressed IFN induction from its own stimulus but actively shut down typeI IFN induction induced by other exogenous stimuli.
It is noteworthy that UV inactivated T953 virus did not induce any significant type-I IFNs
(Fig 3.3, 3.4) at all-time points suggesting that active viral gene expression is necessary for the
initial IFN-α/β production. It was expected that PRRs would recognize the UV inactivated T953
and produce type-I IFNs which did not happen in this study. It is possible that UV inactivated
T953 virus did not have the threshold level stimuli to initiate the type-I IFN production.
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4.3 Relationship of EHV-1 Late Gene(s) to Suppression of Type-I IFN Induction
There was an indication that EHV-1 late genes might be responsible for the inhibition of type-I
IFN induction as at later time points post infection there was no significant IFN production. Since
the expression of EHV-1 late genes is dependent on the replication of viral DNA by DNA
polymerase, the expression of EHV-1 late genes were blocked by inhibiting EHV-1 DNA
polymerase using PAA. Although there are several reports that PAA preferentially inhibits
herpesviral DNA polymerase and thereby inhibits the late gene expression of herpesvirus [369]
we verified that PAA also blocked EHV-1 DNA polymerase without host cell toxicity. The
immunofluorescence data (Fig 3.7) showed that in the presence of PAA, the T953 virus failed to
express a marker late gene (gC) while expression of a marker IE gene (IR1) was unaffected.
Interestingly, when EHV-1 late gene expression was blocked, a robust type-I IFN response
both at mRNA as well as protein level (Fig 3.8 A and 3.8 B) was observed at later time points (12
h and 18 h). At these time points IFN was undetectable in the T953 infected EECs if late gene
expression was not blocked. This result indicates that viral late gene(s) are partly or completely
responsible for the anti-IFN activity. However, the specific gene(s) responsible for this inhibitory
effect have not been determined and further investigations are required.

4.4 Mechanism(s) of Suppression of Type-I IFN Induction by T953 Virus
To explore the mechanism(s) EHV-1 uses to suppress IFN production at later time points,
additional studies were carried out to determine whether EHV-1 interferes with any of the steps in
the activation of the principal pathways for type-I IFN production, such as IRF-3 signaling
pathways. A number of different viruses from diverse families have been reported to interfere
with IRF-3 signaling pathways [303, 307, 331, 360, 370-372]. From the recognition of PAMPs by
PRRs to the production of IFN-β through IRF-3 signaling pathways, multiple signaling molecules
and multiple steps are involved and viruses, therefore, have multiple opportunities to evade this
important host response. While some viruses degrade the endogenous level of IRF-3, others
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inhibit its activation by preventing phosphorylation, or dimerization, or even nuclear
accumulation of activated IRF-3 [303, 306, 371, 373]. While other viruses that cannot interfere in
the activation of IRF-3, they may interfere with the interaction between CBP/p300 and IRF-3
[306]. Alphaherpesvirus HSV-1 was shown to suppress IRF-3 hyperphosphorylation as well as
IRF-3 mediated ISG promoter activity by HSV-1 IE protein ICP0 [307]. HSV-1 however has not
been reported to degrade endogenous IRF-3 protein [307]. On the other hand, BHV-1, another
alphaherpesvirus, but a different genus, Varicellovirus through its IE protein ICP0 degrades
endogenous level of IRF-3 protein to inhibit type-I IFN production [303]. Therefore, it was
thought that EHV-1 being a Varicellovirus could adapt the same technique in order to evade host
type-I IFN response. The Western blot (WB) data (Fig 3.9) indeed indicated that T953 virus
down-regulates endogenous level of IRF-3 protein at later time points (6 h.p.i. and 12 h.p.i.) when
compared to mock infected cell lysates. It is also to be noted that the down-regulation of IRF-3
protein increased with the increase of the amount of late protein gC expression. This suggested
that expression of T953 late gene(s) could be responsible for the degradation of IRF-3 at later
time points resulting into the suppression of IFN production. Another possibility is that the downregulation of the total amount of endogenous IRF-3 protein at later time points could be
nonspecific and it is due to the global shut down of gene expression after EHV-1 infection. This
seems less likely to happen, since unlike HSV-1, EHV-1 infection does not show much inhibition
of global gene expression [108].
Many viruses evolve multiple targets to interfere with IRF-3 mediated signaling pathways.
HSV-1 inhibits nuclear accumulation of IRF-3, induces degradation of activated IRF-3, and
interferes with the binding of IRF-3 to CBP/p300 required transcriptional activation of different
genes [306]. Therefore, it was also interesting to explore whether T953 evolved similar multiple
strategies to subvert IRF-3 signaling pathways. Data from this study (Fig 3.10) show that at an
early time points (3 h) T953 infection of EECs caused IRF-3 phosphorylation which was reduced
at a later time points (12 h). The WB data from the subcellular fractionized cell lysates also
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showed that initially the majority of the pIRF-3 molecules were located in the nucleus while
cytoplasmic pIRF-3 increased at later time points. This phenomenon suggests that at the
beginning of the infection IRF-3 is activated and translocated into the nucleus from the cytoplasm
and this activated pIRF-3 might stimulate downstream signaling resulting in the IFN-β
transcription that was observed at earlier time points in this study. At later time points the
observed downregulation of pIRF-3 molecules in the nucleus explained why IFN-β was not found
during that time. But a specific reason for this downregulation of pIRF-3 molecules in the nucleus
was not identified in this study. However, T953 virus-induced down-regulation of endogenous
IRF-3 molecules would likely be the major reason. In addition to this, it is possible that some
unidentified viral proteins (late gene products) might interact with pIRF-3 and trigger the
translocation of pIRF-3 back to the cytoplasm from the nucleus, downregulating the level of
pIRF-3 in the nucleus. A similar mechanism has been proposed by Melroe et al [306] for HSV-1:
viral ICP0 targets activated IRF-3 molecules for posttranslational modification to translocate back
to the cytoplasm. An alternative possibility is that an unidentified T953 viral protein(s) could
interact with activated IRF-3 (pIRF-3) and trigger its degradation at later time points. It has been
shown that rotavirus NSP1 protein interacts with activated IRF-3 and enhances its degradation
through cellular proteasomes [374]. It has been suggested that ICP0 of HSV-1 also associates
with IRF-3 and targets activated IRF-3 molecules through the E3-ubiquitin ligase for enhanced
ubiquitination and degradation [306].
When cell lysates were analyzed with IRF-3 Ab rather than pIRF-3 Ab, it was observed that IRF3 was translocated into the nucleus suggesting activation of IRF-3 at the early time points when
IFN-β was also expressed. But at later time points the level of nuclear IRF-3 was drastically
downregulated. Densitometric analyses of the band intensity also indicated that the total
cytoplasmic IRF-3 level was increased at 12 h.p.i. compared to 3 h.p.i. This indicated that either
IRF-3 phosphorylation was downregulated reducing the total nuclear level of IRF-3, or
translocation of pIRF-3 to the nucleus from the cytoplasm was inhibited at later time points. In
137

either case there would be reduced nuclear IRF-3 but comparatively increased cytoplasmic IRF-3.
But when the ratio of pIRF-3/IRF-3 was calculated to find out the fraction of IRF-3 molecules
that was activated, it was observed that although the ratio was decreased in the nucleus from 3 h
to 12 h, there was also an increase in the ratio in the cytoplasm, and the total pIRF-3/IRF-3 ratio
(cytoplasmic + nuclear) was not altered much. This indicated that perhaps T953 infection
prevented pIRF-3 nuclear translocation from the cytoplasm at later time points rather than
preventing phosphorylation of IRF-3.
The IFA data (3.11) also suggested that T953 infection induces IRF-3 activation followed
by nuclear translocation as early as 1 h.p.i. and peaks at 3 h.p.i. At 6 h.p.i., although the majority
of T953 infected cells showed nuclear IRF-3, a number of cells also showed cytoplasmic IRF-3
indicating T953 infection either reduced IRF-3 activation or reduced translocation into the
nucleus. At 12 h.p.i. however, the majority of cells showed cytoplasmic IRF-3 suggesting the
virus infection prevents nuclear accumulation of IRF-3. Therefore, whether T953 infection
degrades activated IRF-3 or prevents activation of IRF-3 or inhibits translocation of activated
IRF-3 is not clear in this study and further studies are required to specifically identify the step(s)
in the IRF-3 signaling pathways at which virus interfered. But it is certainly clear that in all cases
T953 infection induced down-regulation of endogenous IRF-3 and also prevented nuclear
accumulation of IRF-3 at later time points thus down-regulating IRF-3 signaling pathways. These
interferences in the IRF-3 signaling pathways probably were responsible for the absence of IFN-β
in the later time points.
This study was also intended to see whether T953 virus infection also inhibited NF-κB
signaling pathways as the activation of the transcription factor NF-κB also plays a role in IFN-β
induction [375]. In the inactive state, the NF-κB subunits, p50 and p65 are associated with an
inhibitory protein IκBα and thus sequestered in the cytoplasm [351, 376]. When activated by
different stimuli like LPS or infectious agents like virus or bacteria, the inhibitory protein IκBα is
phosphorylated by cellular kinases and then degraded by cellular proteasomes resulting in the
138

activation of p50 and p65 subunits which then translocate into the nucleus to transactivate
transcription of a diverse set of genes [376]. In this study it was observed that T953 virus
infection induced degradation of the inhibitory protein IκBα (Fig 3.11.i) at later time points (12
h.p.i.) indirectly suggesting an activation of the NF-κB signaling pathways. During the early
phase of the infection IκBα was not degraded indicating that at early time points (3 h.p.i.) NF-κB
signaling pathways were not activated. The IFA data (Fig 3.12.ii) using anti-p50 Ab showed that
at early time points the p50 protein was located in the cytoplasm of T953 infected cells. But at the
later time points p50 protein was found to be translocated from the cytoplasm into the nucleus in
T953 infected cells. This indicates that T953 infection of EECs does not activate NF-κB signaling
pathways at early times post infection but at later times post infection the virus activates the
transcription factor NF-κB. This also indicates that probably the type-I response induced by T953
infection at early time points is not due to the involvement of NF-κB signaling pathways, rather,
it is a result of the activation of IRF-3 signaling pathways. Also at later time points, the
suppression of type-I IFN is probably not due to the inhibition NF-κB signaling pathways but due
to interference with IRF-3 signaling pathways at multiple levels. By activating NF-κB signaling
pathways at later time points, the virus may trigger the expression of NF-κB dependent gene
expressions especially expression of pro-inflammatory cytokines like IL-1β, IL-6 and TNF-α.
These proinflammatory cytokines in turn could play vital role in the inflammation of the blood
vessels of uterus and CNS causing EHV-1-induced pathology [377]. Again by activating the
expression of NF-κB dependent genes, the virus also could trigger cell survival [377] which in
turn would be advantageous to the virus for its replication. Some viral proteins like African Swine
Fever virus protein A238L interact with p300 protein and inhibit the association between NF-κBp65 and p300 which is required for transactivation of genes and thus prevents NF-κB signaling
mediated gene transcription [378]. Adenovirus protein E1, Simian Virus 40 (SV40) T large Ag
and E6 or E7 protein of human papillomavirus (HPV) have also been reported to interact with
p300 and inhibit the association of NF-κB sububit and CBP/p300 [379-382]. As a result of this, in
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spite of activation of NF-κB signaling pathways sometimes there is no transcription of NF-κB
dependent genes.

Therefore, an alternative explanation could be that in addition to IRF-3

activation pathways, NF-κB signaling pathways are also inhibited but downstream to the
activation and nuclear accumulation of the transcription factor NF-κB. It is entirely possible that
T953 virus proteins may interact with CBP/p300 and interfere with the association between
activated NF-κB subunits and CBP/p300 which also could suppress type-I IFN production at later
time points.
Taken together, these data indicate that during the early stage of the T953 infection in vitro
in EECs, the host cells respond by inducing a type-I IFN response. At the late stage of the
infection, however, viral late proteins interfere with the IRF-3 signaling pathways by inducing
down-regulation of IRF-3 as well as by interfering with the translocation of activated IRF-3 into
the nucleus from the cytoplasm. Further studies are required to confirm whether the NF-κB
signaling pathways are also inhibited at single or multiple steps by T953 virus infection. This
study was not focused on the identification of the specific proteins of T953 virus that may have a
role in suppressing type-I IFN production by interfering with IRF-3 signaling pathways. Future
studies in this area are very important in order to identify the specific viral proteins that could
help understand the virus-host interaction better and may provide insights in designing of future
therapies against this viral disease.

4.5 Resistance of T953 Virus to the Effect of rEqIFN-α
The next part of this study was focused on characterization of the efficacy of type-I IFNs
against T953 infection. As reviewed earlier, type-I IFNs bind to its cognate receptors IFNAR1
and IFNAR2 which trigger a cascade of signaling events (JAK-STAT signaling) resulting inthe
activation of STAT-1and STAT-2 proteins by phosphorylation [278]. Phosphorylated STATs
then dimerize and enter into the nucleus and bind to the interferon stimulated response elements
(ISRE) of a number of ISGs enhancing their transcription [288]. These ISGs actually inhibit
replication of viruses from diverse families through various mechanisms [288]. It was very
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important to know whether T953 was sensitive or resistant to the inhibitory effects of type-I IFNs.
Viruses like SeV and VSV have been shown to be very sensitive to the inhibitory effect of type-I
IFNs [383-385]. On the other hand herpesviruses like HSV-1 have been known to be resistant to
the effect of IFN-α/β because of the ICP0 protein [386]. In this study also the effect of exogenous
rEqIFN-α on the replication of EHV-1 T953 strain in vitro in EECs was evaluated. It was
observed that pre-treatment of EECs with rEqIFN-α at a concentration of 1000 IU/ml for 24 h had
very little inhibitory effect on T953 replication indicating that T953 virus is very resistant to the
inhibitory effect of IFN-α (Fig 3.13). The IFN-α treatment could not even decrease the number of
plaques by 10 fold (1 log scale). On the other hand, replication of IFN-sensitive virus VSV was
shown to be completely blocked. Interestingly, the minimal inhibitory effect that was shown by
rEqIFN-α against T953 virus at 12 and 24 h.p.i. were reduced at 36 and 48 h.p.i. This could occur
if rEqIFN-α treatment prolonged the replication cycle of T953 virus but not completely blocking
it. It is also possible that pre-treatment of rEqIFN-α caused interference with the entry of the
T953 virus and less number of the virus got entry to the cells. This could explain the lower
number of plaques in the beginning of infection (12 and 24 h.p.i.) in IFN-treated cells. But while
few viruses entered into EECs and replicated, those progeny viruses then would have infected
nearby cells producing more progeny viruses and this increased the titer of the virus at 36 and 48
h.p.i. To investigate that possibility, an infectious center assay was performed and the result
showed no differences in the number of infectious centers in IFN-treated and non-treated EECs.
This suggests that rEqIFN-α pre-treatment could not restrict T953 replication in EECs but it
delayed the replication cycle. By resisting the effect of type-I IFN, the virus may interfere with
the MHC-I expression or DC maturation both of which interferes with the Ag presentation to the
CTLs. This would be advantageous to the virus for its replication. Although rEqIFN-α pretreatment did not block EHV-1 replication, other IFNs such as IFN-β have not been tried in this
study. However, it is very unlikely that IFN-β could make a significant difference since both IFNα and IFN-β signal through the same receptors and exert their biological effects through very
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similar mechanisms mediated by ISGs. On the other hand, it would be interesting to see if IFN-α,
IFN-λ and IFN-γ together had any synergistic effect and whether these combination therapies
could restrict EHV-1 replication. There has been multiple reports that replication of HSV is
restricted significantly by the synergistic effects of either IFN-α and IFN-γ [387] or IFN-β and
IFN-γ [388] combination therapies in fibroblasts as well as in epidermal cells or even in vivo in
mice [389]. Therefore, it is possible that same combination therapy may work for EHV-1 also.

4.6 T953 Mediated Suppression of JAK-STAT Signaling Pathways
Because rEqIFN-α had no significant inhibitory effect on T953 replication, it was thought
that the virus must be interfering with the effector arm of type-I IFNs, i.e., signaling of type-I
IFNs. An alternative explanation could be that the virus does not interfere with JAK-STAT
signaling but interferes with the transcription of ISGs which actually provide antiviral immunity
to the host cells. It is, however, also possible that T953 virus may not even inhibit ISG induction
but could inhibit ISGs by posttranslational modifications such as ubiquitination for enhanced
degradation by cellular proteasomes.
To understand the mechanism of resistance against rEqIFN-α inhibitory effect, studies were
designed to evaluate whether the virus interfered with JAK-STAT signaling pathways. In the WB
results (Fig 3.16) it was observed that in early phase of the infection T953 virus not only activated
STAT-1 molecules by phosphorylation but also the virus did not prevent exogenous rEqIFN-α
induced STAT-1 phosphorylation. This suggested that T953 virus infection activated JAK-STAT
signaling at early time points of infection. However, by late phase of the infection T953 virus
inhibited STAT-1 phosphorylation without exogenous rEqIFN-α treatment and the virus also
down-regulated exogenous rEqIFN-α induced STAT-1 phosphorylation, indicating an
interference with the JAK-STAT signaling.
These findings from WB were confirmed by the IFA (Fig 3.17) showing that T953 downregulated nuclear accumulation of STAT-1 molecules both in the presence or absence of rEqIFN142

α at later time points of the infection, as the majority of the STAT-1 molecules were in the
cytoplasm of the infected cells. The virus infection did not change the endogenous level of
STAT-1 molecules based on the WB data (Fig 3.16 B). Therefore, the down-regulation of the
pSTAT-1 in T953 infected cells were not due to the down-regulation of the endogenous level of
STAT-1. Moreover, the densitometric analyses of the WB image showed that there was a downregulation in the pSTAT-1/STAT-1 ratio indicating a suppression of STAT-1 phosphorylation in
the later time points of the infection. The presence of a majority of STAT-1 molecules in the
cytoplasm of T953 infected cells at 12 h.p.i. (Fig 3.17.iii and 3.17.iv) also suggests that in the late
phase of infection the virus prevents STAT-1 phosphorylation. It is also possible that T953
infection triggers STAT-1 molecules to translocate back into the cytoplasm from the nucleus at
12 h.p.i. In both cases, however, there is down-regulation of STAT-1 phosphorylation and
therefore, the interference with JAK-STAT signaling provids T953 virus with resistance to the
inhibitory effect of rEqIFN-α. Similar cases of JAK-STAT signaling inhibition by herpesviruses
such as HSV-1, VZV and cytomegalovirus have been reported [313, 390, 391]. HSV-1 ICP27
was shown to be the major protein that inhibits STAT-1 phosphorylation induced by exogenous
IFN-α/β [313]. Being an alphaherpesvirus, EHV-1 also might evolve the same strategies to
subvert type-I IFN signaling and gain resistance to the inhibitory effects of rEqIFN-α.
The next goal was to determine the importance of viral gene expression for inhibition of
JAK-STAT signaling induced by rEqIFN-α. When T953 was UV inactivated to restrict its gene
expression, it was observed that inactivated T953 infection could not prevent STAT-1
phosphorylation anymore induced by exogenous rEqIFN-α (Fig 3.18). This indicates that viral
gene expression is necessary for the resistance to the inhibitory effect of rEqIFN-α.
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4.7 Involvement of ORF1/2 in the Inhibition of JAK-STAT Signaling Pathways
In the next step, studies were designed to identify the viral proteins that were involved in the
suppression of type-I IFN signaling. Reports have earlier been published about the importance of
EHV-1 ORF1 and ORF2 as virulence factors in the in vivo challenge of horses as well as also in
vitro infection [106, 342]. A deletion mutant of Ab4 virus devoid of ORF1 and ORF2 (Δ1/2 Ab4)
has been shown to cause decreased interleukin-8 (IL-8) and increased T-bet mRNA expression.
Again IFN-β has been reported to decrease IL-8 expression in several reports [392, 393] and Tbet is a transcription factor known to induce the hallmark Th1 cytokine, IFN-γ expression [394].
Therefore, the in vivo study with Δ1/2 Ab4 recombinant virus suggests that the mutant virus
likely modulate the IFN-β as well as IFN-γ mediated immune response when compared to WT
Ab4 although that study did not involve IFN-β responses. Another study with ORF1 deletion Ab4
(d1 Ab4) mutant virus showed that ORF1 is involved in the EHV-1 induced down-regulation of
MHC-I molecules. MHC-I is involved in the Ag presentation by APCs such as DCs and
macrophages but MHC-I is also an ISG inducible with type-I IFNs through JAK-STAT signaling
[395]. Therefore, these studies raise the possibility that ORF1/2 of EHV-1 could be candidate
genes involved in suppressing the STAT-1 phosphorylation at the later phase of the infection. The
WB results (Fig 3.19) indeed showed that Δ1/2 Ab4 mutant virus did not prevent STAT-1
phosphorylation induced by exogenous treatment of EECs with rEqIFN-α when compared to its
WT parent virus (WT Ab4). There was no difference in the endogenous levels of STAT-1
proteins among mock, Δ1/2 Ab4 and WT Ab4 infected EECs. It could be argued that deletion of
ORF1 and ORF2 cause the mutant virus to be inefficient in the entry or replication processes in
infected cells. But Dr. Klaus Osterrieder who provided the virus already characterized the virus in
RK-13 cells and found that the mutant virus is capable of replicating with titers comparable to
WT Ab4 [342]. In this study, however, the entry and gene expression capacity of the Δ1/2 Ab4
mutant virus were analyzed by IFA using anti-IE1 (IE gene product) and anti-gC (L gene
product) Abs. The IFA (Fig 3.20) results showed that the mutant virus is capable of entry and
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expression of viral genes, indirectly supporting the replication capacity of mutant Ab4 virus.
Thus, these findings suggest that EHV-1 ORF1 or ORF2, or ORF1 and ORF2 together, are
capable of interfering with JAK-STAT signaling by preventing STAT-1 phosphorylation.
However, there could be other proteins of EHV-1 which also inhibit type-I IFN signaling and
further studies are required to identify those proteins.

4.8 T953 Virus Mediated Inhibition of ISG Induction
Because the virus down-regulated type-I IFN production as well as signaling at later time
points (12 h.p.i.), further studies were conducted to evaluate whether the virus was interfering
downstream to the JAK-STAT signaling. Two important ISGs, viperin and ISG56 which have
been shown to have antiviral properties against diverse group of viruses such as HCV, Dengue
virus, influenza virus, HPV including herpesviruses were evaluated in the study [296, 298, 396398]. It was tested whether T953 virus was influencing the expression of these two ISGs at either
the transcriptional level or the translational level, by real-time RT-PCR assay and WB
respectively.
In the absence of rEqIFN-α treatment T953 infection did not induce any viperin protein
expression (Fig 3.21, 3.23) at either early or later time points although at early time points IFN-β
was found. At late time points T953 also prevented poly I:C induced viperin expression.
However, when viral late gene expression was blocked then T953 infection of EECs induced
viperin protein expression even in the absence of any external stimuli such as poly I:C (Fig 3.21
B). These suggested that inhibition of viperin expression by T953 is viral late gene dependent.
When EECs were treated with rEqIFN-α to induce expression of viperin as well as ISG56
mRNA, T953 infection in the presence of rEqIFN-α showed a significant decrease of viperin and
ISG56 mRNA when compared with mock infected cells treated with rEqIFN-α (Fig 3.22). This
inhibitory effect of T953 virus on viperin and ISG56 expression was also seen at the protein level
(Fig 3.23). Similar to this, HSV-1 inhibits ISG56 induction at both mRNA and protein level
[399]. HSV-1 ICP0 protein is sufficient to inhibit ISG56 induction [400] although other proteins
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are also possibly involved in the inhibition of ISG56 and other ISGs [399, 401]. In summary, the
data suggests that T953 infection not only inhibits type-I IFN induction but also suppresses type-I
IFN signaling and its downstream effects in vitro in EECs. By these mechanisms EHV-1 subverts
the host’s principal type-I IFN mediated immune responses which is undoubtedly related to its
success as a pathogen.

4.9 Future Scope
To the best of our knowledge, for the first time, results from this dissertation have identified
new and novel strategies that EHV-1 T953 strain adopts to subvert the host’s most important
innate antiviral immunity. This study has also identified for the first time that EHV-1 genes ORF1
and/or ORF2 have anti-IFN activity. Maa et al [106] and Soboll Hussey et al [342] also have
identified ORF1 and ORF2 as viral virulence factors. The ORF1 and ORF2 encode membrane
protein UL56 (pUL56) and membrane protein VI respectively (Table 1.1). Identification of these
virulence factors will give new insights for the design of more effective modified live virus
vaccines (MLV), by creating recombinant viruses devoid of those pathogenicity factors to control
EHV-1 infection. Future studies to identify more viral proteins which are responsible for
suppressing type-I IFN induction will also improve the quality of MLV and the control of the
infection.
This study provides the groundwork for a new prospective area in the field of EHV-1
research. Findings from this dissertation show that EHV-1 suppresses type-I IFN induction in
EECs which is a relevant cell type for the pathogenesis of EHV-1. Previous reports showed that
serum IFN levels in EHV-1 infected horses are at their peak when clinical signs are highest
suggesting that a high level of serum IFN correlates with the severity of clinical disease. We think
that EHV-1 infection causes induction of type-I IFN by other cells in the body such as PBMCs,
dentritic cells but for the benefit of virus replication, EHV-1 shuts down the production of type-I
IFN in the endothelial cells of the blood vessels after an initial transient induction. Furthermore,
EHV-1 infection also down-regulates type-I IFN signaling by suppressing STAT-1 translocation
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into the nucleus from the cytoplasm and preventing subsequent ISG induction. This inhibition of
ISG production makes the virus highly resistant to the effect of type-I IFN.
While this study was done using a neuropathogenic virus T953 as a model virus, to show
the relationship of type-I IFNs to EHM, for comparison a non-neuropathogenic EHV-1 virus
should be studied to evaluate the type-I IFN response. Although this study shows that the T953
late genes are probably responsible to suppress the type-I IFN induction, the specific viral genes
or proteins were, however, not identified. Viral proteins encoded by ORF1/2 appear to be
involved in the evasion of type-I IFN mediated JAK-STAT signaling. There could be other
proteins also involving in this type-I IFNs evasion strategies. Further studies are required to
identify those novel anti-IFN proteins. Taken together all the data, we propose the following
model:

All the blocks in the type-I IFN signaling in our model may be non-specific to the downstream
effect to the downregulation of IFNAR1 and IFNAR2 which was not studied.
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During natural infection in horses, endothelial cells of the blood vessels of particular
targeted organs including the nasal mucosa, lungs, pregnant uterus and nervous system become
infected with EHV-1. The local IFN milieu in those targeted organs might strongly influence the
pathogenesis of EHV-1 disease [338]. So, another important area of study will be why endothelial
cells of some targeted organs or systems of horse are particularly affected by T953 infection.
Does IFN-β have any role in the EHV-1 infection process particularly in endothelial cells of some
targeted organs? The answers to these questions may give us clues to identify host factors that
could be responsible for EHV-1 abortions as well as EHM.

Copyright © Sanjay Sarkar 2014
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APPENDIX I
List of abbreviations

Aa

Amino acid

Ab

Antibody

ADCC

Antibody dependent cell cytotoxicity

ATCC

American type culture collection

Ag

Antigen

AHV-1

Asinine herpesvirus-1

AHV-2

Asinine herpesvirus-2

AHV-3

Asinine herpesvirus-3

AMV

Avian myeloblastoma virus

β2m

β2-microglobulin

BHV-1

Bovine herpesvirus-1

BHV-5

Bovine herpesvirus-5

BHK

Baby hamster kidney

bICP0

infected cell protein 0 of bovine herpesvirus-1

BSA

Bovine serum albumin

CER

Cytoplasmic extraction reagent

CF

Complement fixing

CMC

Carboxy-methyl cellulose

CMV

Cytomegalovirus

CNS

Central nervous system

CPE

Cytopathic effect

CTL

Cytotoxic T Lymphocyte

CTLp

Cytotoxic T lymphocyte precursor
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d.p.i.

days post infection

DNA

Deoxyribonucleic acid

DTT

Dithiotreitol

DC

Dendritic cell

E

Early

ECE

Equine coital exanthema

EEC

Equine endothelial cell

EHV-1

Equine herpesvirus-1

EHV-2

Equine herpesvirus-2

EHV-3

Equine herpesvirus-3

EHV-4

Equine herpesvirus-4

EHV-5

Equine herpesvirus-5

EHV-6

Equine herpesvirus-6

EHV-7

Equine herpesvirus-7

EHV-8

Equine herpesvirus-8

EHV-9

Equine herpesvirus-9

EHM

Equine herpesvirus myeloencephalopathy

ELISA

Enzyme linked immunosorbent assay

EMEM

Eagle’s minimal essential medium

ER

Endoplasmic reticulum

ETIF

EHV-1 α-gene transinducing factor

FBS

Fetal bovine serum

FCS

Fetal calf serum

FEK

Fetal equine kidney

FITC

Fluorescein isothiocyanate

FTE

Full-time effect
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GAG

Glycosaminoglycans

gB

Glycoprotein B

gC

Glycoprotein C

gD

Glycoprotein D

GFP

Green fluorescent protein

GHV-1

Gazelle herpesvirus-1

h

hour

HCMV

Human cytomegalovirus

h.p.i.

hour post infection

HPV

Human papillomavirus

HRP

Horseradish peroxidase

HS

Heparan sulfate

HSV

Herpes simplex virus

ICP

Infected cell protein

ICTV

International Committee on Taxonomy of Viruses

IE

Immediate early

IFA

Indirect immunofluorescence assay

IFN

Interferon

IFNAR1

Interferon α receptor 1

IFNAR2

Interferon α receptor 2

IFNGR

Interferon γ receptor

IFNλR

Interferon λ receptor

IgG

Immunoglobulin G

IL-2

Interleukin-2

IL-4

Interleukin-4

IRF-3

Interferon regulatory factor 3
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IRF-7

Interferon regulatory factor 7

IR

Internal repeat

ISG

Interferon stimulated genes

ISRE

Interferon stimulated response elements

IU

International unit

JAK

Janus kinase

KyED

Kentucky equine dermis cells

L

Late

LGP2

Laboratory of Genetics and Physiology 2

LPS

Lipopolysaccharides

LU

Laboratory unit

mAb

Monoclonal antibody

MCMV

Murine cytomegalovirus

MDBK

Madin-Darby bovine kidney cells

MDA-5

Melanoma differentiation associated gene 5

MHC-I

Major histocompatibility complex-I

MLV

Modified live virus vaccine

MOI

Multiplicity of infection

mRNA

Messenger RNA

MTOC

Microtubule organizing center

NER

Nuclear extraction reagent

NF-κB

Nuclear factor κB

NK

Natural killer cells

NPC

Nuclear pore complex

OAS

Oligoadenylate synthetase

OD

Optical density
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ORF

Open reading frame

PAA

Phosphonoacetic acid

pAb

Polyclonal antibody

PAGE

Polyacrylamide gel electrophoresis

PAMP

Pathogen associated molecular pattern

PBMC

Peripheral blood mononuclear cells

PBS

Phosphate buffered saline

PCR

Polymerase chain reaction

pDC

Plasmacytoid dendritic cells

PFA

Paraformaldehyde

PFU

Plaque forming unit

PKR

Protein kinase R

Poly I:C

Polyinosinic acid:polycytidylic acid

PRR

Pattern recognition receptor

PrV

Pseudorabies virus

PVDF

Polyvinylidene difluoride

rEqIFN-α

Recombinant equine interferon α

RIG-I

Retinoic acid inducible gene I

RK-13

Rabbit kidney cells

RLR

RIG like receptor

ROCK-1

Rho associated coiled coil kinase-1

RSAD2

Radical S-adenosylmethionine domain containing 2

RT

Room temperature

RT-PCR

Reverse-transcription polymerase chain reaction

SDS

Sodium dodecyl sulfate

SeV

Sendai virus
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STAT

Signal transducers and activators of transcription

TAP

Transporter associated with antigen processing

TBS

Tris-buffered saline

TCF

Tissue culture fluid

TGF-β

transforming growth factor β

TGN

Trans -Golgi network

TK

Thymidine kinase

TMV

Tobacco-mosaic virus

TNF

Tumor necrosis factor

TR

Terminal repeat

UL

Unique long

US

Unique short

USD

United States Dollar

Vhs

Virion host shut off protein

VN

Virus neutralizing

VSV

Vesicular stomatitis virus

VZV

Varicella-zoster virus

WT

Wild type
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